Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
c39756d214ebcd8f0927a400b0232a162e46aeeea90fdbc289db41678192fa6f.png
complex
<table><tr><td>Bacteria</td><td>Aligner</td><td>Bracket</td><td><i>P</i></td></tr><tr><td></td><td><i>n</i>/<i>N</i> (%)</td><td><i>n</i>/<i>N</i> (%)</td><td></td></tr><tr><td colspan="4"><i>S</i>. <i>mutans</i></td></tr><tr><td> Present T0</td><td>13/15 (87%)</td><td>14/15 (93%)</td><td>1.00</td></tr><tr><td> Present T1</td><td>12/15 (80%)</td><td>12/15 (80%)</td><td>1.00</td></tr><tr><td> Present T2</td><td>12/15 (80%)</td><td>14/15 (93%)</td><td>0.60</td></tr><tr><td colspan="4"><i>L</i>. <i>acidophilus</i></td></tr><tr><td> Present T0</td><td>0/15 (0%)</td><td>0/15 (0%)</td><td>NC</td></tr><tr><td> Present T1</td><td>0/15 (0%)</td><td>1/15 (7%)</td><td>1.00</td></tr><tr><td> Present T2</td><td>0/15 (0%)</td><td>1/15 (7%)</td><td>1.00</td></tr><tr><td colspan="4"><i>S</i>. <i>sanguinis</i></td></tr><tr><td> Present T0</td><td>15/15 (100%)</td><td>15/15 (100%)</td><td>NC</td></tr><tr><td> Present T1</td><td>15/15 (100%)</td><td>15/15 (100%)</td><td>NC</td></tr><tr><td> Present T2</td><td>15/15 (100%)</td><td>15/15 (100%)</td><td>NC</td></tr></table>
1b530d12f0003b38d5cdd711722e711e25a3c433099b9c5342ac1b89e5992115.png
complex
<table><tr><td colspan="8">Average percent nucleotide identity (APNI)</td></tr><tr><td><i>Lactobacillus plantarum</i> strains</td><td>WJL</td><td>WCFS1</td><td>ST-III</td><td>P-8</td><td>NC8</td><td>IPLA88</td><td><i>plantarum</i><sup>F</sup></td></tr><tr><td>ZJ316</td><td>98.8</td><td>98.9</td><td>98.9</td><td>99.1</td><td>98.9</td><td>99.2</td><td>98.9</td></tr><tr><td><i>plantarum</i><sup>F</sup></td><td>99.3</td><td>99.1</td><td>99.3</td><td>98.9</td><td>99.9</td><td>99.1</td><td>99.0</td></tr><tr><td>IPLA88</td><td>99.1</td><td>99.3</td><td>99.1</td><td>98.9</td><td>99.1</td><td></td><td></td></tr><tr><td>NC8</td><td>99.2</td><td>99.1</td><td>99.3</td><td>98.9</td><td></td><td></td><td></td></tr><tr><td>P-8</td><td>98.7</td><td>98.9</td><td>98.9</td><td></td><td></td><td></td><td></td></tr><tr><td>ST-III</td><td>99.6</td><td>99.1</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>WCFS1</td><td>98.9</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Lactobacillus</i> species</td><td><i>fructivorans</i><sup>F</sup></td><td><i>fructivorans</i> KCTC 3543</td><td><i>brevis</i><sup>F</sup></td><td><i>brevis</i> KB290</td><td><i>brevis</i> EW</td><td><i>brevis</i> ATCC 27305</td><td></td></tr><tr><td><i>brevis</i> ATCC 14869</td><td>89.4</td><td>87.6</td><td>99.0</td><td>97.7</td><td>99.0</td><td>88.6</td><td></td></tr><tr><td><i>brevis</i> ATCC 27305</td><td>87.0</td><td>85.3</td><td>91.3</td><td>92.2</td><td>90.0</td><td></td><td></td></tr><tr><td><i>brevis</i> EW</td><td>89.8</td><td>88.8</td><td>98.7</td><td>97.6</td><td></td><td></td><td></td></tr><tr><td><i>brevis</i> KB290</td><td>88.7</td><td>87.4</td><td>97.5</td><td></td><td></td><td></td><td></td></tr><tr><td><i>brevis</i><sup>F</sup></td><td>89.7</td><td>88.3</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>fructivorans</i> KCTC 3543</td><td>97.3</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
29e25f2a8043ff62073573f12b7c576bae154d99e03e1829ea9839774c0087f1.png
complex
<table><tr><td>Name gene</td><td>Oligo direct</td><td>Oligo reverse</td><td>PCR conditions</td><td>Cycle number</td><td>GeneInfo identifier</td></tr><tr><td rowspan="2"><i>18S</i></td><td rowspan="2">CTACCACATCCAAGGAAGGCA</td><td rowspan="2">TTTTTCGTCACTACCTCCCCG</td><td>95&#176;C 15 sec</td><td rowspan="2">35</td><td rowspan="2">124517659</td></tr><tr><td>67&#176;C 30 sec</td></tr><tr><td rowspan="2"><i>ERK1</i></td><td rowspan="2">CTAAAGCCCTCCAACCTGCT</td><td rowspan="2">CAGCCCACAGACCAGATGT</td><td>95&#176;C 15 sec</td><td rowspan="2">45</td><td rowspan="2">158138506</td></tr><tr><td>60&#176;C 30 sec</td></tr><tr><td rowspan="2"><i>STAT3</i></td><td rowspan="2">AAAGTCAGGTTGCTGGTCAAA</td><td rowspan="2">TGCCGTTGTTGGATTCTTC</td><td>95&#176;C 15 sec</td><td rowspan="2">45</td><td rowspan="2">76253927</td></tr><tr><td>60&#176;C 30 sec</td></tr></table>
a515c61f7b365c22af02c47d37e6c920de5b4c61caf4beb09a10716cbbc4881e.png
complex
<table><tr><td>Region</td><td><i>x</i></td><td><i>y</i></td><td><i>z</i></td><td><i>t</i><sub>peak</sub></td><td colspan="2"><i>p</i><sub>corr</sub>(<i>p</i><sub>uncorr</sub>)</td></tr><tr><td colspan="7">TEMPORALLY STABLE EFFECTS: POST-REAL rTMS &gt; POST-SHAM rTMS</td></tr><tr><td colspan="7">Haptic S2&#8212;crossmodal: VHi</td></tr><tr><td colspan="7">No significant results</td></tr><tr><td colspan="7">Haptic S2&#8212;unimodal: HHi</td></tr><tr><td colspan="7">No significant results</td></tr><tr><td colspan="7">Visual S2&#8212;crossmodal: HVi</td></tr><tr><td colspan="7">No significant results</td></tr><tr><td colspan="6">Visual S2&#8212;unimodal: VVi</td><td>&gt;haptic S2</td></tr><tr><td>L FG</td><td>&#8722;33</td><td>&#8722;43</td><td>&#8722;26</td><td>2.70</td><td>0.051<sup>&#167;</sup></td><td>0.289<sup>&#167;</sup></td></tr><tr><td>L pIPS</td><td>&#8722;30</td><td>&#8722;64</td><td>55</td><td>2.91</td><td>0.034<sup>&#167;</sup></td><td>0.192<sup>&#167;</sup></td></tr><tr><td colspan="7">LINEAR TIME DEPENDENT EFFECTS: POST-REAL rTMS &gt; POST-SHAM rTMS</td></tr><tr><td colspan="6">Haptic S2&#8212;crossmodal: VHi &#215; time &gt; visual S2</td><td>&gt;visual S2</td></tr><tr><td>L parahippocampus / FG</td><td>&#8722;36</td><td>&#8722;16</td><td>&#8722;20</td><td>5.69</td><td>0.001</td><td>(&lt;0.001)</td></tr><tr><td>R middle frontal gyrus</td><td>39</td><td>&#8722;4</td><td>61</td><td>5.46</td><td>0.004</td><td>0.014</td></tr><tr><td>R superior frontal gyrus</td><td>27</td><td>5</td><td>64</td><td>5.13</td><td>0.013</td><td>(&lt;0.001)</td></tr><tr><td>R anterior parahippocampus</td><td>24</td><td>&#8722;1</td><td>&#8722;26</td><td>5.28</td><td>0.007</td><td></td></tr><tr><td>L pSTS/MTG</td><td>&#8722;48</td><td>&#8722;73</td><td>13</td><td>5.14</td><td>0.013</td><td>(&lt;0.001)</td></tr><tr><td>R pSTS/MTG</td><td>42</td><td>&#8722;70</td><td>10</td><td>4.66</td><td>(&lt;0.001)</td><td>(&lt;0.001)</td></tr><tr><td>R LO</td><td>48</td><td>&#8722;73</td><td>&#8722;2</td><td>3.56</td><td>0.006<sup>&#167;</sup></td><td>0.024<sup>&#167;</sup></td></tr><tr><td>L aIPS</td><td>&#8722;36</td><td>&#8722;37</td><td>37</td><td>3.55</td><td>0.006<sup>&#167;</sup></td><td>0.002<sup>&#167;</sup></td></tr><tr><td>L pIPS</td><td>&#8722;21</td><td>&#8722;67</td><td>49</td><td>3.65</td><td>0.005<sup>&#167;</sup></td><td>0.001<sup>&#167;</sup></td></tr><tr><td>R pIPS</td><td>27</td><td>&#8722;61</td><td>46</td><td>2.99</td><td>0.026<sup>&#167;</sup></td><td>0.017<sup>&#167;</sup></td></tr><tr><td colspan="7">Haptic S2&#8212;unimodal: HHi &#215; time</td></tr><tr><td colspan="7">No significant results</td></tr><tr><td colspan="7">Visual S2&#8212;crossmodal: VHi &#215; time</td></tr><tr><td colspan="7">No significant results</td></tr><tr><td colspan="7">Visual S2&#8212;unimodal: VVi &#215; time</td></tr><tr><td colspan="7">No significant results</td></tr></table>
cd5eb61306665787b5e325f6f43a1017fd3f4cbdbc7bb82ea63c6aad65229b61.png
simple
<table><tr><td>Probe</td><td><i>BRCA1/2</i>-N, median % (range)</td><td>Non-<i>BRCA</i>-related-N, median % (range)</td><td>Test statistic<sup>a</sup></td><td><i>p</i> Value</td></tr><tr><td>BRCA1.1</td><td>2 (0&#8211;3)</td><td>3 (0&#8211;5)</td><td>15.500</td><td>0.325</td></tr><tr><td>BRCA1.2</td><td>17 (13&#8211;26)</td><td>13 (13&#8211;17)</td><td>8.500</td><td>0.057</td></tr><tr><td>BRCA1.3</td><td>9 (6&#8211;16)</td><td>7 (5&#8211;8)</td><td>8.000</td><td>0.050</td></tr><tr><td>BRCA2.1</td><td>19 (15&#8211;26)</td><td>16 (14&#8211;19)</td><td>8.500</td><td>0.060</td></tr><tr><td>BRCA2.2</td><td>8 (6&#8211;16)</td><td>6 (5&#8211;12)</td><td>12.000</td><td>0.158</td></tr><tr><td>BRCA2.3</td><td>13 (10&#8211;28)</td><td>9 (8&#8211;14)</td><td>6.500</td><td>0.031*</td></tr><tr><td>BRCA2.4</td><td>8 (6&#8211;9)</td><td>5 (5&#8211;6)</td><td>2.000</td><td>0.005*</td></tr></table>
cd221d96c49d250f095afb9c91e31caccc7dd097745c06c4388c8a647868a527.png
complex
<table><tr><td></td><td colspan="2">Algorithm 1</td><td colspan="2">Algorithm 2</td><td colspan="2">Algorithm 3</td><td colspan="2">Algorithm 4</td></tr><tr><td>Descriptor elements count</td><td>avg.</td><td>std. dev.</td><td>avg.</td><td>std. dev.</td><td>avg.</td><td>std. dev.</td><td>avg.</td><td>std. dev.</td></tr><tr><td>3</td><td>4.3</td><td>0.5</td><td>7.8</td><td>0.5</td><td>9.4</td><td>0.5</td><td>5.3</td><td>0.5</td></tr><tr><td>4</td><td>5.3</td><td>0.6</td><td>8.9</td><td>0.7</td><td>15.1</td><td>0.9</td><td>7.0</td><td>1.3</td></tr><tr><td>5</td><td>5.1</td><td>0.8</td><td>8.0</td><td>1.8</td><td>20.5</td><td>4.9</td><td>13.3</td><td>11.2</td></tr><tr><td>6</td><td>5.9</td><td>0.9</td><td>12.4</td><td>2.3</td><td>39.5</td><td>6.1</td><td>42.2</td><td>48.6</td></tr><tr><td>7</td><td>6.1</td><td>0.9</td><td>14.0</td><td>2.5</td><td>61.5</td><td>6.8</td><td>97.0</td><td>124.6</td></tr><tr><td>8</td><td>6.2</td><td>0.9</td><td>14.8</td><td>2.8</td><td>91.1</td><td>7.5</td><td>448.8</td><td>372.2</td></tr><tr><td>9</td><td>6.0</td><td>1.1</td><td>16.5</td><td>3.5</td><td>109.8</td><td>7.6</td><td>2743.7</td><td>3362.4</td></tr><tr><td>10</td><td>5.9</td><td>1.1</td><td>16.2</td><td>4.0</td><td>121.8</td><td>9.7</td><td>12267.0</td><td>21504.2</td></tr><tr><td>11</td><td>6.6</td><td>1.3</td><td>28.5</td><td>7.4</td><td>140.6</td><td>8.3</td><td>256785.6</td><td>424309.9</td></tr></table>
097bb9a0cbb9963877b3f48d0e0c39cdab42338064b3334bb23da6104210450e.png
simple
<table><tr><td>Concentration (mg/mL)</td><td>The ratio of green and red fluorescence</td></tr><tr><td>Control</td><td>1.332 &#177; 0.045</td></tr><tr><td>0.005</td><td>1.420 &#177; 0.042<sup><i>&#8727;&#8727;</i></sup></td></tr><tr><td>0.025</td><td>1.088 &#177; 0.037<sup><i>&#8727;&#8727;</i></sup></td></tr><tr><td>0.1</td><td>0.801 &#177; 0.042<sup><i>&#8727;&#8727;</i></sup></td></tr><tr><td>Positive control</td><td>0.477 &#177; 0.033<sup><i>&#8727;&#8727;</i></sup></td></tr></table>
7fc4b476ff588581918c383afee8343c7cc20ff8fe1ee5034308831abed37d9f.png
simple
<table><tr><td>Clinical Variables</td><td>ET (<i>n</i> = 50)</td><td>ScT (<i>n</i> = 51)</td><td><i>p</i> Value *</td></tr><tr><td>Gestational age, wks, median (IQR)</td><td>28 (26&#8211;31)</td><td>26 (24&#8211;29)</td><td>0.05</td></tr><tr><td>Birth weight, g, median (IQR)</td><td>1060 (770&#8211;2000)</td><td>750 (580&#8211;1100)</td><td>0.003</td></tr><tr><td>&#8804;1000 g, <i>n</i> (%)</td><td>23 (46)</td><td>37 (72.5)</td><td>0.008</td></tr><tr><td>1001&#8211;1500 g, <i>n</i> (%)</td><td>11 (22)</td><td>5 (5.8)</td><td>0.11</td></tr><tr><td>&gt;1500 g, <i>n</i> (%)</td><td>16 (32)</td><td>9 (17.6)</td><td>0.11</td></tr><tr><td>SGA, <i>n</i> (%)</td><td>5 (10)</td><td>13 (25.5)</td><td>0.07</td></tr><tr><td>Inborn, <i>n</i> (%)</td><td>44 (88)</td><td>44 (86.3)</td><td>1</td></tr><tr><td>Twin, <i>n</i> (%)</td><td>14 (28)</td><td>11 (21.6)</td><td>0.49</td></tr><tr><td>Male, <i>n</i> (%)</td><td>31 (62)</td><td>33 (64.7)</td><td>0.83</td></tr><tr><td>Apgar 1 min, median (IQR)</td><td>5 (2&#8211;7)</td><td>5 (2&#8211;6)</td><td>0.43</td></tr><tr><td>Apgar 5 min, median (IQR)</td><td>8 (7&#8211;8)</td><td>7 (7&#8211;8)</td><td>0.66</td></tr><tr><td>Resuscitation in delivery room, <i>n</i> (%) <sup>1</sup></td><td>42 (84)</td><td>45 (88.2)</td><td>0.57</td></tr><tr><td>Early-onset sepsis, <i>n</i> (%)</td><td>27</td><td>14</td><td>0.008</td></tr><tr><td>Late-onset sepsis, <i>n</i> (%)</td><td>23</td><td>37</td><td>0.008</td></tr><tr><td>Age at sepsis evaluation, d, median (IQR)</td><td>2 (0&#8211;11)</td><td>9 (3&#8211;22)</td><td>0.003</td></tr><tr><td>Weight at sepsis evaluation, g, median (IQR)</td><td>1212.5 (820&#8211;1960)</td><td>880 (600&#8211;1610)</td><td>0.05</td></tr><tr><td>Time between sepsis and septic shock, h, median (IQR)</td><td>4.5 (3&#8211;10)</td><td>13 (5&#8211;29)</td><td>0.001</td></tr><tr><td>Time between septic shock and ET, h, median (IQR)</td><td>7 (4&#8211;18)</td><td>NA</td><td>NA</td></tr></table>
a4a9d1f92e39e0d94e656baf074c1c6ce8b707873e058b549ff47eb5ac168acc.png
simple
<table><tr><td>Sample</td><td>Metal organic line pressure (Torr)</td><td>Nanowire diameter (nm)</td><td>Gate-to-nanowire distance (nm)</td><td>Gate length (nm)</td><td>Source-to-drain distance (nm)</td></tr><tr><td>a</td><td>0</td><td>29</td><td>120</td><td>750</td><td>1,200</td></tr><tr><td>b</td><td>0.05</td><td>33</td><td>140</td><td>700</td><td>1,200</td></tr><tr><td>c</td><td>0.1</td><td>39</td><td>140</td><td>750</td><td>1,250</td></tr><tr><td>d</td><td>0.2</td><td>40</td><td>160</td><td>870</td><td>1,400</td></tr><tr><td>e</td><td>0.4</td><td>80</td><td>140</td><td>1,700</td><td>2,500</td></tr></table>
fd54d563641d3da177efc0a568a4ecdfe965fa1d2838df45c297879e7b304ca1.png
simple
<table><tr><td>Gene<sup>a</sup></td><td>Reference (PubMedID)</td><td>Affected in</td><td>Peak length (bp)</td><td>Peak to transcription start site (bp)</td><td>Promoter class</td></tr><tr><td><i>Nos1</i></td><td>20645313</td><td>Hippocampus</td><td>334</td><td>-3,719</td><td>LCP</td></tr><tr><td><i>Map6</i></td><td>16624526</td><td>Hippocampus</td><td>169</td><td>-2,382</td><td>ICP</td></tr><tr><td><i>Drd5</i></td><td>11304828</td><td>Hippocampus</td><td>844</td><td>41</td><td>HCP</td></tr><tr><td><i>Cacna1c</i></td><td>23183239</td><td>Hippocampus</td><td>425</td><td>-3,692</td><td>LCP</td></tr><tr><td><i>Bdnf</i></td><td>16818862</td><td>Hippocampus</td><td>329</td><td>-492</td><td>ICP</td></tr><tr><td><i>Gsksb</i></td><td>18500637</td><td>Hippocampus</td><td>573</td><td>-1,042</td><td>HCP</td></tr><tr><td><i>Tf</i></td><td>18045615</td><td>Hippocampus</td><td>159</td><td>-3,020</td><td>LCP</td></tr><tr><td><i>Cnp</i></td><td>16389193</td><td>Hippocampus</td><td>464</td><td>1,198</td><td>HCP</td></tr><tr><td><i>Amacr</i></td><td>20875727</td><td>Hippocampus</td><td>558</td><td>164</td><td>HCP</td></tr><tr><td><i>Psen2</i></td><td>19232479</td><td>Hippocampus</td><td>249</td><td>620</td><td>LCP</td></tr><tr><td><i>Pax6</i></td><td>10376119</td><td>Hippocampus</td><td>341</td><td>326</td><td>ICP</td></tr><tr><td><i>Dlx1</i></td><td>18384059</td><td>Hippocampus</td><td>431</td><td>-2,043</td><td>HCP</td></tr><tr><td><i>Dlx1</i></td><td>18384059</td><td>Cerebellum</td><td>1,330</td><td>257</td><td>HCP</td></tr><tr><td><i>Cnp</i></td><td>16389193</td><td>Cerebellum</td><td>769</td><td>940</td><td>HCP</td></tr><tr><td><i>Psen2</i></td><td>19232479</td><td>Cerebellum</td><td>455</td><td>442</td><td>LCP</td></tr><tr><td><i>Pax6</i></td><td>10376119</td><td>Cerebellum</td><td>349</td><td>-3,481</td><td>ICP</td></tr><tr><td><i>Stx1a</i></td><td>15219469</td><td>Cerebellum</td><td>149</td><td>72</td><td>HCP</td></tr><tr><td><i>Drd5</i></td><td>11304828</td><td>Cerebellum</td><td>264</td><td>-169</td><td>HCP</td></tr><tr><td><i>Mmp9</i></td><td>20037727</td><td>Cerebellum</td><td>138</td><td>-325</td><td>LCP</td></tr><tr><td><i>Tnf</i></td><td>11244489</td><td>Cerebellum</td><td>269</td><td>49</td><td>LCP</td></tr><tr><td><i>Grin1</i></td><td>12679240</td><td>Cerebellum</td><td>264</td><td>-1,595</td><td>HCP</td></tr><tr><td><i>Tf</i></td><td>18045615</td><td>Cerebellum</td><td>749</td><td>-1,704</td><td>LCP</td></tr><tr><td><i>Dlg4</i></td><td>21151988</td><td>Cerebellum</td><td>134</td><td>-1,459</td><td>LCP</td></tr><tr><td><i>Amacr</i></td><td>20875727</td><td>Cerebellum</td><td>138</td><td>-48</td><td>HCP</td></tr><tr><td><i>Dao</i></td><td>19685198</td><td>Cerebellum</td><td>287</td><td>-2,385</td><td>LCP</td></tr><tr><td><i>Dlx1</i></td><td>18384059</td><td>Liver</td><td>171</td><td>-2,993</td><td>HCP</td></tr><tr><td><i>Cnp</i></td><td>16389193</td><td>Liver</td><td>644</td><td>-2,644</td><td>HCP</td></tr><tr><td><i>Sod2</i></td><td>15193990</td><td>Liver</td><td>550</td><td>594</td><td>HCP</td></tr><tr><td><i>Drd5</i></td><td>11304828</td><td>Liver</td><td>369</td><td>-316</td><td>HCP</td></tr><tr><td><i>Il6</i></td><td>20393813</td><td>Liver</td><td>789</td><td>-3,030</td><td>LCP</td></tr><tr><td><i>Comt</i></td><td>11381111</td><td>Liver</td><td>638</td><td>-3,542</td><td>HCP</td></tr><tr><td><i>Apoe</i></td><td>14674716</td><td>Liver</td><td>2,158</td><td>-1,223</td><td>LCP</td></tr><tr><td><i>Drd2</i></td><td>18829695</td><td>Liver</td><td>257</td><td>-91</td><td>HCP</td></tr><tr><td><i>Nos1</i></td><td>20645313</td><td>Liver</td><td>348</td><td>172</td><td>LCP</td></tr><tr><td><i>Drd1</i></td><td>20127886</td><td>Liver</td><td>540</td><td>739</td><td>LCP</td></tr></table>
204608a02aa961c5ec5fba9c31e5202cea4b178332377516954e5ee6f1c1d193.png
complex
<table><tr><td>Mentorship demographics</td><td colspan="4">No. (%)</td></tr><tr><td></td><td colspan="4">(N=389 with mentor)</td></tr><tr><td></td><td>Male</td><td>Female</td><td>p</td><td>Fisher Exact Test</td></tr><tr><td>Department of mentor</td><td></td><td></td><td></td><td></td></tr><tr><td>Same department</td><td>255 (91.1)</td><td>95 (91.3)</td><td>0.93</td><td>1.0</td></tr><tr><td>Another department</td><td>25 (8.9)</td><td>9 (8.7)</td><td></td><td></td></tr><tr><td>Position of mentor</td><td></td><td></td><td></td><td></td></tr><tr><td>Dept. Chair / Professor</td><td>67 (23.9)</td><td>22 (21.4)</td><td>0.62</td><td>0.66</td></tr><tr><td>Associate Prof.</td><td>59 (21.1)</td><td>27 (26.2)</td><td></td><td></td></tr><tr><td>Lecturer</td><td>58 (20.7)</td><td>19 (18.4)</td><td></td><td></td></tr><tr><td>Assistant Prof.</td><td>80 (28.6)</td><td>32 (31.1)</td><td></td><td></td></tr><tr><td>Other</td><td>16 (5.7)</td><td>3 (2.9)</td><td></td><td></td></tr><tr><td>Mentor assignment initiated by</td><td></td><td></td><td></td><td></td></tr><tr><td>Mentor</td><td>242 (87.7)</td><td>84 (88.4)</td><td>&lt;0.01</td><td>0.01</td></tr><tr><td>Mentee</td><td>34 (12.3)</td><td>11 (11.6)</td><td></td><td></td></tr><tr><td>Other</td><td>4 (1.4)</td><td>8 (7.8)</td><td></td><td></td></tr><tr><td>Mentoring Meeting Frequency</td><td></td><td></td><td></td><td></td></tr><tr><td>Every month or more</td><td>213 (76.1)</td><td>83 (79.8)</td><td>0.44</td><td>0.50</td></tr><tr><td>Other (combining all other categories)</td><td>67 (23.9)</td><td>21 (20.2)</td><td></td><td></td></tr><tr><td>Satisfaction with Mentoring</td><td></td><td></td><td></td><td></td></tr><tr><td>Very satisfied/ A little satisfied</td><td>212 (75.7)</td><td>75 (72.8)</td><td>0.56</td><td>0.60</td></tr><tr><td>Not Satisfied\Neutral</td><td>68 (24.3)</td><td>28 (27.2)</td><td></td><td></td></tr></table>
a546058032b159423d80e40f4e12d363e193cebf641447eb07cf668086caf1ef.png
complex
<table><tr><td>Characteristics</td><td> </td><td> </td></tr><tr><td>Body mass index </td><td>&gt;30 Kg/m<sup>2</sup></td><td>10 (8.4%)</td></tr><tr><td rowspan="3">Onset of labour</td><td>Spontaneous</td><td>87 (73.1%)</td></tr><tr><td>Induced</td><td>21 (17.6%)</td></tr><tr><td>Augmented</td><td>11 (9.2%)</td></tr><tr><td rowspan="3">Use of oxytocin</td><td>None</td><td>44 (37.0%)</td></tr><tr><td>Yes</td><td>75 (63.0%)</td></tr><tr><td colspan="2">&lt;4 cm = 19, 4&#8211;7 cm = 30, 8&#8211;10 cm = 26</td></tr><tr><td rowspan="4">Position of fetal head</td><td>Right/left/direct occipitoanterior</td><td>34 (28.5%)</td></tr><tr><td>Right//left/direct occipitoposterior</td><td>40 (33.6%)</td></tr><tr><td>Occipitotransverse</td><td>43 (36.1%)</td></tr><tr><td>Others</td><td>2 (1.8%)</td></tr><tr><td rowspan="5">Station of the fetal head (distance of the leading bony point of fetal skull below the ischial spines, measured in centimeters)</td><td>Above &#8722;1</td><td>1</td></tr><tr><td>&#8722;1</td><td>2</td></tr><tr><td>0</td><td>68</td></tr><tr><td>+1</td><td>48</td></tr><tr><td>+2</td><td>2</td></tr><tr><td>Fetal size</td><td colspan="2">Mean 3588 g (2365 g&#8211;4840 g)</td></tr><tr><td rowspan="3">Operator experience </td><td>Trainee &lt;5 years</td><td>13 (10.9%)</td></tr><tr><td>Trainee 6-7 years</td><td>82 (68.9%)</td></tr><tr><td>Consultant (&gt;8 years)</td><td>24 (20.2%)</td></tr><tr><td rowspan="3">Time of decision to perform operative vaginal birth </td><td>0800&#8211;1700</td><td>36 (30.3%)</td></tr><tr><td>1701&#8211;2000</td><td>11 (9.2%)</td></tr><tr><td>2001&#8211;0759</td><td>72 (60.5%)</td></tr><tr><td rowspan="3">Length of second stage of labour (in cases where the indication was &#8220;failure to progress&#8221;)</td><td>&lt;3 hr</td><td>5.2%</td></tr><tr><td>3.01&#8211;&#8804;4 hr</td><td>14.4%</td></tr><tr><td>&#8805;4.01 hr</td><td>80.4%</td></tr></table>
f2aebe171bdeaa9ea66ae9318c769a2b5303365da4cd29053aa4fe03e0894a10.png
simple
<table><tr><td>Variables</td><td>NSCLC patients</td><td>Disease controls</td><td>Healthy controls</td><td><i>P</i> value</td></tr><tr><td>Number of subjects</td><td>188</td><td>112</td><td>130</td><td> </td></tr><tr><td>Age (years)</td><td>45.2 &#177; 12.3</td><td>47.1 &#177; 11.4</td><td>47.9 &#177; 13.2</td><td>&gt;0.05</td></tr><tr><td>Sex (M/F)</td><td>118/70</td><td>61/51</td><td>72/58</td><td>&gt;0.05</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>25.3 &#177; 2.7</td><td>26.1 &#177; 3.0</td><td>25.5 &#177; 2.7</td><td>&gt;0.05</td></tr><tr><td>Smoking subjects (M/F)</td><td>94/17</td><td>45/15</td><td>60/17</td><td>&gt;0.05</td></tr><tr><td>SBP (mmHg)</td><td>130 &#177; 15</td><td>132 &#177; 14</td><td>133 &#177; 12</td><td>&gt;0.05</td></tr><tr><td>DBP (mmHg)</td><td>82 &#177; 10</td><td>80 &#177; 11</td><td>79 &#177; 12</td><td>&gt;0.05</td></tr><tr><td>Glu (mmol/L)</td><td>5.12 &#177; 1.55</td><td>5.30 &#177; 1.69</td><td>5.25 &#177; 1.77</td><td>&gt;0.05</td></tr><tr><td>WBC (10<sup>9</sup>/L)</td><td>6.17 &#177; 2.22</td><td>5.74 &#177; 3.01</td><td>5.42 &#177; 2.15</td><td>&gt;0.05</td></tr><tr><td>PLT (10<sup>9</sup>/L)</td><td>190.1 &#177; 21.5</td><td>199.3 &#177; 18.0</td><td>210.1 &#177; 20.1</td><td>&gt;0.05</td></tr><tr><td>CRP (mg/L)</td><td>5.5 (0.5&#8211;19.5)<sup>&#9651;</sup></td><td>4.5 (0.5&#8211;14.6)<sup>&#9651;</sup></td><td>2.4 (0.5&#8211;7.6)</td><td>&lt;0.05</td></tr><tr><td>PT (seconds)</td><td>11.0 &#177; 3.1</td><td>11.6 &#177; 2.6</td><td>11.7 &#177; 2.2</td><td>&gt;0.05</td></tr><tr><td>aPTT (seconds)</td><td>24.1 &#177; 5.0</td><td>25.8 &#177; 3.9</td><td>26.0 &#177; 3.8</td><td>&gt;0.05</td></tr><tr><td>Fbg (g/L)</td><td>3.35 &#177; 1.20<sup><i>&#8727;</i></sup></td><td>2.68 &#177; 1.30</td><td>2.54 &#177; 2.01</td><td>&lt;0.01</td></tr><tr><td>D-D (mg/L)</td><td>0.65 &#177; 0.14<sup><i>&#8727;</i></sup></td><td>0.42 &#177; 0.10</td><td>0.26 &#177; 0.04</td><td>&lt;0.01</td></tr><tr><td>FVIII:C (%)</td><td>107.5 &#177; 12.3<sup><i>&#8727;</i></sup></td><td>95.1 &#177; 11.2</td><td>91.2 &#177; 13.0</td><td>&lt;0.05</td></tr><tr><td>AT (%)</td><td>77.0 &#177; 10.1<sup><i>&#8727;</i></sup></td><td>92.4 &#177; 10.8</td><td>98.5 &#177; 13.1</td><td>&lt;0.01</td></tr><tr><td>TFPI-1 (ng/ml)</td><td>51.0 &#177; 8.6<sup><i>&#8727;</i></sup></td><td>79.2 &#177; 13.2</td><td>87.1 &#177; 15.9</td><td>&lt;0.01</td></tr></table>
6dab946a87ae9540e219145581e1a143457747e54ec8a54a150d5ce639b4f683.png
complex
<table><tr><td>N</td><td>Complications</td><td>Additional comments</td><td>Surgical procedure</td></tr><tr><td rowspan="5">5</td><td rowspan="5">Equipment failure</td><td>Loose halter</td><td>Exploratory laparotomy</td></tr><tr><td>Tail hair broke</td><td>Sarcoid removal</td></tr><tr><td>Tail hair broke</td><td>Tooth extraction</td></tr><tr><td>Tail rope slipped off</td><td>Castration</td></tr><tr><td>Facial paralysis</td><td>Wound closure</td></tr><tr><td rowspan="4">4</td><td rowspan="4">Poor quality</td><td>Fell down after standing</td><td>Arthroscopy</td></tr><tr><td>Several attempts to stand</td><td>Arthroscopy</td></tr><tr><td>Lost shoe and broke hoof wall</td><td>Sarcoid removal</td></tr><tr><td>None</td><td>Arthroscopy</td></tr><tr><td rowspan="3">3</td><td rowspan="3">Long recovery</td><td>None</td><td>Tumour removal</td></tr><tr><td>None</td><td>Exploratory laparotomy</td></tr><tr><td>Cardiac arrest. Resuscitated</td><td>Arthroscopy</td></tr><tr><td rowspan="2">2</td><td rowspan="2">Excitation</td><td>Respiratory problem</td><td>Neurectomy</td></tr><tr><td>Wound to coronary band.</td><td>Desmotomy/Neurectomy</td></tr><tr><td rowspan="2">2</td><td rowspan="2">Myopathy</td><td>None</td><td>Exploratory laparotomy</td></tr><tr><td>None</td><td>Metatarsal fracture repair</td></tr><tr><td>1</td><td>Restless</td><td>Dog&#8211;sitting position</td><td>Eye surgery</td></tr><tr><td>1</td><td>Hindlimb Weakness</td><td>None</td><td>Mandibular fracture</td></tr></table>
9d097b09f106a11764102ffe9f6f2d7831fe92b9cd0c95581b4f2ab29f7015c8.png
complex
<table><tr><td>Variables</td><td colspan="3">SCA2 patients</td><td colspan="3">Preclinical carriers</td><td colspan="3">Healthy controls</td></tr><tr><td></td><td>ICC</td><td>p</td><td>H</td><td>ICC</td><td>p</td><td>H</td><td>ICC</td><td>p</td><td>H</td></tr><tr><td>Saccade velocity (&#176;/s)</td><td>0.47</td><td>0.002</td><td>~94%</td><td>0.19</td><td>0.222</td><td><i>NA</i></td><td>0.136</td><td>0.289</td><td><i>NA</i></td></tr><tr><td>Saccade accuracy (%)</td><td>0.16</td><td>0.170</td><td><i>NA</i></td><td>0.20</td><td>0.208</td><td><i>NA</i></td><td>0.013</td><td>0.473</td><td><i>NA</i></td></tr><tr><td>Saccade latency (ms)</td><td>0.16</td><td>0.170</td><td><i>NA</i></td><td>0.13</td><td>0.294</td><td><i>NA</i></td><td>0.286</td><td>0.121</td><td><i>NA</i></td></tr></table>
e8188beff0ebb1b6a0211777ddcfbf3ccdd38da6a1a4b3c0e0e790a9ede33dad.png
simple
<table><tr><td>Gene identifier</td><td>Gene label</td><td>Description</td><td>Protein identifier</td></tr><tr><td>http://bio2rdf.org/sgd:S000004688</td><td>YMR083W</td><td>Mitochondrial alcohol dehydrogenase isozyme III</td><td>http://bio2rdf.org/sgd:S000004688gp</td></tr><tr><td>http://bio2rdf.org/sgd:S000000349</td><td>YBR145W</td><td>Alcohol dehydrogenase isoenzyme V</td><td>http://bio2rdf.org/sgd:S000000349gp</td></tr><tr><td>http://bio2rdf.org/sgd:S000002624</td><td>YDR216W</td><td>Carbon source-responsive zinc-finger transcription factor</td><td>http://bio2rdf.org/sgd:S000002624gp</td></tr><tr><td>http://bio2rdf.org/sgd:S000000819</td><td>YER017C</td><td>Component of the mitochondrial inner membrane m-AAA protease</td><td>http://bio2rdf.org/sgd:S000000819gp</td></tr><tr><td>http://bio2rdf.org/sgd:S000001306</td><td>YIL044C</td><td>ADP-ribosylation factor (ARF) GTPase activating protein (GAP) effector</td><td>http://bio2rdf.org/sgd:S000001306gp</td></tr></table>
339c4de5599f1f38977b927aea20f2a11ee104a6da039442b6195bbd1b27f67d.png
simple
<table><tr><td>Histotype<sup>a</sup></td><td>Cell line<sup>b</sup></td><td>IC50 &#956;M (&#177; SE)<sup>c,f</sup></td><td>Genetic alteration<sup>d</sup></td><td>Doubling time (hours)<sup>e,f</sup></td></tr><tr><td>RHABDOMYOSARCOMA</td><td>RD/18</td><td>6.8 (&#177; 2.1)</td><td>Altered 11p15.5 chromosome</td><td>22 &#177; 0.1</td></tr><tr><td> </td><td>SJ-RH4</td><td>5.6 (&#177; 1.3)</td><td>(2;13)(q35;q14) PAX3 FKHR</td><td>25 &#177; 1.2</td></tr><tr><td> </td><td>SJ-RH30</td><td>9.9 (&#177; 2.7)</td><td>(2;13)(q35;q14) PAX3 FKHR</td><td>26 &#177; 1.0</td></tr><tr><td>OSTEOSARCOMA</td><td>IOR/OS10</td><td>5.5 (&#177; 1.3)</td><td>Complex Karyotype</td><td>30.4 &#177; 2.6</td></tr><tr><td> </td><td>IOR/OS9</td><td>8.6 (&#177; 1.8)</td><td>Complex Karyotype</td><td>44.5 &#177; 2.4</td></tr><tr><td> </td><td>Saos-2</td><td>11.9 (&#177; 3.1)</td><td>Complex Karyotype</td><td>36.1 &#177; 4.4</td></tr><tr><td> </td><td>Saos-2/DX<sup>580</sup></td><td>39.3 (&#177; 2.6)</td><td>Complex Karyotype</td><td>75.6 &#177; 5.7</td></tr><tr><td> </td><td>Saos-2/CDDP6ug</td><td>43.3 (&#177; 6.8)</td><td>Complex Karyotype</td><td>44.3 &#177; 4.1</td></tr><tr><td> </td><td>U-2OS</td><td>12.5 (&#177; 0.7)</td><td>Complex Karyotype</td><td>18.3 &#177; 0.2</td></tr><tr><td> </td><td>U-2OS/DX<sup>580</sup></td><td>16.5 (&#177; 0.4)</td><td>Complex Karyotype</td><td>45.3 &#177; 4.7</td></tr><tr><td> </td><td>U-2OS/CDDP4ug</td><td>56.1 (&#177; 1.4)</td><td>Complex Karyotype</td><td>38.6 &#177; 4.1</td></tr><tr><td>EWING SARCOMA</td><td>6647</td><td>3.1 (&#177; 1.4)</td><td>t(11;22)(q24;q12) EWSR1-FLI1 TYPE II</td><td>29 &#177; 2.3</td></tr><tr><td> </td><td>LAP-35</td><td>11.6 (&#177; 0.7)</td><td>t(11;22)(q24;q12) EWSR1-FLI1 TYPE II</td><td>48.6 &#177; 4.2</td></tr><tr><td> </td><td>SK-N-MC</td><td>3.9 (&#177; 0.5)</td><td>t(11;22)(q24;q12) EWSR1-FLI1 TYPE I</td><td>26.9 &#177; 0.5</td></tr><tr><td> </td><td>TC-71</td><td>2.6 (&#177; 1.4)</td><td>t(11;22)(q24;q12) EWSR1-FLI1 TYPE I</td><td>14.9 &#177; 1.4</td></tr><tr><td> </td><td>TC/DOXO8</td><td>5.0 (&#177; 0.1)</td><td>t(11;22)(q24;q12) EWSR1-FLI1 TYPE I</td><td>22.6 &#177; 2.8</td></tr><tr><td>h-MSC</td><td>MES1</td><td>&gt;50</td><td><i>n.d.</i></td><td><i>n.d.</i></td></tr><tr><td> </td><td>MES2</td><td>&gt;50</td><td><i>n.d.</i></td><td><i>n.d.</i></td></tr><tr><td> </td><td>DP-15</td><td>&gt;50</td><td><i>n.d.</i></td><td><i>n.d.</i></td></tr></table>
5bfc00664706295c33fcc43dbec58ca110e3ce1a4cf7188f540481b5ce534c0a.png
complex
<table><tr><td>Spice</td><td>Number of portion sizes</td><td colspan="3">Level of intake (% of portion sizes)</td></tr><tr><td></td><td></td><td>&lt;1.0</td><td>1.0-5.0</td><td>&gt;5.0</td></tr><tr><td>R. chillies</td><td>364</td><td>15.1</td><td>69.5</td><td>15.4</td></tr><tr><td>Turmeric</td><td>351</td><td>78.3</td><td>21.7</td><td>-</td></tr><tr><td>Cumin</td><td>198</td><td>39.4</td><td>54.5</td><td>6.1</td></tr><tr><td>Coriander</td><td>97</td><td>57.7</td><td>35</td><td>7.2</td></tr><tr><td>Mustard</td><td>121</td><td>61.1</td><td>38.8</td><td>-</td></tr><tr><td>Cloves</td><td>122</td><td>92.6</td><td>7.4</td><td>-</td></tr><tr><td>Cardamom</td><td>170</td><td>93</td><td>7</td><td>-</td></tr><tr><td>Cinnamon</td><td>118</td><td>75.4</td><td>24.6</td><td>-</td></tr><tr><td>Caraway</td><td>109</td><td>63.3</td><td>36.7</td><td>-</td></tr><tr><td>B. pepper</td><td>108</td><td>67.6</td><td>32.4</td><td>-</td></tr><tr><td>Nutmeg</td><td>30</td><td>100</td><td>-</td><td>-</td></tr><tr><td>Mace</td><td>23</td><td>100</td><td>-</td><td>-</td></tr><tr><td>Fenugreek</td><td>31</td><td>71</td><td>29</td><td>-</td></tr><tr><td>Asafoetida</td><td>41</td><td>78</td><td>22</td><td>-</td></tr><tr><td>Carom</td><td>25</td><td>76</td><td>24</td><td>-</td></tr></table>
ad6a721e4da70017530a9e34c2965bc3d458b0e225dafdda1a019be57d60b600.png
simple
<table><tr><td>Country</td><td>Paliperidone (maximum), %</td></tr><tr><td>Austria</td><td>0.04</td></tr><tr><td>Belgium</td><td>4.8</td></tr><tr><td>Bury PCT</td><td>0.07</td></tr><tr><td>Ireland (GMS population)</td><td>1.01</td></tr><tr><td>Scotland</td><td>0.03</td></tr><tr><td>Spain (Catalonia)</td><td>3.99</td></tr><tr><td>Sweden</td><td>1.5</td></tr></table>
ad077e944280c01bc17bb5d02dc7f54fcd715561be8c653225974fa2405fbffe.png
complex
<table><tr><td rowspan="2">Walking Speed (Steps/min)</td><td rowspan="2">Actual ZVI Number</td><td colspan="2">Detected ZVI Number</td></tr><tr><td>Fixed Threshold Method</td><td>Adaptive ZVI Detection Algorithm</td></tr><tr><td>80</td><td>100</td><td>102</td><td>100</td></tr><tr><td>100</td><td>100</td><td>100</td><td>100</td></tr><tr><td>120</td><td>100</td><td>94</td><td>100</td></tr></table>
b2c1aa5b812d6d0bd1f5a3d18aa7b1b80caa8b55ba4c986435305af4cea69745.png
simple
<table><tr><td></td><td>Total Epidemic Size</td><td>Days to Epidemic Season Peak</td><td>Length of Epidemic Season</td></tr><tr><td>Regression Intercept (S.E.)</td><td>321.0 (417)</td><td>87.5 (13.5)</td><td>192.3 (24.0)</td></tr><tr><td>Regression Slope (S.E.)</td><td>15383 (7175)</td><td>-255.3 (233)</td><td>-659 (413)</td></tr><tr><td>Regression Model p-value</td><td>0.08</td><td>0.32</td><td>0.17</td></tr><tr><td>R<sup>2</sup></td><td>0.48</td><td>0.19</td><td>0.20</td></tr><tr><td>Root Mean Square Error</td><td>17.6</td><td>3.2</td><td>4.2</td></tr><tr><td>Mean of Absolute % Error</td><td>16</td><td>11</td><td>8</td></tr></table>
a3d40bdcd29dd577e60702370809929a125889797a88427bff89817f4f839b9a.png
complex
<table><tr><td> </td><td colspan="3">Men (n = 10,235)</td><td colspan="3">Women (n = 12,234)</td></tr><tr><td> </td><td>Deaths</td><td>Univariate</td><td>Multivariable<sup>b</sup></td><td>Deaths</td><td>Univariate</td><td>Multivariable<sup>b</sup></td></tr><tr><td>Smoking category</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Never smokers</td><td>209</td><td>1.00</td><td>1.00</td><td>273</td><td>1.00</td><td>1.00</td></tr><tr><td>Long-term quitters</td><td>313</td><td>1.29 (1.09, 1.54)</td><td>1.21 (1.01, 1.44)</td><td>84</td><td>1.01 (0.79, 1.29)</td><td>1.03 (0.80, 1.32)</td></tr><tr><td>Short-term quitters</td><td>118</td><td>2.13 (1.70, 2.68)</td><td>1.87 (1.49, 2.35)</td><td>33</td><td>1.10 (0.77, 1.58)</td><td>1.14 (0.79, 1.64)</td></tr><tr><td>Light smokers</td><td>71</td><td>2.26 (1.73, 2.96)</td><td>2.02 (1.54, 2.65)</td><td>66</td><td>1.93 (1.47, 2.53)</td><td>2.00 (1.52, 2.63)</td></tr><tr><td>Heavy smokers</td><td>329</td><td>4.20 (3.53, 5.00)</td><td>3.49 (2.90, 4.18)</td><td>103</td><td>2.82 (2.23, 3.55)</td><td>2.75 (2.16, 3.48)</td></tr><tr><td>Body weight status</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Optimal BMI</td><td>164</td><td>1.00</td><td>1.00</td><td>114</td><td>1.00</td><td>1.00</td></tr><tr><td>Low BMI</td><td>90</td><td>1.78 (1.37, 2.30)</td><td>1.61 (1.23, 2.07)</td><td>127</td><td>1.38 (1.07, 1.78)</td><td>1.34 (1.04, 1.73)</td></tr><tr><td>Overweight</td><td>535</td><td>1.28 (1.08, 1.53)</td><td>1.16 (0.97, 1.38)</td><td>185</td><td>1.10 (0.87, 1.39)</td><td>1.08 (0.85, 1.37)</td></tr><tr><td>Obesity</td><td>251</td><td>1.83 (1.50, 2.22)</td><td>1.51 (1.23, 1.86)</td><td>133</td><td>1.56 (1.21, 2.00)</td><td>1.55 (1.19, 2.02)</td></tr><tr><td>Alcoholic drinks/day</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>&#8804;2 (men)/ &#8804;0.5 (women)</td><td>494</td><td>1.00</td><td>1.00</td><td>343</td><td>1.00</td><td>1.00</td></tr><tr><td>2.1 to 4 (men)/ 0.6 to 1 (women)</td><td>299</td><td>1.36 (1.18, 1.57)</td><td>1.24 (1.07, 1.44)</td><td>101</td><td>0.87 (0.70, 1.09)</td><td>0.86 (0.69, 1.08)</td></tr><tr><td>&gt;4 (men)/ &gt;1 (women)</td><td>247</td><td>2.07 (1.78, 2.42)</td><td>1.50 (1.28, 1.75)</td><td>115</td><td>1.24 (1.00, 1.53)</td><td>1.15 (0.92, 1.44)</td></tr><tr><td>Leisure time physical activity</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Low versus high</td><td>555/485</td><td>1.11 (0.98, 1.26)</td><td>1.05 (0.93, 1.19)</td><td>310/249</td><td>1.24 (1.05, 1.46)</td><td>1.16 (0.98, 1.37)</td></tr><tr><td>Processed/red meat consumption</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>High versus low</td><td>393/647</td><td>1.43 (1.26, 1.62)</td><td>1.21 (1.06, 1.38)</td><td>72/487</td><td>1.54 (1.20, 1.97)</td><td>1.40 (1.08, 1.80)</td></tr><tr><td>Vegetable/fruit consumption</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Low versus high</td><td>578/462</td><td>1.32 (1.16, 1.49)</td><td>1.19 (1.05, 1.35)</td><td>222/337</td><td>1.19 (1.01, 1.41)</td><td>1.11 (0.93, 1.32)</td></tr><tr><td>Cereal consumption</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Low versus high</td><td>596/444</td><td>1.19 (1.06, 1.35)</td><td>1.08 (0.96, 1.23)</td><td>407/152</td><td>1.10 (0.91, 1.33)</td><td>1.04 (0.86, 1.26)</td></tr><tr><td>Fish consumption</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Low versus high</td><td>427/613</td><td>1.11 (0.98, 1.26)</td><td>1.04 (0.91, 1.18)</td><td>296/263</td><td>1.20 (1.02, 1.42)</td><td>1.17 (0.99, 1.39)</td></tr><tr><td>Dairy product consumption</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>High versus low</td><td>407/633</td><td>0.92 (0.81, 1.05)</td><td>1.07 (0.95, 1.22)</td><td>277/282</td><td>0.95 (0.81, 1.12)</td><td>1.02 (0.86, 1.21)</td></tr></table>
cae010986e25fd7070e549200c102951c8a71259d766e8ea78f09f41fb4ee1a5.png
complex
<table><tr><td></td><td>Early phase</td><td>Middle phase</td><td>Late phase</td><td>Total</td></tr><tr><td colspan="5">CORRECT RESPONSES</td></tr><tr><td>Literal compliment</td><td>2022.88 (464.33)</td><td>553.59 (146.04)</td><td>754.90 (148.53)</td><td>3226.34 (858.03)</td></tr><tr><td>Literal criticism</td><td>2771.90 (737.72)</td><td>607.19 (165.84)</td><td>975.49 (658.10)</td><td>3879.39 (1050.40)</td></tr><tr><td>Ironic criticism</td><td>2788.04 (1168.27)</td><td>516.56 (126.70)</td><td>809.08 (212.46)</td><td>4113.68 (1389.53)</td></tr><tr><td colspan="5">INCORRECT RESPONSES</td></tr><tr><td>Ironic criticism</td><td>2905.82 (1894.20)</td><td>537.87 (129.48)</td><td>932.28 (378.45)</td><td>4375.97 (2175.79)</td></tr></table>
d915794865c3cded72fdb49e233a57cda2ed3820429f09f7b400d829839d2065.png
simple
<table><tr><td></td><td>Mean</td><td>Median</td><td>Min</td><td>Max</td><td>Range<sup>*1</sup></td><td>SD<sup>*2</sup></td></tr><tr><td>Referral rate of participating GPs</td><td>0.68</td><td>0.65</td><td>0.53</td><td>0.88</td><td>0.35</td><td>0.11</td></tr><tr><td>Referral rate of non-participating GPs</td><td>0.74</td><td>0.76</td><td>0.47</td><td>1.00</td><td>0.53</td><td>0.15</td></tr></table>
b167fed36766552fd1199a8bb4e69c7a8f07ab2cf86185657b9909a207da3d53.png
complex
<table><tr><td>Molecular Class</td><td>Number of Molecules Altered Within Each Pathway</td></tr><tr><td colspan="2">Nitrite (80 mg/day)</td></tr><tr><td>Glycerophospholipids</td><td>13</td></tr><tr><td>Sphingolipids</td><td>2</td></tr><tr><td>Glycerolipids</td><td>1</td></tr><tr><td>Fatty Acyls</td><td>3</td></tr><tr><td>Carbohydrates and Carbohydrate Conjugates</td><td>1</td></tr><tr><td>Carboxylic Acids and Derivatives</td><td>2</td></tr><tr><td>Imidazole Ribonucleosides and Ribonucleotides</td><td>1</td></tr><tr><td>Pyridines and Derivatives</td><td>1</td></tr><tr><td>Peptide Hormones</td><td>1</td></tr><tr><td>Unknown</td><td>20</td></tr><tr><td colspan="2">Nitrite (160 mg/day)</td></tr><tr><td>Glycerophospholipids</td><td>9</td></tr><tr><td>Sphingolipids</td><td>2</td></tr><tr><td>Carboxylic Acids and Derivatives</td><td>2</td></tr><tr><td>Polypeptide</td><td>1</td></tr><tr><td>Pyridines and Derivatives</td><td>1</td></tr><tr><td>Unknown</td><td>18</td></tr></table>
587d62a0820234d4ab6a34de3a8ebb0ba179551896f1de3ddce4adbd5be212bd.png
simple
<table><tr><td>NO.</td><td>TF</td><td>Target</td><td>p. DCG</td><td>Cor.1</td><td>Cor.2</td><td>Type</td><td>NO.</td><td>TF</td><td>Target</td><td>p. DCG</td><td>Cor.1</td><td>Cor.2</td><td>Type</td></tr><tr><td>1</td><td>AHR</td><td>TLE4<sup>*</sup></td><td>6.77E&#8211;23</td><td>0.94</td><td>0.14</td><td>0</td><td>26</td><td>NFYA</td><td>PANK2<sup>*</sup></td><td>5.37E&#8211;05</td><td>&#8211;0.13</td><td>0.97</td><td>1</td></tr><tr><td>2</td><td>ZEB1</td><td>ATP12A<sup>*</sup></td><td>3.56E-73</td><td>-0.54</td><td>0.95</td><td>1</td><td>27</td><td>MRPL36</td><td>NR4A1<sup>*</sup></td><td>1.34E&#8211;08</td><td>0.88</td><td>&#8211;0.94</td><td>1</td></tr><tr><td>3</td><td>FOXL1<sup>*</sup></td><td>CBX6</td><td>0.014521</td><td>0.95</td><td>0.13</td><td>0</td><td>28</td><td>NF1</td><td>NUPL2<sup>*</sup></td><td>1.86E&#8211;35</td><td>0.91</td><td>0.10</td><td>0</td></tr><tr><td>4</td><td>CEBPB</td><td>PLEKHM1<sup>*</sup></td><td>0.000574</td><td>0.18</td><td>0.94</td><td>0</td><td>29</td><td>ZEB1</td><td>OTOF<sup>*</sup></td><td>2.62E&#8211;07</td><td>0.06</td><td>-0.96</td><td>1</td></tr><tr><td>5</td><td>CREB1</td><td>TGM1<sup>*</sup></td><td>0.001644</td><td>0.87</td><td>0.05</td><td>0</td><td>30</td><td>HAND1</td><td>PITX2<sup>*</sup></td><td>5.83E&#8211;06</td><td>-0.90</td><td>-0.01</td><td>0</td></tr><tr><td>6</td><td>CREB1</td><td>CROCCP2<sup>*</sup></td><td>5.02E&#8211;09</td><td>0.92</td><td>0.07</td><td>0</td><td>31</td><td>PLAU</td><td>LNP1<sup>*</sup></td><td>2.00E&#8211;19</td><td>-0.01</td><td>-0.92</td><td>0</td></tr><tr><td>7</td><td>PATZ1</td><td>DYRK2<sup>*</sup></td><td>2.79E&#8211;16</td><td>-0.88</td><td>-0.02</td><td>0</td><td>32</td><td>PSG1</td><td>YRDC<sup>*</sup></td><td>6.27E&#8211;11</td><td>0.11</td><td>0.93</td><td>0</td></tr><tr><td>8</td><td>FOS</td><td>FEZ2<sup>*</sup></td><td>0.000107</td><td>0.03</td><td>0.96</td><td>0</td><td>33</td><td>RFX1</td><td>SNORA21<sup>*</sup></td><td>3.87E&#8211;38</td><td>0.98</td><td>-0.05</td><td>1</td></tr><tr><td>9</td><td>MYCN</td><td>FLRT2<sup>*</sup></td><td>9.32E&#8211;05</td><td>0.29</td><td>-0.98</td><td>1</td><td>34</td><td>RFX1</td><td>LOC283481<sup>*</sup></td><td>3.34E&#8211;55</td><td>0.96</td><td>-0.33</td><td>1</td></tr><tr><td>10</td><td>FOSL1<sup>*</sup></td><td>HIVEP3</td><td>6.37E&#8211;06</td><td>0.94</td><td>0.02</td><td>0</td><td>35</td><td>SOX9<sup>*</sup></td><td>FLAD1</td><td>8.34E&#8211;09</td><td>-0.92</td><td>-0.10</td><td>0</td></tr><tr><td>11</td><td>FOSL1<sup>*</sup></td><td>DSCAML1</td><td>6.37E&#8211;06</td><td>0.91</td><td>0.16</td><td>0</td><td>36</td><td>SREBF1</td><td>PHOX2B<sup>*</sup></td><td>0.002661</td><td>0.89</td><td>0.06</td><td>0</td></tr><tr><td>12</td><td>GATA1</td><td>COL19A1<sup>*</sup></td><td>9.63E&#8211;10</td><td>0.12</td><td>0.93</td><td>0</td><td>37</td><td>SRF<sup>*</sup></td><td>C4orf7</td><td>1.23E&#8211;18</td><td>-0.96</td><td>0.74</td><td>1</td></tr><tr><td>13</td><td>JUN<sup>*</sup></td><td>GRIA4</td><td>4.30E&#8211;10</td><td>-0.60</td><td>0.97</td><td>1</td><td>38</td><td>SRF<sup>*</sup></td><td>SHMT1</td><td>1.23E&#9472;18</td><td>-0.92</td><td>-0.12</td><td>0</td></tr><tr><td>14</td><td>SRF<sup>*</sup></td><td>HCG18</td><td>1.23E&#9472;18</td><td>-0.91</td><td>-0.14</td><td>0</td><td>39</td><td>STAT5B</td><td>TRAK2<sup>*</sup></td><td>1.42E&#9472;06</td><td>0.45</td><td>-0.95</td><td>1</td></tr><tr><td>15</td><td>HLF<sup>*</sup></td><td>LRRTM4</td><td>0.022779</td><td>0.92</td><td>0.18</td><td>0</td><td>40</td><td>TCF3</td><td>C11orf61<sup>*</sup></td><td>0.003455</td><td>-0.87</td><td>-0.10</td><td>0</td></tr><tr><td>16</td><td>E2F5</td><td>ID1<sup>*</sup></td><td>0.008474</td><td>-0.88</td><td>-0.11</td><td>0</td><td>41</td><td>TFAP4<sup>*</sup></td><td>BSCL2</td><td>3.03E&#8211;16</td><td>-0.06</td><td>-0.94</td><td>0</td></tr><tr><td>17</td><td>JUN<sup>*</sup></td><td>ZNF830</td><td>4.30E&#8211;10</td><td>-0.09</td><td>-0.93</td><td>0</td><td>42</td><td>TLX2<sup>*</sup></td><td>C3orf70<sup>*</sup></td><td></td><td>0.03</td><td>-0.97</td><td>1</td></tr><tr><td>18</td><td>JUN<sup>*</sup></td><td>SPOP</td><td>4.30E&#8211;10</td><td>-0.11</td><td>-0.95</td><td>0</td><td>43</td><td>FOXL1<sup>*</sup></td><td>TOB1</td><td>0.014521</td><td>-0.88</td><td>-0.11</td><td>0</td></tr><tr><td>19</td><td>JUN<sup>*</sup></td><td>GAK</td><td>4.30E&#8211;10</td><td>-0.43</td><td>0.96</td><td>1</td><td>44</td><td>TLX2<sup>*</sup></td><td>TSPAN8</td><td>6.53E&#8211;06</td><td>-0.94</td><td>-0.11</td><td>0</td></tr><tr><td>20</td><td>JUN<sup>*</sup></td><td>CHURC1</td><td>4.30E&#8211;10</td><td>0.51</td><td>-0.95</td><td>1</td><td>45</td><td>CREB1</td><td>VPS26A<sup>*</sup></td><td>6.76E&#8211;05</td><td>0.92</td><td>0.05</td><td>0</td></tr><tr><td>21</td><td>PAX5</td><td>KCTD7<sup>*</sup></td><td>1.14E&#8211;05</td><td>0.97</td><td>-0.54</td><td>1</td><td>46</td><td>SRF<sup>*</sup></td><td>VWA3A</td><td>1.23E&#8211;18</td><td>-0.89</td><td>-0.08</td><td>0</td></tr><tr><td>22</td><td>JUN<sup>*</sup></td><td>KLF6</td><td>4.30E&#8211;10</td><td>0.89</td><td>0.12</td><td>0</td><td>47</td><td>YY1</td><td>ZNF518A<sup>*</sup></td><td>1.93E&#8211;119</td><td>0.90</td><td>0.04</td><td>0</td></tr><tr><td>23</td><td>MZF1</td><td>MID1<sup>*</sup></td><td>0.006234</td><td>0.96</td><td>-0.28</td><td>1</td><td>48</td><td>POU2F1</td><td>ZNF518A<sup>*</sup></td><td>1.93E&#8211;119</td><td>0.98</td><td>-0.15</td><td>1</td></tr><tr><td>24</td><td>MZF1</td><td>EPHB2<sup>*</sup></td><td>0.012953</td><td>-0.93</td><td>-0.13</td><td>0</td><td>49</td><td>ZSCAN1</td><td>KRT13<sup>*</sup></td><td>4.80E&#8211;10</td><td>0.89</td><td>0.15</td><td>0</td></tr><tr><td>25</td><td>SRF<sup>*</sup></td><td>NDUFA1</td><td>1.23E&#8211;18</td><td>0.88</td><td>0.12</td><td>0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
6ffa98176223405f726212ba0fdacd4aaefa3f0e86f3f5c05590fe988c70766e.png
simple
<table><tr><td> </td><td> </td><td><i>Total number of hits</i></td><td><i>Standard articles retrieved</i></td></tr><tr><td>Keyword search (basic topic + sex differences search)</td><td>Stroke</td><td>301</td><td>33/94</td></tr><tr><td> (stroke AND sex difference<sup>*</sup>); filters: human, Englishor(diabetes AND sex difference<sup>*</sup>); filters: human, English</td><td>Diabetes</td><td>539</td><td>23/95</td></tr><tr><td>TTUHSC SGSH PubMed search tool: Basic</td><td>Stroke</td><td>566</td><td>50/94</td></tr><tr><td> (sex based OR sex factors OR sex distribution OR sex characteristics OR sex dimorphism OR gender difference<sup>*</sup> OR gender based) AND (gender[ti] OR sex[ti]); filters: human, EnglishTotal number of hits at the time of validation: 21,315</td><td>Diabetes</td><td>1027</td><td>62/95</td></tr><tr><td>TTUHSC SGSH PubMed search tool: Expanded</td><td>Stroke</td><td>1623</td><td>77/94</td></tr><tr><td> (sex based OR sex factors OR sex distribution OR sex characteristics OR sex dimorphism OR gender difference<sup>*</sup> OR female) AND (gender[ti] OR sex[ti] OR women[ti] OR female[ti]); filters: human, EnglishTotal number of hits at the time of validation: 97,972</td><td>Diabetes</td><td>5569</td><td>81/95</td></tr></table>
5b2bf2be1be99016b17322f1f92662df9e24f796bfa55f9d87cfedbae52108b7.png
complex
<table><tr><td></td><td>ASD (<i>n</i> = 20)</td><td>TD (<i>n</i> = 23)</td><td colspan="3">Statistics</td></tr><tr><td></td><td>(M, SD)</td><td>(M, SD)</td><td><i>t</i> or<i>&#967;</i><sup>2</sup></td><td><i>df</i></td><td><i>p</i></td></tr><tr><td>Age (M, SD)</td><td>13.2 &#177; 2.1</td><td>12.5 &#177; 2.2</td><td><i>t</i> = 1.100</td><td>41</td><td>0.278</td></tr><tr><td>Gender (males:females)</td><td>14:6</td><td>17:6</td><td><i>&#967;</i><sup>2</sup> = 0.393</td><td>1</td><td>0.531</td></tr><tr><td>CARS (M, SD)</td><td>34.1 &#177; 2.4</td><td>17.7 &#177; 1.3</td><td><i>t</i> = 28.955</td><td>41</td><td>&lt;0.001</td></tr></table>
35d0ea85d09ec0bfca4e76f2a0b528516ec5b788f4316ca4034ef62dbea31edd.png
simple
<table><tr><td></td><td>Isoch.</td><td>&#8722;1.21</td><td>&#8722;1.03</td><td>&#8722;0.83</td><td>&#8722;0.60</td><td>&#8722;0.40</td><td>&#8722;0.20</td><td>0.00</td><td>0.19</td><td>0.41</td><td>0.59</td><td>0.98</td><td>1.21</td></tr><tr><td>Mean</td><td>253</td><td>267</td><td>272</td><td>272</td><td>272</td><td>258</td><td>272</td><td>273</td><td>272</td><td>263</td><td>271</td><td>260</td><td>266</td></tr><tr><td><i>SD</i></td><td>4.37</td><td>19.38</td><td>15.43</td><td>16.14</td><td>15.79</td><td>21.02</td><td>15.96</td><td>16.77</td><td>16.05</td><td>17.15</td><td>15.26</td><td>12.37</td><td>28.29</td></tr></table>
7e3e9cb69dfca11b95a5f473dbdcbc0066fa3b0ced97a06be46a97e6a2a300d8.png
simple
<table><tr><td>Dietary change</td><td>Epigenetic effects</td><td>Outcome</td><td>Species</td><td>Reference</td></tr><tr><td>Vitamin B<sub>12</sub>, folate and methionine deficient</td><td>DNA methylation</td><td>Hypomethylation in methyl-deficient diet</td><td>Sheep</td><td>Sinclair et al., 2007</td></tr><tr><td>Betaine supplementation</td><td>DNA methylation</td><td>Increased global measures of DNA methylation</td><td>Chicks</td><td>Hu et al., 2015</td></tr><tr><td>Betaine supplementation</td><td>DNA methylation, Histone modification</td><td><i>PEPCK1</i> hypomethylated and enriched for H3K27me3. <i>PEPCK2</i> and <i>FBP1</i> hypermethylated and enriched for H3K4me3</td><td>Neonatal Piglets</td><td>Cai et al., 2014</td></tr><tr><td>Zinc supplementation</td><td>DNA methylation</td><td>Hypomethylation and increased expression of gene <i>A20</i></td><td>Hens</td><td>Li et al., 2015</td></tr><tr><td>Variable zinc levels</td><td>DNA methylation</td><td>Hypermethylation in regulatory regions of gene <i>ZIP4</i></td><td>Piglets</td><td>Karweina et al., 2015</td></tr><tr><td>Restrictive feeding</td><td>Histone modification</td><td>Increased global measures of H3K9 acetylation and reduction in H3K9me3 in IUGR pigs subjected to restrictive feeding</td><td>Pigs</td><td>Nebendahl et al., 2016</td></tr><tr><td>Folic acid supplementation</td><td>DNA methylation</td><td>Hypermethylation in IUGR piglets with folic acid supplementation compared to piglets fed control diet</td><td>Pigs</td><td>Jing-bo et al., 2013</td></tr><tr><td>Maternal protein insufficiency</td><td>DNA methylation</td><td>Hypomethylation in <i>POMC</i> and <i>GR</i> in the sheep brain</td><td>Sheep</td><td>Begum et al., 2012</td></tr><tr><td>Methylating micronutrients</td><td>DNA methylation</td><td><i>IYD</i> gene differentially methylated between groups of pigs with extreme obesity related phenotypes</td><td>Pigs</td><td>Braunschweig et al., 2012</td></tr></table>
3a6c99bd52917a5b14fac0e1671d78c491c8364662f7fb870c1f72ce51932925.png
complex
<table><tr><td rowspan="2">Marker</td><td colspan="6">Two-point LOD score values at recombination fraction (&#952;=)</td><td rowspan="2">Zmax</td><td rowspan="2">&#952;max</td></tr><tr><td>0.0</td><td>0.1</td><td>0.2</td><td>0.3</td><td>0.4</td><td>0.5</td></tr><tr><td>D1S1677</td><td>-4.21</td><td>1.37</td><td>1.38</td><td>1.00</td><td>0.45</td><td>0</td><td>1.38</td><td>0.2</td></tr><tr><td>D1S 2878</td><td>4.82</td><td>3.98</td><td>3.05</td><td>2.03</td><td>0.93</td><td>0</td><td>4.82</td><td>0.0</td></tr><tr><td>D1S 382</td><td>1.52</td><td>1.25</td><td>0.96</td><td>0.65</td><td>0.32</td><td>0</td><td>1.52</td><td>0.0</td></tr><tr><td>D1S 1158</td><td>-1.51</td><td>1.39</td><td>1.31</td><td>0.98</td><td>0.54</td><td>0</td><td>1.39</td><td>0.1</td></tr><tr><td>D1S 2630</td><td>1.85</td><td>1.62</td><td>1.09</td><td>0.51</td><td>0.09</td><td>0</td><td>1.85</td><td>0.0</td></tr><tr><td>D1S 196</td><td>-2.37</td><td>0.50</td><td>0.52</td><td>0.34</td><td>0.11</td><td>0</td><td>0.52</td><td>0.2</td></tr><tr><td>D1S 218</td><td>3.00</td><td>2.88</td><td>2.38</td><td>1.65</td><td>0.78</td><td>0</td><td>3.00</td><td>0.0</td></tr><tr><td>D1S 2818</td><td>5.46*</td><td>4.52</td><td>3.48</td><td>2.34</td><td>1.09</td><td>0</td><td>5.46</td><td>0.0</td></tr><tr><td>D1S 238</td><td>-5.5</td><td>0.84</td><td>0.80</td><td>0.59</td><td>0.32</td><td>0</td><td>0.84</td><td>0.1</td></tr></table>
b994411ee672a367ce266bdf17ceb6f3403a90869ce978af02daf0e21144c239.png
complex
<table><tr><td></td><td colspan="4">Histological results</td></tr><tr><td>HPV Genotype</td><td>&lt; CIN 2(<i>n</i> = 44)</td><td>CIN 2(<i>n</i> = 12)</td><td>CIN 3(<i>n</i> = 18)</td><td>ICC</td></tr><tr><td>HPV 16</td><td>32% (14/44)</td><td>25% (3/12)</td><td>44%(8/18)</td><td></td></tr><tr><td>HPV 53</td><td>25% (11/44)</td><td>17% (2/12)</td><td>28% (5/18)</td><td>1</td></tr><tr><td>HPV 52</td><td>16% (7/44)</td><td>42% (5/12)</td><td>17% (3/18)</td><td></td></tr><tr><td>HPV 56</td><td>18% (8/44)</td><td>8% (1/12)</td><td>33% (6/18)</td><td></td></tr><tr><td>HPV 58</td><td>16% (7/44)</td><td>42% (5/12)</td><td>6% (1/18)</td><td></td></tr><tr><td>HPV 18</td><td>16% (7/44)</td><td>25% (3/12)</td><td>17% (3/18)</td><td></td></tr><tr><td>HPV 35</td><td>14% (6/44)</td><td>25% (3/12)</td><td>18% (4/18)</td><td></td></tr><tr><td>HPV 31</td><td>7% (3/44)</td><td>33% (4/12)</td><td>18% (4/18)</td><td></td></tr><tr><td>HPV 33</td><td>7% (4/44)</td><td>25% (3/12)</td><td>28% (5/18)</td><td></td></tr><tr><td>HPV 39</td><td>7% (3/44)</td><td>17% (2/12)</td><td>17% (3/18)</td><td></td></tr><tr><td>HPV 45</td><td>0%</td><td>8% (1/12)</td><td>11% (2/18)</td><td></td></tr><tr><td>HPV 59</td><td>2% (1/44)</td><td>8% (1/12)</td><td>11% (2/18)</td><td></td></tr><tr><td>HPV 66</td><td>20% (9/44)</td><td>8% (1/12)</td><td>9% (1/18)</td><td></td></tr><tr><td>HPV 68</td><td>7% (3/44)</td><td>0% (0/12)</td><td>9% (1/18)</td><td></td></tr><tr><td>Multiple HPV coinfection</td><td>60% (26/44)</td><td>83% (10/12)</td><td>67% (12/18)</td><td></td></tr></table>
bcd6e530fc274c427f53585bde0b07a8b1946aa6eeec4816354044a8e513eb06.png
complex
<table><tr><td rowspan="2">Region</td><td rowspan="2">Methylation status</td><td colspan="2"># CpG in</td><td colspan="4"># of molecules detected</td><td rowspan="2">% of total</td></tr><tr><td>MseI frag.</td><td>Ampl-icon</td><td>Exp 1</td><td>Exp 2</td><td>Exp 3</td><td>Exp 4</td></tr><tr><td rowspan="4">1</td><td>unmethylated</td><td>0</td><td>0</td><td>1</td><td>0</td><td rowspan="2"></td><td></td><td rowspan="2">3.0</td></tr><tr><td>Hha-methylated</td><td>2</td><td>0</td><td>0</td><td>0</td><td></td></tr><tr><td>HpaII-methylated</td><td>11</td><td>2</td><td>1</td><td>0</td><td></td><td></td><td>3.0</td></tr><tr><td>Fully methylated</td><td>54</td><td>11</td><td>15</td><td>16</td><td></td><td></td><td>93.9</td></tr><tr><td rowspan="4">2</td><td>unmethylated</td><td>0</td><td>0</td><td>1</td><td>1</td><td rowspan="2"></td><td></td><td rowspan="2">11.8</td></tr><tr><td>Hha-methylated</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td></tr><tr><td>HpaII-methylated</td><td>2</td><td>1</td><td>1</td><td>0</td><td></td><td></td><td>5.9</td></tr><tr><td>Fully methylated</td><td>12</td><td>11</td><td>6</td><td>8</td><td></td><td></td><td>82.4</td></tr><tr><td rowspan="4">3</td><td>unmethylated</td><td>0</td><td>0</td><td>15</td><td>14</td><td>7</td><td>5</td><td>80.4</td></tr><tr><td>Hha-methylated</td><td>3</td><td>2</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>HpaII-methylated</td><td>3</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Fully methylated</td><td>23</td><td>17</td><td>0</td><td>6</td><td>1</td><td>3</td><td>19.6</td></tr></table>
f17c1d3f4486a8048be902e3fd48da6e5edef04baa7218e1decdf582abdf7464.png
complex
<table><tr><td></td><td></td><td></td><td colspan="3">Trial I (unselective supplementation in all mothers from week 18)</td><td></td><td colspan="3">Trial II (selective supplementation in nutritionally at risk mothers from week 28) </td><td></td></tr><tr><td>Trial Group</td><td></td><td></td><td>Protein, Carbohydrate and Vitamins<sup><i>1</i></sup></td><td>Carbohydrate and vitamins<sup><i>2</i></sup></td><td>Vitamins only<sup><i>3</i></sup></td><td>p<sup>7</sup></td><td>Protein, Carbohydrate and Vitamins<sup><i>4</i></sup></td><td>Carbohydrate and vitamins<sup><i>5</i></sup></td><td>Vitamins only<sup><i>6</i></sup></td><td>p<sup>7</sup></td></tr><tr><td></td><td>Mean Birthweight kg</td><td>Original trial (n)</td><td>3.01 &#177; 0.06 (47)</td><td>3.02 &#177; 0.07 (50)</td><td>3.06 &#177; 0.07 (45)</td><td>0.87</td><td>3.34 &#177; 0.14 (14)</td><td>2.95 &#177; 0.15 (17)</td><td>3.01 &#177; 0.07 (14)</td><td>0.09</td></tr><tr><td></td><td></td><td>Traced participants (n) </td><td>2.97 &#177; 0.07 (40)</td><td>2.96 &#177; 0.07 (41)</td><td>3.07 &#177; 0.08 (38)</td><td>0.53</td><td>3.34 &#177; 0.14 (14)</td><td>2.96 &#177; 0.17 (15)</td><td>3.01 &#177; 0.07 (13)</td><td>0.15</td></tr><tr><td></td><td></td><td>Assessed in clinic (n)<sup><i>8</i></sup></td><td>3.11 &#177; 0.09 (21)</td><td>2.95 &#177; 0.08 (23)</td><td>3.08 &#177; 0.12 (21)</td><td>0.48</td><td>3.23 &#177; 0.13 (8)</td><td>3.42 &#177; 0.15 (4)</td><td>3.03 &#177; 0.11 (8)</td><td>0.18</td></tr></table>
8a266337ee4ce5f5522dae1ba852b593dafdf9a44530d5c5d5ae1999bcf586e0.png
simple
<table><tr><td>Independent variables<sup>1</sup></td><td>Coefficients (SE)</td><td><i>z</i>-value(<i>P</i> value)</td><td>Odds ratio (OR)</td><td>95% CI OR</td></tr><tr><td>Age</td><td>&#8722;0.005 (0.01)</td><td>&#8722;0.49 (0.63)</td><td>0.99</td><td>(0.98, 1.01)</td></tr><tr><td>Marital status (married)</td><td>0.25 (0.21)</td><td>1.21 (0.23)</td><td>1.28</td><td>(0.85, 1.93)</td></tr><tr><td>Level of education<sup>2</sup></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> 12 years formal education </td><td>0.63 (0.25)</td><td>2.52 (0.01)</td><td>1.87</td><td>(1.15, 3.07)</td></tr><tr><td> University graduate</td><td>1.28 (0.24)</td><td>5.35 (0.0)</td><td>3.60</td><td>(2.24, 5.77)</td></tr><tr><td>Family history (Yes) </td><td>0.40 (0.23)</td><td>1.79 (0.08)</td><td>1.49</td><td>(0.96, 2.32)</td></tr><tr><td>Personal history (Yes) </td><td>0.84 (0.47)</td><td>1.80 (0.07)</td><td>2.32</td><td>(0.93, 5.77)</td></tr><tr><td>Attending in screening and educational program (Yes)</td><td>0.95 (0.32)</td><td>2.99 (0.003)</td><td>2.58</td><td>(1.39, 4.81)</td></tr></table>
a597d1a2b5b325bf17217ca1db2e33aeb885fd975d954491562509f9dceee423.png
simple
<table><tr><td>Factors</td><td>Domains</td><td>Major themes and their dimensions</td></tr><tr><td>Enabling</td><td>Availability of support</td><td>Formal support</td></tr><tr><td></td><td></td><td> Conflict with centre's hours of operation</td></tr><tr><td></td><td></td><td> Lack of an effective appointment reminder system</td></tr><tr><td></td><td></td><td> Proximity to the centre</td></tr><tr><td></td><td></td><td> Difficulties in locating the centre</td></tr><tr><td></td><td></td><td> Regular physician visits</td></tr><tr><td></td><td></td><td>Informal support</td></tr><tr><td></td><td></td><td> Dependent on family assistance</td></tr><tr><td></td><td></td><td> Family responsibilities</td></tr><tr><td></td><td>Familiarity with resources</td><td>Diabetes education centre and its services </td></tr><tr><td></td><td></td><td> Familiarity with DEC services</td></tr><tr><td>Predisposing</td><td>Self-efficacy</td><td>Diabetes self-management</td></tr><tr><td></td><td></td><td> Sufficient amount of information</td></tr><tr><td></td><td></td><td> Adherent to self-management activities</td></tr><tr><td></td><td></td><td> Non-adherent to self-management activities</td></tr><tr><td></td><td>Attitudes</td><td>Diabetes education</td></tr><tr><td></td><td></td><td> Level of priority</td></tr><tr><td></td><td></td><td> Apathy</td></tr><tr><td></td><td>Co-morbidity</td><td>Competing health conditions</td></tr><tr><td>Need</td><td>Perceived/evaluated</td><td>Disease severity</td></tr><tr><td></td><td></td><td> Patient judgment of severity</td></tr><tr><td></td><td></td><td> Physician judgment of severity</td></tr></table>
d3519d5bf914ba0312d61fee786a3eb39660705b49cf4ebcec22aad3058250c7.png
simple
<table><tr><td>Method</td><td>P</td><td>R</td><td>F</td><td>Sn</td><td>PPV</td><td>Acc</td></tr><tr><td>MCODE</td><td>0.612</td><td>0.081</td><td>0.142</td><td>0.273</td><td>0.345</td><td>0.307</td></tr><tr><td>CFinder</td><td>0.451</td><td>0.15</td><td>0.225</td><td>0.56</td><td>0.22</td><td>0.351</td></tr><tr><td>CMC</td><td>0.224</td><td>0.377</td><td>0.281</td><td>0.472</td><td>0.58</td><td>0.523</td></tr><tr><td>RRW</td><td>0.581</td><td>0.277</td><td>0.375</td><td>0.32</td><td>0.605</td><td>0.44</td></tr><tr><td>COACH</td><td>0.472</td><td>0.38</td><td>0.421</td><td>0.477</td><td>0.498</td><td>0.487</td></tr><tr><td>CORE</td><td>0.275</td><td>0.691</td><td>0.394</td><td>0.566</td><td>0.537</td><td>0.551</td></tr><tr><td>Ours</td><td>0.626</td><td>0.559</td><td>0.59</td><td>0.509</td><td>0.663</td><td>0.581</td></tr></table>
59f1e11f26e109b102ce756702bf8bcff5d46f81d422697a51f04881a7723580.png
simple
<table><tr><td>Outcome</td><td>RR</td><td>95% Confidence interval</td><td><i>p</i>-value</td></tr><tr><td>Total cesarean SSIs</td><td>1.10</td><td>0.58&#8211;2.08</td><td>0.765</td></tr><tr><td>Cesarean incisional SSIs</td><td>0.23</td><td>0.03&#8211;1.78</td><td>0.158</td></tr><tr><td>Cesarean organ/space SSIs</td><td>1.62</td><td>0.83&#8211;3.18</td><td>0.160</td></tr></table>
5233876f014afce1145ad87f6c1562132fd49b46afe5a3f865a5cb2fb71fadaf.png
complex
<table><tr><td>Variable</td><td><i>b</i></td><td><i>SE</i></td><td>Wald</td><td><i>p</i></td><td>Odds ratio (95% CI)</td></tr><tr><td colspan="6">Unadjusted model</td></tr><tr><td>EAL</td><td>0.25</td><td>.20</td><td>1.59</td><td>.207</td><td>1.28 (0.87, 1.89)</td></tr><tr><td>CCC&#8211;S score</td><td>&#8722;0.20</td><td>.01</td><td>1,420.33</td><td>&lt; .001</td><td>0.82 (0.81, 0.83)</td></tr><tr><td>CCC&#8211;S &#215; EAL</td><td>0.02</td><td>.01</td><td>1.28</td><td>.258</td><td>1.02 (0.99, 1.04)</td></tr><tr><td>Constant</td><td>2.01</td><td>.05</td><td>1,508.96</td><td>&lt; .001</td><td></td></tr><tr><td colspan="6">Adjusted model</td></tr><tr><td>EAL</td><td>0.24</td><td>.20</td><td>1.48</td><td>.223</td><td>1.28 (0.86, 1.89)</td></tr><tr><td>CCC&#8211;S score</td><td>&#8722;0.19</td><td>.01</td><td>1,256.44</td><td>&lt; .001</td><td>0.83 (0.82, 0.84)</td></tr><tr><td>CCC&#8211;S &#215; EAL</td><td>0.01</td><td>.01</td><td>0.77</td><td>.381</td><td>1.01 (0.98, 1.04)</td></tr><tr><td>Male sex</td><td>&#8722;0.56</td><td>.06</td><td>89.58</td><td>&lt; .001</td><td>0.57 (0.51, 0.64)</td></tr><tr><td>Age in months</td><td>0.07</td><td>.01</td><td>68.00</td><td>&lt; .001</td><td>1.07 (1.06, 1.09)</td></tr><tr><td>IDACI rank</td><td>&lt; 0.01</td><td>&lt; .01</td><td>4.84</td><td>.028</td><td>1.00 (1.00, 1.00)</td></tr><tr><td>Constant</td><td>&#8722;2.46</td><td>.56</td><td>19.45</td><td>&lt; .001</td><td></td></tr></table>
583129357eb3dac817f338ca6eca9089b38a27ec98d287c35da98b70df93e0d0.png
simple
<table><tr><td>Sampling sites</td><td>n</td><td>N<sub>A</sub></td><td>P<sub>A</sub> (%)</td><td>A</td><td>H<sub>O</sub></td><td>H<sub>E</sub></td><td>F<sub>IS</sub></td></tr><tr><td>All individuals tested</td><td>313</td><td>64</td><td>&#8212;</td><td>5.818</td><td>0.430 &#177; 0.113</td><td>0.578 &#177; 0.148</td><td>0.255</td></tr><tr><td>Microsatellite dataset I</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> East (North and South)</td><td>151</td><td>61</td><td>32 (52.46 %)</td><td>5.546</td><td>0.532 &#177; 0.150</td><td>0.618 &#177; 0.156</td><td>0.141</td></tr><tr><td>Northeast</td><td>107</td><td>59</td><td>20 (33.90 %)</td><td>5.364</td><td>0.559 &#177; 0.153</td><td>0.613 &#177; 0.164</td><td>0.089</td></tr><tr><td>Russia</td><td>88</td><td>57</td><td>13 (22.81 %)</td><td>5.182</td><td>0.569 &#177; 0.151</td><td>0.619 &#177; 0.159</td><td>0.082</td></tr><tr><td>Belarus + Estonia</td><td>19</td><td>42</td><td>2 (4.76 %)</td><td>3.818</td><td>0.503 &#177; 0.230</td><td>0.54 &#177; 0.207</td><td>0.095</td></tr><tr><td>Southeast(Romania)</td><td>44</td><td>35</td><td>2 (5.71 %)</td><td>3.182</td><td>0.464 &#177; 0.170</td><td>0.496 &#177; 0.139</td><td>0.065</td></tr><tr><td> West</td><td>162</td><td>32</td><td>3 (9.38 %)</td><td>2.909</td><td>0.336 &#177; 0.161</td><td>0.439 &#177; 0.201</td><td>0.236</td></tr><tr><td>France</td><td>73</td><td>29</td><td>1 (3.45 %)</td><td>2.636</td><td>0.389 &#177; 0.182</td><td>0.430 &#177; 0.206</td><td>0.095</td></tr><tr><td>Spain</td><td>89</td><td>29</td><td>1 (3.45 %)</td><td>2.636</td><td>0.291 &#177; 0.184</td><td>0.353 &#177; 0.215</td><td>0.178</td></tr><tr><td>Microsatellite dataset II</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> North Dvina</td><td>40</td><td>54</td><td>3 (5.56 %)</td><td>4.909</td><td>0.563 &#177; 0.188</td><td>0.618 &#177; 0.181</td><td>0.090</td></tr><tr><td> West Dvina</td><td>28</td><td>47</td><td>2 (4.26 %)</td><td>4.273</td><td>0.546 &#177; 0.187</td><td>0.582 &#177; 0.185</td><td>0.064</td></tr><tr><td> Volga</td><td>39</td><td>51</td><td>2 (3.92 %)</td><td>4.636</td><td>0.560 &#177; 0.147</td><td>0.598 &#177; 0.146</td><td>0.065</td></tr><tr><td> Charentes</td><td>9</td><td>25</td><td>&#8212;</td><td>2.273</td><td>0.364 &#177; 0.223</td><td>0.409 &#177; 0.213</td><td>0.117</td></tr><tr><td> Garonne</td><td>44</td><td>33</td><td>1 (3.03 %)</td><td>3</td><td>0.373 &#177; 0.186</td><td>0.426 &#177; 0.205</td><td>0.128</td></tr><tr><td> Adour</td><td>23</td><td>26</td><td>&#8212;</td><td>2.364</td><td>0.451 &#177; 0.233</td><td>0.432 &#177; 0.198</td><td>&#8722;0.045</td></tr><tr><td> Cantabrian rivers</td><td>16</td><td>25</td><td>&#8212;</td><td>2.273</td><td>0.317 &#177; 0.193</td><td>0.382 &#177; 0.252</td><td>0.176</td></tr><tr><td> Ebro</td><td>73</td><td>29</td><td>&#8212;</td><td>2.636</td><td>0.285 &#177; 0.185</td><td>0.337 &#177; 0.210</td><td>0.155</td></tr></table>
6236fefe404781aa4b74eba650f567a3201cc8cb0b591104818bdbd5bd8e465e.png
simple
<table><tr><td>Year</td><td>Milestone</td><td>References</td></tr><tr><td>1994</td><td>Discovery of serum autoantibodies recognizing the nuclear DFS-IIF pattern in patients with interstitial cystitis</td><td>[4]</td></tr><tr><td>1997</td><td>Partial cDNA sequence encoding the autoepitope region of the DFS70 autoantigen deposited in GenBank under accession number U94319</td><td>[3]</td></tr><tr><td>1998</td><td>Discovery of transcription co-activator p75, later known to be identical to DFS70 and LEDGFp75</td><td>[13]</td></tr><tr><td>1999</td><td>Discovery of LEDGFp75 using autoantibodies from a cataract patient</td><td>[14]</td></tr><tr><td>2000</td><td>Characterization of DFS70 using autoantibodies from patients with atopic dermatitis and other conditions, and initial observation that these autoantibodies are present at low frequencies in SARD patients</td><td>[3]</td></tr><tr><td>2001&#8211;2002</td><td>Demonstration that DFS70/LEDGFp75 is cleaved during cell death into fragments that are recognized by autoantibodies</td><td>[32, 98]</td></tr><tr><td>2003&#8211;2004</td><td>Discovery of DFS70/LEDGFp75 as a key cellular co-factor of HIV-1 integration</td><td>[17-20]</td></tr><tr><td>2004</td><td>Initial observation that anti-DFS70/LEDGFp75 autoantibodies are present in apparently healthy individuals</td><td>[125]</td></tr><tr><td>2004</td><td>Identification of a major B cell autoepitope in the carboxy-terminal region of DFS70/LEDGFp75</td><td>[62]</td></tr><tr><td>2005</td><td>Identification of DFS70/LEDGFp75 as a tumor associated autoantigen</td><td>[99]</td></tr><tr><td>2005</td><td>Demonstration that anti-DFS70/LEDGFp75 autoantibodies are a very common occurrence in human sera screened for ANAs by HEp-2 IIF in a clinical laboratory and can be detected in a wide array of immunological conditions</td><td>[7]</td></tr><tr><td>2008</td><td>Observation that patients producing anti-DFS70/LEDGFp75 autoantibodies as the only serum ANA pattern are rarely diagnosed with SARD</td><td>[28]</td></tr><tr><td>2011&#8211;2012</td><td>Description of anti-DFS70/LEDGFp75 autoantibodies as a potential exclusion biomarker for SARD</td><td>[26, 107]</td></tr><tr><td>2012</td><td>Development of a highly specific ANA test based on immunoadsorption of anti-DFS70/LEDGFp75 autoantibodies</td><td>[5]</td></tr><tr><td>2012</td><td>Introduction of a new algorithm for ANA testing that considers anti-DFS70/LEDGFp75 autoantibodies</td><td>[6]</td></tr><tr><td>2013</td><td>First commercially available diagnostic test (Inova Diagnostics) for the detection of anti-DFS70/ LEDGFp75 antibodies</td><td>N/A</td></tr></table>
97f9d6152ec61258baf865d33d6703551fed035596dd6e9f68c853c51698a918.png
simple
<table><tr><td></td><td>Group I (n=29)</td><td>Group II (n=31)</td><td>Group III (n=24)</td><td>Group IV (n=32)</td><td>Group V (n=27)</td><td>P values *</td></tr><tr><td></td><td>Severe inflammation in semen</td><td>Severe inflammation in EPS and/or post-M</td><td>Mild inflammation in semen, EPS and/or post-M</td><td>Oligospermia without inflammation</td><td>Controls</td><td></td></tr><tr><td>Age (y)</td><td>33.6 &#177; 6.2</td><td>31.0 &#177; 7.8</td><td>31.7 &#177; 5.2</td><td>32.2 &#177; 6.6</td><td>30.0 &#177; 5.2</td><td>NS</td></tr><tr><td>Period of abstinence (d)</td><td>3.7 &#177; 1.4</td><td>3.9 &#177; 1.7</td><td>3.2 &#177; 0.9 <sup>1</sup></td><td>3.9 &#177; 1.5</td><td>5.9 &#177; 6.7 <sup>1</sup></td><td>p=0.024</td></tr><tr><td>Total sperm count (M)</td><td>57.8 &#177; 51.8 <sup>1</sup></td><td>41.2&#177; 45.6 <sup>2</sup></td><td>36.8 &#177; 53.1 <sup>3</sup></td><td>12.6 &#177; 26.3 <sup>4</sup></td><td>446.7 &#177; 295.8 <sup>1-4</sup></td><td>p&lt;0.001</td></tr><tr><td>Semen volume (ml)</td><td>4.4 &#177; 1.6</td><td>4.5 &#177; 1.5</td><td>4.1 &#177; 1.5</td><td>4.1 &#177; 1.5</td><td>4.4 &#177; 1.7</td><td>NS</td></tr><tr><td>Motility A+B (%)</td><td>37.3 &#177; 17.4 <sup>1</sup></td><td>34.3 &#177; 14.3 <sup>2</sup></td><td>36.1 &#177; 18.3 <sup>3</sup></td><td>27.0 &#177; 19.0 <sup>4</sup></td><td>50.0 &#177; 11.5 <sup>1-4</sup></td><td>p&lt;0.001</td></tr><tr><td>Morphologically normal spermatozoa (%)</td><td>6.0 &#177; 4.7 <sup>1</sup></td><td>5.6 &#177;4.1 <sup>2</sup></td><td>5.5 &#177; 4.1 <sup>3</sup></td><td>4.1 &#177; 3.4 <sup>4</sup></td><td>12.7 &#177; 7.0 <sup>1-4</sup></td><td>p&lt;0.001</td></tr><tr><td>WBCs in semen (M/ml)</td><td>2.7 &#177; 1.9 <sup>1-4</sup></td><td>0.2 &#177; 0.2 <sup>1</sup></td><td>0.3 &#177; 0.2 <sup>2</sup></td><td>0.0 &#177; 0.1 <sup>3</sup></td><td>0.0 &#177; 0.1 <sup>4</sup></td><td>p&lt;0.001</td></tr><tr><td>IL-6 in semen (pg/ml)</td><td>154 &#177; 161 <sup>1-4</sup></td><td>39 &#177; 41 <sup>1</sup></td><td>28 &#177; 18 <sup>2</sup></td><td>22 &#177; 15 <sup>3</sup></td><td>20 &#177; 12 <sup>4</sup></td><td>p&lt;0.001</td></tr><tr><td>WBCs in EPS (M/ml)</td><td>2.3 &#177; 3.3</td><td>4.5 &#177; 5.5 <sup>1,2</sup></td><td>0.4 &#177; 0.3 <sup>1</sup></td><td>0.0 &#177; 0.1 <sup>2</sup></td><td>nd</td><td>p&lt;0.001</td></tr><tr><td>WBCs in post-M by cytology (WBC per HPF visual field)</td><td>6.7 &#177; 7.3 <sup>1</sup></td><td>12.6 &#177; 11.7 <sup>1,2,3</sup></td><td>0.8 &#177; 0.8 <sup>2</sup></td><td>0.7 &#177; 0.8 <sup>3</sup></td><td>nd</td><td>p&lt;0.001</td></tr><tr><td>WBCs in post-M by haemocytometer (WBC/mm<sup>3</sup>)</td><td>98.2 &#177; 172.2 <sup>1,2</sup></td><td>69.3 &#177; 123.1 <sup>3,4</sup></td><td>0.1 &#177; 0.3 <sup>1,3</sup></td><td>0.3 &#177; 0.6 <sup>2,4</sup></td><td>nd</td><td>p=0.002</td></tr><tr><td>IL-6 in EPS (pg/ml)</td><td>209 &#177; 223 <sup>1,2</sup></td><td>283 &#177; 784 <sup>3,4</sup></td><td>45 &#177; 58 <sup>1,3</sup></td><td>37 &#177; 16 <sup>2,4</sup></td><td>nd</td><td>p=0.002</td></tr><tr><td>DC in seminal plasma (&#956;M)</td><td>11.6 &#177; 6.0 <sup>1,2</sup></td><td>9.9 &#177; 7.4 <sup>3,4</sup></td><td>9.2 &#177; 7.5</td><td>5.5 &#177; 4.1 <sup>1,3</sup></td><td>5.1 &#177; 2.0 <sup>2,4</sup></td><td>p&lt;0.001</td></tr><tr><td>ROS-TAC score</td><td>5.9 &#177; 4.1 <sup>1-3</sup></td><td>4.5 &#177; 3.5 <sup>4,5</sup></td><td>3.5 &#177; 2.9 <sup>1</sup></td><td>2.3 &#177; 1.6 <sup>2,4</sup></td><td>1.8 &#177; 0.9 <sup>3,5</sup></td><td>p&lt;0.001</td></tr><tr><td>8-isoprostanes in urine (ng/mmol creatinine)</td><td>86.7 &#177; 26.3 <sup>1-3</sup></td><td>69.9 &#177; 34.9 <sup>4,5</sup></td><td>51.1 &#177; 27.2 <sup>1</sup></td><td>49.3 &#177; 21.6 <sup>2,4</sup></td><td>39.3 &#177; 14.8 <sup>3,5</sup></td><td>p&lt;0.001</td></tr></table>
ab0e0daf03f7068d8953c5de85b8d97624cee44f61b9495ccbd4ba14ae4c2c17.png
complex
<table><tr><td>Characteristic<sup>b</sup></td><td colspan="2">Cases</td><td colspan="2">Controls</td></tr><tr><td></td><td>Adult Glioma Study (<i>n</i> = 622)</td><td>The Cancer Genome Atlas (<i>n</i> = 70)</td><td>Adult Glioma Study (<i>n</i> = 602)</td><td>Illumina iControls (<i>n</i> = 3,390)</td></tr><tr><td>Age</td><td>55 &#177; 0.5</td><td>54 &#177; 1.7</td><td>56 &#177; 0.6</td><td>29 &#177; 0.4</td></tr><tr><td colspan="5">GENDER</td></tr><tr><td>Male</td><td>398 (64%)</td><td>40 (57%)</td><td>319 (53%)</td><td>1,254 (37%)</td></tr><tr><td>Female</td><td>224 (36%)</td><td>30 (43%)</td><td>283 (47%)</td><td>2,136 (63%)</td></tr><tr><td colspan="5">TUMOR SUBTYPE</td></tr><tr><td>Grade III</td><td>97 (16%)</td><td>0 (0%)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Grade IV</td><td>525 (84%)</td><td>70 (100%)</td><td>&#8211;</td><td>&#8211;</td></tr></table>
17756dc40c50a4d7e9b329256cc2f24151505b01d6a16f1c9f1c323c301fbccf.png
complex
<table><tr><td></td><td>Components</td><td rowspan="2">East-West</td><td rowspan="2">North-South</td><td rowspan="2">Vertical</td></tr><tr><td>RMS</td><td></td></tr><tr><td rowspan="2">Relative positioning</td><td>Code (m)</td><td>0.66</td><td>1.07</td><td>1.80</td></tr><tr><td>Carrier-phase (cm)</td><td>1.35</td><td>2.49</td><td>3.15</td></tr><tr><td colspan="2">Velocity estimation (cm/s)</td><td>1.35</td><td>1.70</td><td>3.23</td></tr></table>
123b563f95e566706941c6433c1d9770727a7c53f4775c9029f28fb6196856c8.png
simple
<table><tr><td>Variable</td><td>&#223; (95 % CI)</td><td><i>P</i></td><td>Adjusted R<sup>2</sup></td></tr><tr><td>PAP</td><td>2.0 (0.3, 3.8)</td><td>0.025</td><td>0.19</td></tr><tr><td>PCWP</td><td>4.0 (0.8, 7.3)</td><td>0.017</td><td>0.22</td></tr><tr><td>RAP</td><td>5.6 (2.3, 8.9)</td><td>0.002</td><td>0.38</td></tr></table>
74bba954da6b23c64a607ba853337a98b306de03c2626960b05b82eacbc4f032.png
complex
<table><tr><td></td><td>Estimate</td><td>Standard error</td><td><i>z</i> Value</td><td>Pr(&gt;|<i>z</i>|)</td></tr><tr><td colspan="2">Reference value: the fifth graders</td><td></td><td></td><td></td></tr><tr><td>Intercept</td><td>-0.89</td><td>0.13</td><td>-6.68</td><td>0.000***</td></tr><tr><td>Strategy</td><td>-0.37</td><td>0.09</td><td>-4.36</td><td>0.000***</td></tr><tr><td>Cued strategy</td><td>1.18</td><td>0.09</td><td>13.69</td><td>0.000***</td></tr><tr><td>Correct sum</td><td>0.00</td><td>0.00</td><td>2.11</td><td>0.035*</td></tr><tr><td>Sum of unit digits</td><td>0.02</td><td>0.02</td><td>0.74</td><td>0.458</td></tr><tr><td>Arithmetic fluency</td><td>-0.01</td><td>0.01</td><td>-0.89</td><td>0.371</td></tr><tr><td colspan="2">Age value: the third graders</td><td></td><td></td></tr><tr><td>Age</td><td>0.11</td><td>0.19</td><td>0.58</td><td>0.561</td></tr><tr><td>Age &#215; Strategy</td><td>1.03</td><td>0.12</td><td>8.36</td><td>0.000***</td></tr><tr><td>Age &#215; Cued strategy</td><td>-0.82</td><td>0.12</td><td>-6.64</td><td>0.000***</td></tr><tr><td>Age &#215; Sum of unit digits</td><td>0.00</td><td>0.04</td><td>0.00</td><td>0.999</td></tr><tr><td>Age &#215; Correct sum</td><td>0.00</td><td>0.00</td><td>-1.67</td><td>0.096</td></tr><tr><td>Age &#215; Arithmetic fluency</td><td>0.01</td><td>0.01</td><td>0.40</td><td>0.689</td></tr><tr><td colspan="2">Age value: the seventh graders</td><td></td><td></td></tr><tr><td>Age</td><td>-0.42</td><td>0.18</td><td>-2.27</td><td>0.023*</td></tr><tr><td>Age &#215; Strategy</td><td>0.09</td><td>0.13</td><td>0.74</td><td>0.460</td></tr><tr><td>Age &#215; Cued strategy</td><td>1.27</td><td>0.13</td><td>9.94</td><td>0.000***</td></tr><tr><td>Age &#215; Correct sum</td><td>0.00</td><td>0.00</td><td>-0.11</td><td>0.911</td></tr><tr><td>Age &#215; Sum of unit digits</td><td>-0.03</td><td>0.04</td><td>-0.86</td><td>0.389</td></tr><tr><td>Age &#215; Arithmetic fluency</td><td>0.01</td><td>0.01</td><td>0.49</td><td>0.628</td></tr></table>
b879c40213026aa4145abbf9cc4aec24979b524f7f7001f04f5ffb28c6f37eea.png
simple
<table><tr><td>Disease category</td><td># of specific genes</td><td>Total genes</td><td>% of specific genes</td></tr><tr><td>ASD</td><td>189</td><td>321</td><td>69.8</td></tr><tr><td>FASD</td><td>27</td><td>106</td><td>25.5</td></tr><tr><td>CP</td><td>23</td><td>124</td><td>22.1</td></tr></table>
66110f9d38868543894ab26c0bb35ffd9c5c208e75a10776962739a4269e36c0.png
simple
<table><tr><td> </td><td>Gr A (<i>N</i> = 32)</td><td>Gr B (<i>N</i> = 87)</td><td><i>P</i> value</td></tr><tr><td>Mean follow-up </td><td>710 &#177; 242</td><td>766 &#177; 426 days</td><td>0.48</td></tr><tr><td>Binary restenosis rate (by duplex US PSV ratio&gt;2.5)</td><td> </td><td> </td><td> </td></tr><tr><td> 6 months </td><td>11/30 = 37%</td><td>11/80 = 14%</td><td> 0.007</td></tr><tr><td> 12 months </td><td>20/30 = 67%</td><td>24/74 = 32%</td><td> 0.001</td></tr><tr><td> 24 months </td><td>19/23 = 83%</td><td>31/55 = 56%</td><td> 0.028</td></tr><tr><td>Target vessel revascularization rate</td><td> </td><td> </td><td> </td></tr><tr><td> 6 months </td><td>9/30 = 30% </td><td>7/80 = 9%</td><td> 0.005</td></tr><tr><td> 12 months </td><td>16/30 = 53%</td><td>21/73 = 29%</td><td> 0.018</td></tr><tr><td> 24 months </td><td>15/23 = 65%</td><td>24/53 = 45%</td><td>0.11</td></tr><tr><td>Stent fracture rate</td><td> </td><td> </td><td> </td></tr><tr><td> 12 months </td><td>0</td><td>3/122 (2.5%)</td><td>0.51</td></tr><tr><td> 24 months </td><td>1/16 (6.3%)</td><td>5/74 (6.8%)</td><td>0.71</td></tr></table>
1b3f87186a260e1089461fb36cb20bd9721e0ec66e33f2ff28f44bae35bf2c16.png
simple
<table><tr><td>Metabolite</td><td>Gene involved in biosynthesis</td><td>Locus number</td><td>Biological Evidence</td><td>Reference</td></tr><tr><td>Pyoverdine</td><td><i>pvdSL; pvdIJKDEONMP; fpvI; pvdA</i></td><td>PSF113_1749-1750; PSF113_1836-1847; PSF113_1856-1860</td><td>Yes</td><td>[2]</td></tr><tr><td>Pyridine-2,6-bis-thiocarboxylic acid (PDTC)</td><td><i>pdtCKPELMFGHIJON</i></td><td>PSF113_2605-2618</td><td>No</td><td> </td></tr><tr><td>2,4 diacetyl-phloroglucinol (DAPG)</td><td><i>phlIEDBCAFGH</i></td><td>PSF113_2457-2464</td><td>Yes</td><td>[4]</td></tr><tr><td>Hydrogen cyanide (HCN)</td><td><i>hcnABC</i></td><td>PSF113_2367-2369</td><td>Yes</td><td>[83]</td></tr><tr><td>Putative Lankacidin</td><td><i>lkcABCDEFGJ; pqqFABCDEG</i></td><td>PSF113_3657-3666; PSF113_5383-5388</td><td>No</td><td> </td></tr><tr><td>PKS-like metabolite</td><td> </td><td>PSF113_3045-3053</td><td>No</td><td> </td></tr></table>
c46606c95a180a7dff344bdadd8a4465a4e68bfbabc68ef1d4966cac6d050ab1.png
simple
<table><tr><td>Parameter</td><td><i>P</i></td><td>Odds ratio (OR)</td><td>95% confidence interval (CI)</td></tr><tr><td>Maternal age</td><td>0.846</td><td>0.995</td><td>0.943&#8211;1.050</td></tr><tr><td>Multiparity</td><td>0.293</td><td>0.751</td><td>0.459&#8211;1.235</td></tr><tr><td>Previous uterine surgery (including myomectomy, caesarean section, reconstructive surgery, or septum resection)</td><td>0.490</td><td>1.132</td><td>0.718&#8211;1.784</td></tr><tr><td>BMI </td><td> </td><td> </td><td> </td></tr><tr><td> Extremely low (under 18.5) </td><td>0.402</td><td>0.538</td><td>0.126&#8211;2.290</td></tr><tr><td> High (above 30)</td><td>0.544</td><td>0.764</td><td>0.320&#8211;1.823</td></tr><tr><td>Supernumerary embryos developed in IVF cycle</td><td>0.275</td><td>1.269</td><td>0.827&#8211;1.946</td></tr><tr><td>Transfer of 2 embryos</td><td>0.043</td><td>1.952</td><td>0.020&#8211;3.735</td></tr><tr><td>Spontaneous cycle ET</td><td>0.064</td><td>0.417</td><td>0.150&#8211;1.164</td></tr></table>
161122bdfa32c8e0a4937df023fa662eff5ad3fb3366c56813acc0c4f6c0c3aa.png
simple
<table><tr><td></td><td>Abrupt</td><td>Gradual 1</td><td>Gradual 2</td><td>All treatments</td></tr><tr><td>Randomized, <i>n</i></td><td>41</td><td>40</td><td>42</td><td>123</td></tr><tr><td>Safety population, <i>n</i></td><td>40</td><td>39</td><td>42</td><td>121</td></tr><tr><td>Completed, %</td><td>75</td><td>72</td><td>88</td><td>79</td></tr><tr><td>Discontinued, %</td><td>25</td><td>28</td><td>12</td><td>21</td></tr><tr><td> Adverse event</td><td>5</td><td>15</td><td>5</td><td>8</td></tr><tr><td> Withdrew consent</td><td>10</td><td>8</td><td>0</td><td>6</td></tr><tr><td> Insufficient response</td><td>5</td><td>0</td><td>0</td><td>2</td></tr><tr><td> Lost to follow-up</td><td>0</td><td>3</td><td>2</td><td>2</td></tr><tr><td> Noncompliance</td><td>0</td><td>0</td><td>2</td><td>1</td></tr><tr><td> Other</td><td>5</td><td>3</td><td>2</td><td>2</td></tr></table>
3aedbf6a1cb025be037e4e984aefae7a8b4b20f89568da533dde1881daab16e0.png
complex
<table><tr><td></td><td></td><td colspan="6">Survival rate</td></tr><tr><td></td><td>Total mRNA injected (pg)</td><td>1 day</td><td>2 days<sup>a</sup></td><td>4 days</td><td>6 days</td><td>15 days</td><td>18 weeks</td></tr><tr><td>WT</td><td>N.A.</td><td>86% (6/7)</td><td>80% (4/5)</td><td>80% (4/5)</td><td>80% (4/5)</td><td>80% (4/5)</td><td>80% (4/5)</td></tr><tr><td>TALEN1</td><td>300</td><td>88% (7/8)</td><td>83% (5/6)</td><td>0% (0/6)</td><td>0% (0/6)</td><td>0% (0/6)</td><td>0% (0/6)</td></tr><tr><td></td><td>200</td><td>90% (9/10)</td><td>88% (7/8)</td><td>13% (1/8)</td><td>13% (1/8)</td><td>13% (1/8)</td><td>13% (1/8)</td></tr><tr><td></td><td>100</td><td>100% (9/9)</td><td>100% (7/7)</td><td>43% (3/7)</td><td>29% (2/7)</td><td>14% (1/7)</td><td>0% (0/7)</td></tr><tr><td></td><td>50</td><td>100% (8/8)</td><td>100% (6/6)</td><td>83% (5/6)</td><td>83% (5/6)</td><td>67% (4/6)</td><td>33% (2/6)</td></tr><tr><td>TALEN2</td><td>300</td><td>100% (8/8)</td><td>33% (2/6)</td><td>0% (0/6)</td><td>0% (0/6)</td><td>0% (0/6)</td><td>0% (0/6)</td></tr><tr><td></td><td>200</td><td>88% (7/8)</td><td>67% (4/6)</td><td>0% (0/6)</td><td>0% (0/6)</td><td>0% (0/6)</td><td>0% (0/6)</td></tr><tr><td></td><td>100</td><td>100% (8/8)</td><td>100% (6/6)</td><td>50% (3/6)</td><td>50% (3/6)</td><td>0% (0/6)</td><td>0% (0/6)</td></tr><tr><td></td><td>50</td><td>100% (8/8)</td><td>83% (5/6)</td><td>67% (4/6)</td><td>50% (3/6)</td><td>50% (3/6)</td><td>50% (3/6)</td></tr></table>
246ae9347cd89c658a6cde006d62fc252de87a8031cb486e16d3bc8ae8350347.png
simple
<table><tr><td>Cat Demographics</td><td>Free Cats <i>n</i> = 73 (%)</td><td>Normal-Fee Cats <i>n</i> = 78 (%)</td></tr><tr><td>Cat Ages</td><td></td><td></td></tr><tr><td>Age range</td><td>1&#8211;16 years</td><td>1&#8211;14 years</td></tr><tr><td>Age mean</td><td>4 years</td><td>3 years</td></tr><tr><td>Cat Sex</td><td></td><td></td></tr><tr><td>TOTAL females</td><td>52 (71)</td><td>57 (73)</td></tr><tr><td>Female adults</td><td>46 (63)</td><td>54 (69)</td></tr><tr><td>Female matures</td><td>6 (8)</td><td>3 (4)</td></tr><tr><td>TOTAL males</td><td>21 (29)</td><td>21 (27)</td></tr><tr><td>Male adults</td><td>16 (22)</td><td>19 (24)</td></tr><tr><td>Male matures</td><td>5 (7)</td><td>2 (3)</td></tr><tr><td>Pelage Varieties</td><td></td><td></td></tr><tr><td>Blacks and Browns</td><td>9 (12)</td><td>6 (8)</td></tr><tr><td>Calicos and Tortoiseshells</td><td>8 (11)</td><td>17 (22)</td></tr><tr><td>Brindles and Gingers</td><td>9 (12)</td><td>4 (5)</td></tr><tr><td>Greys and Whites</td><td>9 (12)</td><td>13 (17)</td></tr><tr><td>Piebalds</td><td>12 (16)</td><td>13 (17)</td></tr><tr><td>Tabbies</td><td>26 (36)</td><td>25 (32)</td></tr><tr><td>Cat Fate</td><td></td><td></td></tr><tr><td>Alive and Retained by original adopter</td><td>68 (93)</td><td>75 (96)</td></tr><tr><td><sup>1</sup> Dead</td><td>3 (4)</td><td>0 (0)</td></tr><tr><td><sup>2</sup> Returned to shelter</td><td>0 (0)</td><td>3 (4)</td></tr><tr><td><sup>3</sup> Rehomed privately</td><td>1 (1)</td><td>0 (0)</td></tr><tr><td><sup>4</sup> Ran away</td><td>1 (1)</td><td>0 (0)</td></tr></table>
6f1b5853e66a93084dd9b70b1d750f613bf1f7ae46f02d690d9e1f8aa6c79718.png
simple
<table><tr><td>Variable</td><td>Total (N = 118)</td><td>Non&#8211;diabetes mellitus (N = 109)</td><td>Diabetes mellitus (N = 9)</td><td>P</td></tr><tr><td>Gastric lavage, n (%)</td><td>95 (80.5)</td><td>89 (81.7)</td><td>6 (66.7)</td><td>0.275</td></tr><tr><td>Active charcoal and magnesium citrate, n (%)</td><td>88 (74.6)</td><td>83 (76.1)</td><td>5 (55.6)</td><td>0.173</td></tr><tr><td>Atropine, n (%)</td><td>116 (98.3)</td><td>108 (99.1)</td><td>8 (88.9)</td><td>0.023*</td></tr><tr><td>Pralidoxime, n (%)</td><td>115 (97.5)</td><td>107 (98.2)</td><td>8 (88.9)</td><td>0.089</td></tr><tr><td>Time from poisoning to hospital, hours (median, IQR)</td><td>3.0 (2.0, 5.0)</td><td>3.0 (2.0, 5.0)</td><td>3.5 (2.0, 9.0)</td><td>0.893</td></tr><tr><td>Duration of follow-up, months (median, IQR)</td><td>1.25 (0.40, 9.06)</td><td>1.23 (0.43, 8.63)</td><td>2.27 (0.25, 15.67)</td><td>0.219</td></tr><tr><td>Mortality, n (%)</td><td>18 (15.3)</td><td>15 (13.8)</td><td>3 (33.3)</td><td>0.117</td></tr><tr><td>Cause of death, n (%)</td><td> </td><td> </td><td> </td><td>0.333</td></tr><tr><td>Cardiogenic</td><td>10 (8.5)</td><td>8 (7.3)</td><td>2 (22.2)</td><td> </td></tr><tr><td>Respiratory failure</td><td>6 (5.1)</td><td>5 (4.6)</td><td>1 (11.1)</td><td> </td></tr><tr><td>Sepsis</td><td>2 (1.7)</td><td>2 (1.8)</td><td>0 (0.0)</td><td> </td></tr></table>
59130f4646d11f958d9e6387e451f7839ba95e70865bd78aaeced4f16747f36a.png
simple
<table><tr><td> </td><td>Bariatric Surgery (N = 34)</td><td>Lifestyle Intervention (N = 34)</td><td><i>P</i></td></tr><tr><td>Age (yrs)</td><td>43.3 &#177; 9.4</td><td>40.9 &#177; 10.5</td><td>0.33</td></tr><tr><td>% Female</td><td>76.5</td><td>76.5</td><td>1.00</td></tr><tr><td>% Race</td><td> </td><td> </td><td>0.25</td></tr><tr><td> White</td><td>79.4</td><td>70.6</td><td> </td></tr><tr><td> African-American</td><td>5.9</td><td>14.7</td><td> </td></tr><tr><td> American Indian/Alaskan Native</td><td>2.9</td><td>0.0</td><td> </td></tr><tr><td> Native Hawaiian/Other Pacific Islander</td><td>2.9</td><td>0.0</td><td> </td></tr><tr><td> Other</td><td>8.8</td><td>5.9</td><td> </td></tr><tr><td> Don&#8217;t know</td><td>0.0</td><td>8.8</td><td> </td></tr><tr><td>% Ethnicity</td><td> </td><td> </td><td>1.00</td></tr><tr><td> Non-Hispanic</td><td>91.2</td><td>91.2</td><td> </td></tr><tr><td> Hispanic</td><td>8.8</td><td>8.8</td><td> </td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>46.2 &#177; 7.8</td><td>45.0 &#177; 4.9</td><td>0.49</td></tr><tr><td>Weight (kg)</td><td>129.9 &#177; 27.6</td><td>127.7 &#177; 19.6</td><td>0.71</td></tr></table>
0d0676f63c053a76d06725adab713768afd33de1defb43a36177b19735cc9c5c.png
simple
<table><tr><td></td><td>American (N = 419)*</td><td>Taiwanese (N = 2062)</td><td>P-value</td></tr><tr><td>Age</td><td>53.2 &#177; 13.7</td><td>47.6 &#177; 13.6</td><td></td></tr><tr><td>Gender</td><td></td><td></td><td>&lt;.0001</td></tr><tr><td> Female</td><td>64.6% (265/410)</td><td>51.5%</td><td></td></tr><tr><td> Male</td><td>35.4% (145/410)</td><td>48.5%</td><td></td></tr><tr><td>Acute myocardial infarction</td><td>6% (24/399)</td><td>2.9%</td><td>0.0567</td></tr><tr><td>Comorbidities</td><td></td><td></td><td></td></tr><tr><td> Hypertension</td><td>86.6% (356/411)</td><td>81.1%</td><td>0.0081</td></tr><tr><td> Diabetes mellitus</td><td>8.7% (36/412)</td><td>15.0%</td><td>0.0008</td></tr><tr><td> Dyslipidemia</td><td>45.7% (188/411)</td><td>34.6%</td><td>&lt;.0001</td></tr><tr><td> Arrhythmia</td><td>25.9% (103/398)</td><td>19.3%</td><td>0.0028</td></tr><tr><td> Heart failure</td><td>9.5% (38/400)</td><td>10.5%</td><td>0.5527</td></tr><tr><td> Valvular heart disease</td><td>14.4% (57/397)</td><td>8.5%</td><td>0.0003</td></tr><tr><td> Peripheral vascular disease</td><td>16.5% (66/400)</td><td>6.6%</td><td>&lt;.0001</td></tr></table>
420cd88d91f3d95177cc61d087c99b2de2d7f96ba3f9c4175972bb0c7cfd6499.png
simple
<table><tr><td>Registered indications</td><td>Prophylaxis of bleeding related to surgical or invasive interventions as well as treatment of bleeding in patients with</td></tr><tr><td></td><td>-Congenital hemophilia A or B if inhibitors are present (&gt;5 Bethesda units) or if a strong increase of inhibitors must be expected upon administration of factor VIII or IX [41]</td></tr><tr><td></td><td>- Acquired hemophilia [42]</td></tr><tr><td></td><td>- Congenital factor VII deficiency [43]</td></tr><tr><td></td><td>- Glanzmann thrombasthenia with antibodies to glycoprotein IIb/IIIa and/or human leucocyte antigen and presence or history of refractoriness to platelet concentrates [44]</td></tr><tr><td>Potential indications</td><td>Prophylaxis of surgical bleeding in patients with reduced activity or deficiency of coagulation factors, especially with specific inhibitors to plasmatic factors [45] and acquired von Willebrand disease [46]</td></tr><tr><td></td><td>Treatment of bleedings after all conventional measures have failed in patients with</td></tr><tr><td></td><td>- Chronic liver disease [47]</td></tr><tr><td></td><td>- Thrombocytopathy [48]</td></tr><tr><td></td><td>- Platelet-refractory thrombopenia [49]</td></tr><tr><td></td><td>- Bleeding complications due to trauma or surgery in patients without any detectable systemic impairment of hemostasis (references in Tables 3 and 4)</td></tr><tr><td></td><td>- Drug-induced bleeding, especially by hirudine (in connection with supportive measures), danaparoid, fondaparinux, and glycoprotein IIb/IIIa inhibitors [50]</td></tr></table>
8b7f80c7aa095c949c6271ca55e2f9708aa283c33878f7b2f8f40f2528f96df4.png
simple
<table><tr><td></td><td>Hol</td><td>Tul</td><td>Ban</td><td>Bis</td><td>Gau</td><td>Mit</td><td>Yak</td><td>Anc</td><td>BubB</td><td>BubC</td><td>Ind</td><td>Mur</td><td>Syn</td><td>Ela</td></tr><tr><td>T<sub>N</sub></td><td>-0.13</td><td>0.1</td><td>1.4</td><td>1.2</td><td>1.6</td><td>1.0</td><td>0.9</td><td>2.4</td><td>4.2</td><td>3.9</td><td>5.0</td><td>4.2</td><td>4.1</td><td>7.4</td></tr><tr><td>T<sub>C</sub></td><td>-0.25</td><td>0.15</td><td>2.6</td><td>2.1</td><td>3.0</td><td>1.9</td><td>1.6</td><td>4.5</td><td>7.7</td><td>7.0</td><td>9.1</td><td>7.9</td><td>7.7</td><td>13.7</td></tr></table>
b97a0d397bf601bdfdd54e9077f24470ce8443ddc61fd8e6ddc9d60ed901b98f.png
complex
<table><tr><td colspan="7">Compression Bulge Anterior BulgeL</td></tr><tr><td>Var.</td><td>Df</td><td>Sum of Sq.</td><td>Mean Square</td><td>F Value</td><td><i>p</i>-Value</td><td>Significance Code</td></tr><tr><td>C10</td><td>1</td><td>0.00066</td><td>0.00066</td><td>35.8</td><td>2.41 &#215; 10<sup>&#8722;8</sup></td><td>***</td></tr><tr><td>C0</td><td>1</td><td>0.00031</td><td>0.00031</td><td>16.7</td><td>8.01 &#215; 10<sup>&#8722;5</sup></td><td>***</td></tr><tr><td>Fiber12</td><td>1</td><td>0.00008</td><td>0.00008</td><td>4.1</td><td>4.47 &#215; 10<sup>&#8722;2</sup></td><td>*</td></tr><tr><td>Fiber56</td><td>1</td><td>0.00006</td><td>0.00006</td><td>3.1</td><td>7.96 &#215; 10<sup>&#8722;2</sup></td><td>.</td></tr><tr><td>Fiber78</td><td>1</td><td>0.00004</td><td>0.00004</td><td>2.0</td><td>1.58 &#215; 10<sup>&#8722;1</sup></td><td></td></tr><tr><td>Fiber910</td><td>1</td><td>0.00005</td><td>0.00005</td><td>2.6</td><td>1.09 &#215; 10<sup>&#8722;1</sup></td><td></td></tr><tr><td>Annulus_E</td><td>1</td><td>0.00149</td><td>0.00149</td><td>81.5</td><td>4.25 &#215; 10<sup>&#8722;15</sup></td><td>***</td></tr><tr><td>Annulus_&#956;</td><td>1</td><td>0.08796</td><td>0.08796</td><td>4805.3</td><td>&lt;2.2 &#215; 10<sup>&#8722;16</sup></td><td>***</td></tr><tr><td>Cartil_E</td><td>1</td><td>0.04237</td><td>0.04237</td><td>2314.5</td><td>&lt;2.2 &#215; 10<sup>&#8722;16</sup></td><td>***</td></tr><tr><td>Cartil_&#956;</td><td>1</td><td>0.00054</td><td>0.00054</td><td>29.4</td><td>3.24 &#215; 10<sup>&#8722;7</sup></td><td>***</td></tr><tr><td>Residuals</td><td>117</td><td>0.00214</td><td>0.00002</td><td></td><td></td><td></td></tr></table>
bde0b3eebafad643c0a2fcf7ed46e3639a337fdc2de0ab1bb848e6dee5edf620.png
complex
<table><tr><td>Domain/outcome</td><td>Questionnaire/items</td><td colspan="4">Assessment time point</td><td>Reference</td></tr><tr><td>Primary Outcome</td><td> </td><td>t1</td><td>t2</td><td>t3</td><td>t4</td><td> </td></tr><tr><td>Physical functioning</td><td>Hannover Functional Ability Questionnaire (FfbH-R)</td><td>x</td><td>x</td><td>x</td><td>x</td><td>[51]</td></tr><tr><td>Secondary Outcomes</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Pain</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Pain intensity</td><td>Numeric Rating Scale (NRS)</td><td>x</td><td>x</td><td>x</td><td>x</td><td>[52]</td></tr><tr><td> Pain status</td><td>Graded Chronic Pain Status (GCPS)</td><td>x</td><td>x</td><td>x</td><td>x</td><td>[53]</td></tr><tr><td>Physical activity</td><td>Freiburg questionnaire on physical activity (FFkA)</td><td>x</td><td> </td><td>x</td><td>x</td><td>[54]</td></tr><tr><td>Emotional functioning</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Depression</td><td>Patient Health Questionnaire (PHQ-D)</td><td>x</td><td>x</td><td>x</td><td>x</td><td>[55]</td></tr><tr><td> Anxiety</td><td>Generalized anxiety disorder 7-item scale (GAD-7)</td><td>x</td><td>x</td><td>x</td><td>x</td><td>[56]</td></tr><tr><td>Health related quality of life</td><td>Short-Form-12 (SF-12)</td><td>x</td><td>x</td><td>x</td><td>x</td><td>[57]</td></tr><tr><td>Stress</td><td>Perceived Stress Scale (PSS)</td><td>x</td><td>x</td><td>x</td><td>x</td><td>[58]</td></tr><tr><td>Pain related cognitions, emotions and behavior</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Cognitive and behavioral pain coping strategies</td><td>Pain Management Questionnaire (FESV)</td><td>x</td><td>x</td><td>x</td><td>x</td><td>[59]</td></tr><tr><td> Fear-avoidance and endurance-related responses to pain</td><td>Avoidance-Endurance Questionnaire (AEQ)</td><td>x</td><td>x</td><td>x</td><td>x</td><td>[60]</td></tr><tr><td> Pain related fear</td><td>Tampa Scale for Kinesiophobia (TSK)</td><td>x</td><td>x</td><td>x</td><td>x</td><td>[61,62]</td></tr><tr><td>Motivational and volitional determinants of physical activity</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>risk perception (3 items), self-efficacy (3 items), outcome expectancies (11items), experiences with physical activity (5 items), self-concordance (12 items), intention (7 items), action (4 items) and coping (4 items) planning, action control (6 items)</td><td>x</td><td>x</td><td>x</td><td>x</td><td>[63-67]</td></tr><tr><td> Stage of change algorithm for physical activity</td><td>two Items (Have you performed moderate physical for 30 minutes or longer on a minimum of 3 days per week? and "Since when are you as regularly active as you are now?"; possible answers: 1. Question: no, and I don&#8217;t intend to do so; no, but I am thinking about doing so; no, but I have the strong intention to do so; yes, but it is difficult to me; yes, and it is easy for me; 2. Question: open)</td><td>x</td><td>x</td><td>x</td><td>x</td><td>[68,69]</td></tr><tr><td>Attitudes towards performing physical activity</td><td>modified Version of Short-Questionnaire to measure cognitive and affective attitudes toward sports activities</td><td>x</td><td>x</td><td>x</td><td>x</td><td>[70]</td></tr><tr><td>Treatment satisfactions with exercise therapy</td><td>18 items (e.g. &#8220;I would recommend the exercise therapy other patients.&#8221; measured by using a six-point ordinal scale with 1= &#8220;absolutely agree&#8221;, 6=&#8220;absolutely disagree&#8221;; e.g. &#8220;The time extent of the exercise therapy, I perceived as...&#8221; measured by using a five-point ordinal scale with 1=&#8220;far too high&#8220;, 5=&#8220;far too low&#8220;; e.g. &#8220;Overall, how do you rate the exercise therapy?&#8221; measured by using a six-point ordinal scale with 1= &#8220;very satisfied&#8221;, 6=not &#8220;satisfied at all&#8221;)</td><td> </td><td>x</td><td> </td><td> </td><td>self-designed</td></tr><tr><td>Treatment satisfactions with the rehabilitation process</td><td>five items (e.g. &#8220;Overall, how do you rate the rehabilitation process?&#8221;) measured by using a ten-point ordinal scale (1= &#8220;very poor&#8221;, 10 = &#8222;excellent&#8220;)</td><td> </td><td>x</td><td> </td><td> </td><td>self-designed</td></tr><tr><td>Others</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Demographic characteristics</td><td>sex, age, height, nationality, marital status, education, monthly income, weight, self-reported work status</td><td>x</td><td> </td><td> </td><td> </td><td>[71]</td></tr><tr><td> Social medical characteristics</td><td>a) self-reported low back pain related sick leave, use of health care services, medication use for the last six month and self-reported plan to apply for retirement, severe disabilities</td><td>x</td><td> </td><td> </td><td> </td><td>[71]</td></tr><tr><td> </td><td>b) diagnosis, work status and physical capability taken from the hospital discharge report</td><td> </td><td>x</td><td> </td><td> </td><td> </td></tr><tr><td rowspan="2"> Aftercare</td><td>a) aftercare recommendations taken from the hospital discharge report</td><td> </td><td>x</td><td> </td><td> </td><td>self-designed</td></tr><tr><td>b) self-designed; five items (e.g. &#8220;Have you participated in the last twelve months in a medically prescribed exercise therapy to rehabilitation aftercare?&#8221; with the option to answer yes/no)</td><td> </td><td> </td><td> </td><td>x</td><td> </td></tr><tr><td>Job satisfaction</td><td>scale on job satisfaction (IRES-3)</td><td> </td><td> </td><td>x</td><td>x</td><td>[72]</td></tr></table>
410f9c2c057f0bbf76e3dffcae484f296f29fb088ed40afe2f9f03a6cee75d86.png
complex
<table><tr><td></td><td>Incremental Difference: Complete Ban<i>vs.</i>Current Legislation</td><td>Incremental Difference: Optimistic Case</td><td>Incremental Difference: Worst Case</td></tr><tr><td>Gross Intervention Costs (C)</td><td>3,994,645</td><td>1,996,438</td><td>5,067,102</td></tr><tr><td>AMI Treatment Costs Saved (T)</td><td>40,051,602</td><td>237,927,598</td><td>1,626,740</td></tr><tr><td>All Tobacco-Attributable Treatment Costs Saved (T)</td><td>99,609,250</td><td>946,905,837</td><td>2,527,779</td></tr><tr><td>Net Costs (AMI Treatment) *(C-T)</td><td>&#8211;36,056,957</td><td>&#8211;235,931,160</td><td>3,440,362</td></tr><tr><td>Net Costs (All Tobacco-Attributable Disease Treatment) * (C-T)</td><td>&#8211;95,614,605</td><td>&#8211;944,909,399</td><td>2,539,322</td></tr><tr><td>AMI Cases Averted (A)</td><td>17,478</td><td>53,361</td><td>13,109</td></tr><tr><td>Smokers Quitting (Q)</td><td>221,154</td><td>385,100</td><td>46,060</td></tr><tr><td>Life Years Gained (L)</td><td>437,589</td><td>891,945</td><td>45,268</td></tr><tr><td colspan="4">Incremental Cost-Effectiveness Ratios</td></tr><tr><td>Cost per LY Gained (C-T)/(L)</td><td><i>Cost Saving</i></td><td><i>Cost Saving</i></td><td><i>56 (USD) Highly Cost-Effective</i></td></tr><tr><td>Cost per LY Gained w/out Medical Treatment Saved (C/L)</td><td>9.13 (USD) <i>Highly Cost-Effective</i></td><td>2.24(USD) <i>Highly Cost-Effective</i></td><td>112 (USD) <i>Highly Cost-Effective</i></td></tr><tr><td>Cost per AMI Case Averted (C-T)/A</td><td><i>Cost Saving</i></td><td><i>Cost Saving</i></td><td><i>262 (USD) Highly Cost-Effective</i></td></tr><tr><td>Cost per AMI Case Averted w/out Medical Treatment Saved (C/A)</td><td>229 (USD) <i>Highly Cost-Effective</i></td><td>37 (USD) <i>Highly Cost-Effective</i></td><td><i>387 (USD) Highly Cost-Effective</i></td></tr></table>
8e4093a3580770572bbac5e2db9ffaaf1df2252db35e4bc8df4a0231c139aa69.png
simple
<table><tr><td></td><td><i>stx1a</i></td><td><i>stx2a</i></td><td><i>stx2d</i></td><td><i>stx1a+2a</i></td><td><i>stx1a+2d</i></td><td><i>stx</i> negative</td><td>Total</td></tr><tr><td>ST21</td><td>353</td><td>20</td><td>2</td><td>44</td><td>1</td><td>17</td><td>437</td></tr><tr><td>SLV of ST21</td><td>5</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>6</td></tr><tr><td>ST29</td><td>1</td><td>27</td><td>3</td><td>0</td><td>0</td><td>45</td><td>76</td></tr><tr><td>SLV of ST29</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td><td>1</td></tr><tr><td>Total</td><td>359</td><td>48</td><td>5</td><td>44</td><td>1</td><td>63</td><td>520</td></tr></table>
5107191eb02e7f20f41bc405df2b6d0ddd5d193ab2e75d652d4bb13bca35b2a0.png
simple
<table><tr><td></td><td><i>T. trichiura</i> Uganda</td><td><i>T. trichiura</i> China</td><td><i>T. trichiura</i> Ecuador</td></tr><tr><td><i>T. trichiura</i> Uganda</td><td></td><td>0.979**</td><td>0.932***</td></tr><tr><td><i>T. trichiura</i> China</td><td>0.984**</td><td></td><td>0.551*</td></tr><tr><td><i>T. trichiura</i> Ecuador</td><td>0.967***</td><td>0.778*</td><td></td></tr></table>
d16ec135ea8dc15b7dddda4f7a4e7fece53c25d26ba11f7fee8e612c27f33c5f.png
complex
<table><tr><td rowspan="2">Experimental treatment </td><td><i>Staphylococcus aureus </i></td><td><i>Streptococcus agalactiae </i></td><td>Group G Streptococci</td><td><i>Streptococcus pyogenes </i></td><td><i>Streptococcus pneumoniae </i></td><td>Biofilm-forming strain<i>S. aureus </i>(ATCC 25923)</td><td>Nonbiofilm-forming strain<i>E. coli </i>(ATCC 25922)</td></tr><tr><td>OD &#177; SD</td><td>OD &#177; SD</td><td>OD &#177; SD</td><td>OD &#177; SD</td><td>OD &#177; SD</td><td>OD &#177; SD</td><td>OD &#177; SD</td></tr><tr><td>With compound FR4</td><td>0.254 &#177; 0.004</td><td>0.205 &#177; 0.005</td><td>0.199 &#177; 0.010</td><td>0.191 &#177; 0.003</td><td>0.230 &#177; 0.004</td><td>0.246 &#177; 0.004</td><td>0.186 &#177; 0.004</td></tr><tr><td>Without compound</td><td>0.484 &#177; 0.008</td><td>0.215 &#177; 0.002</td><td>0.253 &#177; 0.002</td><td>0.304 &#177; 0.003</td><td>0.371 &#177; 0.002</td><td>0.395 &#177; 0.003</td><td>0.216 &#177; 0.073</td></tr><tr><td>With compound FR5*</td><td>0.224 &#177; 0.004</td><td>0.166 &#177; 0.005</td><td>0.158 &#177; 0.002</td><td>0.153 &#177; 0.005</td><td>0.224 &#177; 0.004</td><td>0.166 &#177; 0.005</td><td>0.158 &#177; 0.002</td></tr><tr><td>Without compound</td><td>0.368 &#177; 0.028</td><td>0.304 &#177; 0.003</td><td>0.377 &#177; 0.122</td><td>0.363 &#177; 0.079</td><td>0.445 &#177; 0.042</td><td>0.030 &#177; 0.038</td><td>0.224 &#177; 0.005</td></tr><tr><td>With compound FR13</td><td>0.208 &#177; 0.004</td><td>0.205 &#177; 0.004</td><td>0.195 &#177; 0.004</td><td>0.216 &#177; 0.004</td><td>0.235 &#177; 0.004</td><td>0.254 &#177; 0.004</td><td>0.165 &#177; 0.004</td></tr><tr><td>Without compound </td><td>0.404 &#177; 0.003</td><td>0.276 &#177; 0.056</td><td>0.262 &#177; 0.003</td><td>0.257 &#177; 0.024</td><td>0.277 &#177; 0.002</td><td>0.378 &#177; 0.003</td><td>0.254 &#177; 0.003</td></tr><tr><td>With 2(5H)-furanone (+ve control)</td><td>0.119 &#177; 0.002</td><td>0.123 &#177; 0.003</td><td>0.116 &#177; 0.004</td><td>0.117 &#177; 0.001</td><td>0.121 &#177; 0.001</td><td>0.107 &#177; 0.004</td><td>0.116 &#177; 0.002</td></tr><tr><td>Without compound</td><td>0.257 &#177; 0.003</td><td>0.216 &#177; 0.005</td><td>0.206 &#177; 0.055</td><td>0.202 &#177; 0.099</td><td>0.214 &#177; 0.030</td><td>0.216 &#177; 0.005</td><td>0.211 &#177; 0.002</td></tr><tr><td>With BHI broth (&#8722;ve control)</td><td>0.057 &#177; 0.038</td><td>0.050 &#177; 0.006</td><td>0.021 &#177; 0.002</td><td>0.069 &#177; 0.020</td><td>0.095 &#177; 0.012</td><td>0.084 &#177; 0.006</td><td>0.084 &#177; 0.006</td></tr><tr><td>Without compound</td><td>0.254 &#177; 0.003</td><td>0.243 &#177; 0.045</td><td>0.211 &#177; 0.002</td><td>0.243 &#177; 0.045</td><td>0.270 &#177; 0.042</td><td>0.243 &#177; 0.002</td><td>0.208 &#177; 0.074</td></tr></table>
214a7b1c8ac73b3f877a0488037dbe51554ca4c75f4aa91dada5122d513e9d96.png
complex
<table><tr><td></td><td></td><td colspan="3">Aurora A and p27 expression</td><td rowspan="2"><i>P</i></td></tr><tr><td></td><td></td><td>2H</td><td>1H1L</td><td>2L</td></tr><tr><td colspan="6">Sex</td></tr><tr><td>Male</td><td>63</td><td>54</td><td>7</td><td>2</td><td rowspan="2">0.191</td></tr><tr><td>Female</td><td>17</td><td>15</td><td>2</td><td>0</td></tr><tr><td colspan="6">Age (years)</td></tr><tr><td>&lt;60</td><td>27</td><td>22</td><td>5</td><td>0</td><td rowspan="2">0.071</td></tr><tr><td>&gt;=60</td><td>53</td><td>47</td><td>6</td><td>0</td></tr><tr><td colspan="6">Tumor volume (cm<sup>3</sup>)</td></tr><tr><td>&lt;=5</td><td>46</td><td>40</td><td>6</td><td>0</td><td rowspan="2">0.203</td></tr><tr><td>&gt;5</td><td>34</td><td>29</td><td>3</td><td>2</td></tr><tr><td colspan="6">Tumor location</td></tr><tr><td>Up</td><td>19</td><td>15</td><td>4</td><td>0</td><td rowspan="3">0.687</td></tr><tr><td>Middle</td><td>22</td><td>19</td><td>3</td><td>0</td></tr><tr><td>Down</td><td>39</td><td>35</td><td>4</td><td>0</td></tr><tr><td colspan="6">Pathological grade</td></tr><tr><td>II</td><td>26</td><td>20</td><td>6</td><td>0</td><td rowspan="3">0.991</td></tr><tr><td>II&#8211;III</td><td>25</td><td>25</td><td>0</td><td>0</td></tr><tr><td>III</td><td>29</td><td>24</td><td>3</td><td>2</td></tr><tr><td colspan="6">Invasion stage</td></tr><tr><td>Mucosal and submucosal</td><td>1</td><td>1</td><td>0</td><td>0</td><td rowspan="3">0.372</td></tr><tr><td>Muscular layer</td><td>8</td><td>7</td><td>1</td><td>0</td></tr><tr><td>Serous membrane and outmembrane</td><td>71</td><td>61</td><td>8</td><td>2</td></tr><tr><td colspan="6">Lymph node metastasis</td></tr><tr><td>0</td><td>17</td><td>16</td><td>1</td><td>0</td><td rowspan="3">0.510</td></tr><tr><td>1&#8211;6</td><td>36</td><td>29</td><td>7</td><td>0</td></tr><tr><td>&gt;=7</td><td>27</td><td>24</td><td>3</td><td>0</td></tr><tr><td colspan="6">TNM stage</td></tr><tr><td>I</td><td>5</td><td>5</td><td>0</td><td>0</td><td rowspan="4">0.031</td></tr><tr><td>II</td><td>22</td><td>19</td><td>3</td><td>0</td></tr><tr><td>III</td><td>46</td><td>41</td><td>3</td><td>2</td></tr><tr><td>IV</td><td>7</td><td>4</td><td>3</td><td>0</td></tr><tr><td>Total</td><td>80</td><td></td><td></td><td></td><td>80</td></tr></table>
1d211d2b59e24841d2b261112fc14ec52b4cf6ddc157092a0b497c35fa2513a4.png
simple
<table><tr><td>Inhalation repeats</td><td>PIF cut-off value (L/min)</td><td>Sensitivity (%)</td><td>Specificity (%)</td><td>AUC</td><td>Positive predictive value (%)</td><td>Negative predictive value (%)</td></tr><tr><td>I</td><td>140</td><td>84</td><td>53</td><td>0.69</td><td>81</td><td>59</td></tr><tr><td>II</td><td>120</td><td>86</td><td>69</td><td>0.83</td><td>69</td><td>86</td></tr><tr><td>III</td><td>100</td><td>89</td><td>76</td><td>0.89</td><td>59</td><td>95</td></tr><tr><td>IV</td><td>100</td><td>87</td><td>71</td><td>0.86</td><td>48</td><td>95</td></tr></table>
1a96bd8c03cb29dd2c29bf02b1143e4197ba499263f03ec1aea7b11ebee03604.png
complex
<table><tr><td></td><td>Q1 <sup>a</sup></td><td>Q2 <sup>a</sup></td><td>Q3 <sup>a</sup></td><td>Q4 <sup>a</sup></td><td><i>P</i><sup>b</sup></td><td>n</td><td>&#946; % <sup>c</sup></td><td colspan="2">95% CI</td></tr><tr><td colspan="10">Men n=2 264</td></tr><tr><td>PNNS-GS range</td><td>&#8804;8.05</td><td>[8.05-9.30]</td><td>[9.30-10.70]</td><td>&gt;10.70</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>BMI kg/m<sup>2</sup></td><td>26.4 (25.9-26.9)</td><td>25.7 (25.2-26.2)</td><td>25.7 (25.2-26.2)</td><td>25.2 (24.7-25.7)</td><td>&lt;.0001</td><td>2264</td><td>-6.49</td><td>-8.40</td><td>-4.54</td></tr><tr><td>WC (cm)<sup>d</sup></td><td>94.8 (93.3-96.2)</td><td>92.5 (91.1-93.9)</td><td>92.1 (90.7-93.5)</td><td>90.1 (88.8-91.5)</td><td>&lt;.0001</td><td>2264</td><td>-8.37</td><td>-10.15</td><td>-6.55</td></tr><tr><td>HC (cm)<sup>d</sup></td><td>100.4 (99.5-101.3)</td><td>99.0 (98.1-99.9)</td><td>99.2 (98.3-100.1)</td><td>98.1 (97.3-99.0)</td><td>&lt;.0001</td><td>2261</td><td>-6.57</td><td>-8.47</td><td>-4.63</td></tr><tr><td>WHR</td><td>0.94 (0.94-0.95)</td><td>0.93 (0.93-0.94)</td><td>0.93 (0.92-0.94)</td><td>0.92 (0.91-0.93)</td><td>&lt;.0001</td><td>2261</td><td>-7.41</td><td>-9.19</td><td>-5.59</td></tr><tr><td>WHtR</td><td>0.54 (0.54-0.55)</td><td>0.53 (0.52-0.54)</td><td>0.53 (0.52-0.54)</td><td>0.52 (0.51-0.52)</td><td>&lt;.0001</td><td>2264</td><td>-8.26</td><td>-10.00</td><td>-6.47</td></tr><tr><td>% body fat</td><td>21.2 (20.1-22.4)</td><td>19.7 (18.7-20.8)</td><td>19.7 (18.6-20.7)</td><td>17.7 (16.8-18.7)</td><td>&lt;.0001</td><td>2235</td><td>-8.60</td><td>-10.40</td><td>-6.76</td></tr><tr><td>trunk fat mass (kg)<sup>d</sup></td><td>10.2 (9.4-11.0)</td><td>9.1 (8.4-9.9)</td><td>9.0 (8.3-9.8)</td><td>7.7 (7.1-8.4)</td><td>&lt;.0001</td><td>2235</td><td>-7.27</td><td>-9.12</td><td>-5.38</td></tr><tr><td>% trunk fat</td><td>22.3 (20.9-23.9)</td><td>20.5 (19.2-21.9)</td><td>20.3 (19.0-21.7)</td><td>17.8 (16.6-19.0)</td><td>&lt;.0001</td><td>2235</td><td>-9.11</td><td>-11.00</td><td>-7.22</td></tr><tr><td>leg fat mass (kg)<sup>d</sup></td><td>4.99 (4.73-5.27)</td><td>4.58 (4.34-4.83)</td><td>4.61 (4.37-4.87)</td><td>4.26 (4.03-4.49)</td><td>&lt;.0001</td><td>2235</td><td>-9.05</td><td>-10.88</td><td>-7.18</td></tr><tr><td>% leg fat</td><td>19.5 (18.8-20.3)</td><td>18.4 (17.7-19.2)</td><td>18.6 (17.9-19.3)</td><td>17.4 (16.8-18.1)</td><td>&lt;.0001</td><td>2235</td><td>-6.81</td><td>-8.56</td><td>-5.02</td></tr><tr><td>TLR</td><td>2.04 (1.95-2.13)</td><td>1.98 (1.90-2.07)</td><td>1.95 (1.86-2.04)</td><td>1.81 (1.73-1.89)</td><td>&lt;.0001</td><td>2235</td><td>-8.11</td><td>-10.10</td><td>-6.05</td></tr><tr><td colspan="10">Women n=5 638</td></tr><tr><td>PNNS-GS range</td><td>&#8804;8.17</td><td>[8.17-9.52]</td><td>[9.52-10.80]</td><td>&gt;10.8</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>BMI kg/m<sup>2</sup></td><td>24.0 (23.5-24.4)</td><td>23.9 (23.5-24.3)</td><td>23.7 (23.3-24.1)</td><td>23.3 (22.8-23.7)</td><td>&lt;.0001</td><td>5639</td><td>-2.73</td><td>-3.99</td><td>-1.45</td></tr><tr><td>WC (cm)<sup>d</sup></td><td>81.3 (80.2-82.5)</td><td>80.8 (79.7-81.9)</td><td>79.9 (78.8-81.0)</td><td>78.9 (77.8-80.0)</td><td>&lt;.0001</td><td>5639</td><td>-3.96</td><td>-5.21</td><td>-2.69</td></tr><tr><td>HC (cm)<sup>d</sup></td><td>99.3 (98.4-100.2)</td><td>98.9 (98.0-99.8)</td><td>98.5 (97.5-99.4)</td><td>97.6 (96.6-98.5)</td><td>&lt;.0001</td><td>5636</td><td>-3.28</td><td>-4.57</td><td>-1.97</td></tr><tr><td>WHR</td><td>0.82 (0.81-0.83)</td><td>0.82 (0.81-0.82)</td><td>0.81 (0.80-0.82)</td><td>0.81 (0.80-0.82)</td><td>&lt;.0001</td><td>5636</td><td>-2.92</td><td>-4.22</td><td>-1.60</td></tr><tr><td>WHtR</td><td>0.50 (0.49-0.51)</td><td>0.50 (0.49-0.50)</td><td>0.49 (0.48-0.50)</td><td>0.49 (0.48-0.49)</td><td>&lt;.0001</td><td>5639</td><td>-4.09</td><td>-5.32</td><td>-2.85</td></tr><tr><td>% body fat</td><td>29.5 (28.7-30.4)</td><td>29.2 (28.4-30.1)</td><td>28.6 (27.7-29.4)</td><td>27.6 (26.8-28.5)</td><td>&lt;.0001</td><td>5590</td><td>-4.18</td><td>-5.44</td><td>-2.89</td></tr><tr><td>trunk fat mass (kg)<sup>d</sup></td><td>9.3 (8.6-10.0)</td><td>9.1 (8.5-9.9)</td><td>8.8 (8.1-9.5)</td><td>8.3 (7.6-8.9)</td><td>&lt;.0001</td><td>5590</td><td>-1.20</td><td>-1.61</td><td>-0.79</td></tr><tr><td>% trunk fat</td><td>24.8 (23.7-25.9)</td><td>24.7 (23.6-25.9)</td><td>23.9 (22.8-25.0)</td><td>22.8 (21.8-23.9)</td><td>&lt;.0001</td><td>5590</td><td>-3.47</td><td>-4.79</td><td>-2.15</td></tr><tr><td>leg fat mass (kg)<sup>d</sup></td><td>8.2 (7.9-8.5)</td><td>8.1 (7.8-8.4)</td><td>7.9 (7.6-8.2)</td><td>7.6 (7.4-7.9)</td><td>&lt;.0001</td><td>5590</td><td>-2.09</td><td>-2.81</td><td>-1.37</td></tr><tr><td>% leg fat</td><td>36.3 (35.7-37.0)</td><td>35.9 (35.3-36.6)</td><td>35.4 (34.8-36.0)</td><td>34.7 (34.1-35.3)</td><td>&lt;.0001</td><td>5590</td><td>-4.71</td><td>-5.91</td><td>-3.49</td></tr><tr><td>TLR</td><td>1.04 (1.00-1.07)</td><td>1.05 (1.01-1.08)</td><td>1.02 (0.99-1.06)</td><td>1.00 (0.96-1.04)</td><td>0.001</td><td>5590</td><td>-0.67</td><td>-1.12</td><td>-0.21</td></tr></table>
acad95f15152ff50950a7626d4686915c8a7aa2e712553eee9f44b1249d2fac7.png
simple
<table><tr><td></td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td><td>9</td><td>10</td><td>11</td><td>12</td><td>13</td><td>14</td><td>15</td><td>16</td><td>17</td><td>18</td><td>19</td><td>20</td><td>21</td></tr><tr><td>A</td><td>224</td><td>228</td><td>186</td><td>146</td><td>213</td><td>67</td><td>756</td><td>0</td><td>865</td><td>670</td><td>770</td><td>444</td><td>282</td><td>131</td><td>182</td><td>164</td><td>185</td><td>184</td><td>141</td><td>179</td><td>165</td></tr><tr><td>C</td><td>226</td><td>203</td><td>239</td><td>229</td><td>310</td><td>84</td><td>0</td><td>5</td><td>0</td><td>0</td><td>0</td><td>15</td><td>99</td><td>274</td><td>272</td><td>273</td><td>273</td><td>264</td><td>286</td><td>283</td><td>304</td></tr><tr><td>G</td><td>301</td><td>291</td><td>333</td><td>302</td><td>225</td><td>71</td><td>0</td><td>8</td><td>2</td><td>0</td><td>119</td><td>224</td><td>437</td><td>394</td><td>301</td><td>337</td><td>275</td><td>303</td><td>328</td><td>276</td><td>275</td></tr><tr><td>T</td><td>146</td><td>175</td><td>139</td><td>220</td><td>149</td><td>675</td><td>141</td><td>884</td><td>30</td><td>201</td><td>8</td><td>214</td><td>79</td><td>98</td><td>142</td><td>123</td><td>164</td><td>146</td><td>142</td><td>159</td><td>153</td></tr><tr><td>Con</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>T</td><td>A</td><td>T</td><td>A</td><td>A</td><td>A</td><td>D</td><td>W</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td></tr></table>
da4419c230b904407d5f3ad3ead513264ccf579b47fc2593344806ac5004ca60.png
complex
<table><tr><td colspan="8">FIGO stage after definitive histology</td></tr><tr><td>PresumedStage on MRI</td><td>IA</td><td>IB</td><td>IC</td><td>IIA</td><td>IIB</td><td>IIIA</td><td>Total</td></tr><tr><td>IA</td><td>28.5%</td><td>43%</td><td>14.2%</td><td>0</td><td>14.2%</td><td>0</td><td>14</td></tr><tr><td>IB</td><td>31.5%</td><td>40%</td><td>23%</td><td>5.5%</td><td>0</td><td>0</td><td>35</td></tr><tr><td>IC</td><td>0</td><td>18.5%</td><td>74%</td><td>3.7%</td><td>0</td><td>3.7</td><td>27</td></tr><tr><td>IIA</td><td>0</td><td>67%</td><td>33%</td><td>0</td><td>0</td><td>0</td><td>3</td></tr><tr><td>IIB</td><td>0</td><td>50%</td><td>0</td><td>0</td><td>0</td><td>50%</td><td>2</td></tr><tr><td>IIIA</td><td>0</td><td>0</td><td>100%</td><td>0</td><td>0</td><td>0</td><td>1</td></tr><tr><td>Total</td><td>18.3%</td><td>34%</td><td>39%</td><td>3.5%</td><td>2.5%</td><td>2.5%</td><td>82</td></tr></table>
fa3f0112e097c434c7c283dc2feb1240cee3fa545f28d40c17903727c4fd6870.png
simple
<table><tr><td></td><td>Low ox-LDL&lt;69.4 U/L(n = 80)</td><td>High ox-LDL&#8805; 69.4 U/L(n = 80)</td><td><i>P</i>-value*</td></tr><tr><td>Women (%)</td><td>60.8</td><td>52.6</td><td>0.305</td></tr><tr><td>Age (y)</td><td>23.1 &#177; 3.6</td><td>23.4 &#177; 3.4</td><td>0.145</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>21.6 &#177; 2.8</td><td>22.4 &#177; 3.0</td><td><i>0.046</i></td></tr><tr><td>Waist circumference (cm)</td><td>78.0 &#177; 8.7</td><td>78.3 &#177; 8.7</td><td>0.863</td></tr><tr><td>Waist-to-hip ratio</td><td>0.8 &#177; 0.1</td><td>0.8 &#177; 0.1</td><td>0.469</td></tr><tr><td>Sum of 4 ST (mm)</td><td>42.6 &#177; 16.8</td><td>45.0 &#177; 20.4</td><td>0.369</td></tr><tr><td>Truncal fat (%)</td><td>57.4 &#177; 7.1</td><td>59.3 &#177; 6.1</td><td>0.069</td></tr><tr><td>Total body fat (%)</td><td>23.8 &#177; 6.1</td><td>23.4 &#177; 7.0</td><td>0.735</td></tr><tr><td>Body fat mass (kg)</td><td>15.0 &#177; 5.2</td><td>14.7 &#177; 5.4</td><td>0.303</td></tr><tr><td>Systolic blood pressure (mmHg)</td><td>109 &#177; 9</td><td>110 &#177; 9</td><td>0.239</td></tr><tr><td>Diastolic blood pressure (mmHg)</td><td>74 &#177; 7</td><td>73 &#177; 7</td><td>0.257</td></tr><tr><td>Glucose (mg/dL)</td><td>90.8 &#177; 7.0</td><td>90.3 &#177; 6.3</td><td>0.394</td></tr><tr><td>Insulin (&#956;U/mL)**</td><td>10.3 &#177; 5.0</td><td>10.2 &#177; 6.0</td><td>0.302</td></tr><tr><td>HOMA-IR**</td><td>2.3 &#177; 1.2</td><td>2.3 &#177; 1.3</td><td>0.245</td></tr><tr><td>Total cholesterol (mg/dL)</td><td>153.4 &#177; 27.8</td><td>166.5 &#177; 33.5</td><td><i>0.007</i></td></tr><tr><td>HDL-c (mg/dL) <sup>&#8224;</sup></td><td>47.3 &#177; 12.4</td><td>45.7 &#177; 10.4</td><td>0.342</td></tr><tr><td>LDL-c (mg/dL)</td><td>91.0 &#177; 26.6</td><td>100.2 &#177; 26.4</td><td><i>0.009</i></td></tr><tr><td>Triacylglycerol (mg/dL)</td><td>96.1 &#177; 49.1</td><td>103.2 &#177; 38.5</td><td>0.059</td></tr><tr><td>Total cholesterol-to-HDL-c ratio<sup>&#8224;</sup></td><td>3.3 &#177; 0.6</td><td>3.8 &#177; 0.9</td><td><i>&lt;0.001</i></td></tr><tr><td>Uric acid (mg/dL)</td><td>3.4 &#177; 1.1</td><td>3.7 &#177; 1.1</td><td><i>0.049</i></td></tr><tr><td>GPx activity (nmol/[mL/min])<sup>&#8225;</sup></td><td>487.9 &#177; 231.3</td><td>659.1 &#177; 299.2</td><td><i>0.002</i></td></tr><tr><td>Selenium (ng/g of nail)<sup>&#167;</sup></td><td>396.2 &#177; 88.0</td><td>365.5 &#177; 76.7</td><td><i>0.033</i></td></tr><tr><td>Zinc (&#956;g/g of nail)<sup>&#167;</sup></td><td>124.5 &#177; 57.7</td><td>132.3 &#177; 68.7</td><td>0.212</td></tr><tr><td>Copper (&#956;g/g of nail)<sup>&#167;</sup></td><td>7.4 &#177; 5.5</td><td>7.1 &#177; 7.1</td><td>0.247</td></tr></table>
a5762c2be249c10f0017e931f24e41a4f05bfd31f07c3f6f4e380d2edb26c1e4.png
simple
<table><tr><td>Observation</td><td>Genotype</td><td>Males</td><td>Females</td></tr><tr><td>Body weight (g)</td><td>WT</td><td>31.5 &#177; 18.8</td><td>20.3 &#177; 0.9</td></tr><tr><td></td><td>TG</td><td>25.5 &#177; 1.7*</td><td>22.2 &#177; 0.9</td></tr><tr><td>Body length (mm)</td><td>WT</td><td>92.8 &#177; 0.9</td><td>86.6 &#177; 0.5</td></tr><tr><td></td><td>TG</td><td>89.4 &#177; 1.0*</td><td>87.8 &#177; 1.1</td></tr><tr><td>Grip strength (score 0&#8211;4)</td><td>WT</td><td>2.4 &#177; 0.2</td><td>1.0 &#177; 0</td></tr><tr><td></td><td>TG</td><td>0.8 &#177; 0.2**</td><td>1.6 &#177; 0.2</td></tr><tr><td>Wire maneuver (score 0&#8211;4)</td><td>WT</td><td>1.4 &#177; 0.2</td><td>2.8 &#177; 0.5</td></tr><tr><td></td><td>TG</td><td>4.0 &#177; 0***</td><td>2.0 &#177; 0.6</td></tr><tr><td>Tail elevation (score 0&#8211;2)</td><td>WT</td><td>2.0 &#177; 0</td><td>1.4 &#177; 0.2</td></tr><tr><td></td><td>TG</td><td>1.2 &#177; 0.2*</td><td>1.2 &#177; 0.2</td></tr></table>
a7f8011e15b8561a8ed31c9e55630d9b0c5ec74b6da26598154ea30ab4416d9d.png
simple
<table><tr><td></td><td>Quartile 1</td><td>Quartile 2</td><td>Quartile 3</td><td>Quartile 4</td></tr><tr><td>NBA</td><td>340.6 (357.7)</td><td>371.5 (374.9)</td><td>364.6 (369.7)</td><td>408.9 (398.6)</td></tr><tr><td>NFL</td><td>65.0 (60.2)</td><td>64.4 (59.7)</td><td>65.6 (57.7)</td><td>67.7 (63.4)</td></tr><tr><td>NHL</td><td>313.7 (359.3)</td><td>366.6 (424.8)</td><td>394.9 (424.6)</td><td>410.9 (402.6)</td></tr></table>
47568a00074caaca4eb5023c6c125a0577a5ed56dcd6b35d5d6b470ac7ad8ad8.png
simple
<table><tr><td></td><td>n</td><td>Age (years)</td><td>Education (years)</td><td>Frailty index</td><td>Social vulnerability index</td><td>Protection index</td><td>CASI error at baseline</td></tr><tr><td>Full cohort</td><td>3,845</td><td>77.9 (4.7)</td><td>10.5 (3.2)</td><td>0.15 (0.09)</td><td>0.25 (0.13)</td><td>0.36 (0.12)</td><td>17.8 (16.4)</td></tr><tr><td>Alive at first follow-up</td><td>3,347</td><td>77.4 (4.4)</td><td>10.6 (3.2)</td><td>0.14 (0.08)</td><td>0.25 (0.13)</td><td>0.37 (0.11)</td><td>15.5 (12.5)</td></tr><tr><td>Dead at first follow-up</td><td>498</td><td>80.9 (5.4)</td><td>9.8 (3.3)</td><td>0.19 (0.10)</td><td>0.30 (0.15)</td><td>0.30 (0.14)</td><td>33.1 (27.7)</td></tr><tr><td>Alive at second follow-up</td><td>2,759</td><td>76.9 (4.0)</td><td>10.7 (3.2)</td><td>0.14 (0.08)</td><td>0.24 (0.12)</td><td>0.37 (0.11)</td><td>14.1 (9.9)</td></tr><tr><td>Dead at second follow-up</td><td>1,086</td><td>80.3 (5.3)</td><td>10.0 (3.2)</td><td>0.18 (0.10)</td><td>0.29 (0.0.13)</td><td>0.32 (0.13)</td><td>27.4 (24.1)</td></tr></table>
20c60da7a8ddf540d49208881379340cf61b240f248cc11a12516d055cafb77b.png
complex
<table><tr><td>ID</td><td>No. of seed</td><td>FA level</td><td>Oleic acid (C18:1)</td><td>Linoleic acid (C18:2)</td><td>Linolenic acid (C18:3)</td><td>Erucic acid (C22:1 )</td></tr><tr><td rowspan="3">WG4-3</td><td rowspan="3">18</td><td>Mean &#177; SD <sup>a</sup></td><td>20.1 &#177; 2.4**</td><td>2.7 &#177; 0.9**</td><td>3.0 &#177; 0.8**</td><td>65.5 &#177; 3.4**</td></tr><tr><td>Max</td><td>26.3</td><td>4.7</td><td>5.4</td><td>69.3</td></tr><tr><td>Min</td><td>16.8</td><td>1.6</td><td>1.9</td><td>54.6</td></tr><tr><td rowspan="3">WG4-4</td><td rowspan="3">20</td><td>Mean &#177; SD</td><td>20.0 &#177; 1.1**</td><td>2.3 &#177; 0.5**</td><td>3.0 &#177; 0.5**</td><td>67 &#177; 2.5**</td></tr><tr><td>Max</td><td>21.9</td><td>3.3</td><td>4.1</td><td>70.8</td></tr><tr><td>Min</td><td>18.0</td><td>1.5</td><td>2.3</td><td>60.7</td></tr><tr><td rowspan="3">WG4-5</td><td rowspan="3">19</td><td>Mean &#177; SD</td><td>21.9 &#177; 3.5**</td><td>2.1 &#177; 1.8**</td><td>2.3 &#177; 0.9**</td><td>63.5 &#177; 3.2</td></tr><tr><td>Max</td><td>27.4</td><td>7.6</td><td>5.4</td><td>66.6</td></tr><tr><td>Min</td><td>11.5</td><td>1.0</td><td>1.5</td><td>55.5</td></tr><tr><td rowspan="3">WG19-4</td><td rowspan="3">19</td><td>Mean &#177; SD</td><td>22.6 &#177; 2.3**</td><td>1.6 &#177; 0.2**</td><td>2.5 &#177; 0.3**</td><td>60.7 &#177; 5.2</td></tr><tr><td>Max</td><td>29.5</td><td>2.1</td><td>3.1</td><td>65.9</td></tr><tr><td>Min</td><td>20.4</td><td>1.3</td><td>1.8</td><td>46.1</td></tr><tr><td rowspan="3">WG19-5</td><td rowspan="3">20</td><td>Mean &#177; SD</td><td>21.4 &#177; 3.2**</td><td>2.7 &#177; 1.8**</td><td>3.3 &#177; 0.7*</td><td>60 &#177; 4.6</td></tr><tr><td>Max</td><td>27.1</td><td>9.5</td><td>5.3</td><td>64.1</td></tr><tr><td>Min</td><td>11.3</td><td>1.3</td><td>2.3</td><td>50.2</td></tr><tr><td rowspan="3">WG19-6</td><td rowspan="3">20</td><td>Mean &#177; SD</td><td>18.0 &#177; 0.9*</td><td>2.0 &#177; 0.4**</td><td>2.4 &#177; 0.3**</td><td>66.2 &#177; 1.0**</td></tr><tr><td>Max</td><td>20.0</td><td>2.9</td><td>3.0</td><td>68.0</td></tr><tr><td>Min</td><td>16.4</td><td>1.4</td><td>1.9</td><td>64.5</td></tr><tr><td rowspan="2">Control</td><td rowspan="2">19</td><td>Mean &#177; SD</td><td>12.0 &#177; 0.5</td><td>8.2 &#177; 0.4</td><td>5.1 &#177; 0.2</td><td>63.1 &#177; 0.8</td></tr><tr><td>Max</td><td>12.8</td><td>9.0</td><td>5.6</td><td>64.4</td></tr><tr><td> </td><td> </td><td>Min</td><td>10.9</td><td>7.5</td><td>4.7</td><td>61.6</td></tr></table>
07f35eb11569c4d75a787d7db4748c576522387fe5eff5d9128b13bc0e0caeff.png
simple
<table><tr><td>Sample ID</td><td>Tumor type</td><td>Tumor cell (%)</td><td>Sequencing depth (x)</td><td>JAK2 p.V617F allele fraction (%)</td><td>Co-occurring mutation (allele fraction %)</td></tr><tr><td>592</td><td>Non-small cell carcinoma</td><td>30</td><td>1999</td><td>8.2</td><td>KRAS p.G12V (17.2)</td></tr><tr><td>664</td><td>Adenocarcinoma with squamous features</td><td>50</td><td>1996</td><td>7</td><td>BRAF p.V600E (27.3)</td></tr><tr><td>717</td><td>Adenocarcinoma</td><td>40</td><td>1273</td><td>2</td><td>-</td></tr><tr><td>915</td><td>Favoring adenocarcinoma</td><td>60</td><td>1539</td><td>2.1</td><td>EGFR exon19 del (52.1)</td></tr><tr><td>1182</td><td>Adenocarcinoma</td><td>40</td><td>1997</td><td>2.4</td><td>BRAF p.V600E (10.4)</td></tr><tr><td>1200</td><td>Mucinous adenocarcinoma</td><td>10</td><td>1422</td><td>10.5</td><td>KRAS p.G12V (4.8)</td></tr><tr><td>1527</td><td>Adenocarcinoma</td><td>30</td><td>1997</td><td>10.8</td><td>-</td></tr><tr><td>1588</td><td>Adenocarcinoma, acinar type</td><td>20</td><td>892</td><td>6.5</td><td>-</td></tr><tr><td>1825</td><td>Adenocarcinoma with mucinous features</td><td>30</td><td>1998</td><td>13.4</td><td>KRAS p.G12C (25.4)</td></tr></table>
cee52e430fd77f1bf4840cf3a78e3671e58bc19f65271d03fab0df53e43ff830.png
complex
<table><tr><td colspan="2">Instrument</td><td></td><td colspan="2">Before therapy (t<sub>1</sub>)</td><td colspan="2">Four weeks after therapy (t<sub>2</sub>)</td><td colspan="2">One year after therapy (t<sub>3</sub>)</td><td colspan="2">Statistics (t<sub>1 </sub>to t<sub>3</sub>)</td></tr><tr><td></td><td></td><td>N</td><td>Mean Value</td><td>SD</td><td>Mean Value</td><td>SD</td><td>Mean Value</td><td>SD</td><td>Wilcoxon-Test</td><td>Effect size d</td></tr><tr><td>SCL-90 R</td><td>Global Severity Index</td><td>11</td><td>0.93</td><td>0.38</td><td>0.57</td><td>0.21</td><td>0.44</td><td>0.33</td><td>p = 0.008**</td><td>1.30</td></tr><tr><td></td><td>Positive Symptom Total</td><td>11</td><td>44.4</td><td>12.9</td><td>36.3</td><td>10.4</td><td>27.1</td><td>16.5</td><td>p = 0.016*</td><td>1.08</td></tr><tr><td></td><td>Positive Symptom Distress Index</td><td>11</td><td>1.84</td><td>0.39</td><td>1.4</td><td>0.19</td><td>1.37</td><td>0.29</td><td>p = 0.013*</td><td>1.27</td></tr><tr><td></td><td>G1 Somatization</td><td>11</td><td>0.65</td><td>0.43</td><td>0.5</td><td>0.49</td><td>0.36</td><td>0.28</td><td>p = 0.028*</td><td>0.68</td></tr><tr><td></td><td>G2 Obsessive-Compulsive</td><td>11</td><td>0.99</td><td>0.55</td><td>0.6</td><td>0.38</td><td>0.6</td><td>0.4</td><td>p = 0.052</td><td>0.70</td></tr><tr><td></td><td>G3 Interpersonal Sensitivity</td><td>11</td><td>1.21</td><td>0.51</td><td>0.92</td><td>0.49</td><td>0.46</td><td>0.44</td><td>p = 0.011*</td><td>1.49</td></tr><tr><td></td><td>G4 Depression</td><td>11</td><td>1.63</td><td>0.6</td><td>0.79</td><td>0.47</td><td>0.48</td><td>0.4</td><td>p = 0.004**</td><td>2.14</td></tr><tr><td></td><td>G5 Anxiety</td><td>11</td><td>0.84</td><td>0.39</td><td>0.4</td><td>0.26</td><td>0.35</td><td>0.47</td><td>p = 0.014*</td><td>1.05</td></tr><tr><td></td><td>G6 Hostility</td><td>11</td><td>1.08</td><td>0.59</td><td>0.57</td><td>0.45</td><td>0.85</td><td>0.73</td><td>p = 0.563</td><td>0.24</td></tr><tr><td></td><td>G7 Phobic Anxiety</td><td>11</td><td>0.43</td><td>0.61</td><td>0.25</td><td>0.42</td><td>0.29</td><td>0.5</td><td>p = 0.572</td><td>0.23</td></tr><tr><td></td><td>G8 Paranoid Ideation</td><td>11</td><td>0.54</td><td>0.32</td><td>0.52</td><td>0.37</td><td>0.32</td><td>0.32</td><td>p = 0.233</td><td>0.58</td></tr><tr><td></td><td>G9 Psychoticism</td><td>11</td><td>0.42</td><td>0.4</td><td>0.3</td><td>0.21</td><td>0.18</td><td>0.22</td><td>p = 0.075</td><td>0.64</td></tr><tr><td></td><td>S10 Additional Items</td><td>11</td><td>9.42</td><td>5.04</td><td>5.88</td><td>2.85</td><td>4.91</td><td>3.65</td><td>p = 0.032*</td><td>1.01</td></tr><tr><td>YSR</td><td>Global Score</td><td>11</td><td>71.5</td><td>11.3</td><td>45.5</td><td>22.6</td><td>41.8</td><td>19.2</td><td>p = 0.003**</td><td>1.82</td></tr><tr><td></td><td>Internalizing Behavior</td><td>11</td><td>26.8</td><td>5.3</td><td>15.9</td><td>8.1</td><td>14.6</td><td>9.3</td><td>p = 0.007**</td><td>1.54</td></tr><tr><td></td><td>Externalizing Behavior</td><td>11</td><td>19.7</td><td>8.4</td><td>15.2</td><td>9.5</td><td>14.5</td><td>7.4</td><td>p = 0.008**</td><td>0.57</td></tr><tr><td></td><td>Social Withdrawal</td><td>11</td><td>7.08</td><td>2.61</td><td>4.38</td><td>3.16</td><td>3.91</td><td>2.77</td><td>p = 0.016*</td><td>1.13</td></tr><tr><td></td><td>Somatic Complaints</td><td>11</td><td>4.0</td><td>2.63</td><td>2.63</td><td>2.13</td><td>3.09</td><td>2.94</td><td>p = 0.505</td><td>0.26</td></tr><tr><td></td><td>Anxious/Depressed</td><td>11</td><td>17.08</td><td>4.5</td><td>9.75</td><td>5.2</td><td>8.09</td><td>7.03</td><td>p = 0.008**</td><td>1.47</td></tr><tr><td></td><td>Social Problems</td><td>11</td><td>4.0</td><td>2.22</td><td>2.13</td><td>1.64</td><td>1.91</td><td>2.21</td><td>p = 0.058</td><td>0.86</td></tr><tr><td></td><td>Schizoid/Obsessive</td><td>11</td><td>3.0</td><td>2.34</td><td>1.5</td><td>1.51</td><td>0.91</td><td>1.45</td><td>p = 0.011*</td><td>1.04</td></tr><tr><td></td><td>Attention Problems</td><td>11</td><td>8.67</td><td>2.35</td><td>3.88</td><td>2.03</td><td>4.45</td><td>3.14</td><td>p = 0.005**</td><td>1.46</td></tr><tr><td></td><td>Delinquent Behaviors</td><td>11</td><td>6.42</td><td>3.26</td><td>5.0</td><td>2.62</td><td>4.55</td><td>2.07</td><td>p = 0.041*</td><td>0.54</td></tr><tr><td></td><td>Aggressive Behaviors</td><td>11</td><td>13.25</td><td>5.71</td><td>10.13</td><td>7.02</td><td>9.91</td><td>5.74</td><td>p = 0.014*</td><td>0.54</td></tr><tr><td>DIKJ</td><td>Average Score Per Item</td><td>10</td><td>0.78</td><td>0.2</td><td>0.45</td><td>0.21</td><td>0.41</td><td>0.23</td><td>p = 0.022*</td><td>1.51</td></tr></table>
19ae047444c8677f65a60d56b61663b3e0e7630b788a93b401997da5a5247d0a.png
simple
<table><tr><td>Ligand</td><td><i>K</i><sub>d</sub> (&#956;M)</td><td>&#916;H (kcal/mol)</td><td>T&#916;S (kcal/mol)</td><td>n Value</td></tr><tr><td>&#945;-KG</td><td>34.4 &#177; 6.63</td><td>&#8722;6.03 &#177; 0.56</td><td>0.06</td><td>0.80 &#177; 0.05</td></tr><tr><td>NOG</td><td>5.35 &#177; 1.26</td><td>&#8722;5.14 &#177; 0.20</td><td>2.05</td><td>1.04 &#177; 0.03</td></tr><tr><td>Succinate</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>U</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>T</td><td>32.0 &#177; 5.24</td><td>&#8722;8.45 &#177; 0.74</td><td>-2.32</td><td>0.52 &#177; 0.03</td></tr><tr><td>5hmU</td><td>30.5 &#177; 5.59</td><td>&#8722;10.8 &#177; 1.19</td><td>-4.59</td><td>0.45 &#177; 0.04</td></tr><tr><td>5fU</td><td>108 &#177; 13.0</td><td>&#8722;8.73 &#177; 0.60</td><td>-3.31</td><td>0.20 &#177; 0.00</td></tr><tr><td>5caU</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr></table>
504eacfd7ee891857b5ace636d4c59f94aa393c658a0618a80bac818b8d91710.png
simple
<table><tr><td>Category</td><td>Gene</td><td>Homolog</td><td>WT1</td><td>WT2</td><td>MT</td><td>Description</td><td>Reference</td></tr><tr><td>Iron transport</td><td><i>Ftr1</i></td><td>HMPREF1120_04509</td><td>6.76</td><td>64.20</td><td>53.35</td><td>High-affinity iron transporter</td><td>Stearman et al., 1996</td></tr><tr><td></td><td><i>Fet3</i></td><td>HMPREF1120_04510</td><td></td><td>42.88</td><td>23.29</td><td>Ferrooxidoreductase Fet3</td><td></td></tr><tr><td></td><td><i>SidF</i></td><td>HMPREF1120_01438</td><td>4.55</td><td>3.58</td><td>5.95</td><td>Acetyl CoA:N6-hydroxylysine acetyl transferase</td><td>Chen et al., 2014</td></tr><tr><td></td><td><i>SidD</i></td><td>HMPREF1120_01440</td><td>8.74</td><td>4.41</td><td>6.92</td><td>Nonribosomal peptide synthase Pes1</td><td></td></tr><tr><td></td><td><i>SidA</i></td><td>HMPREF1120_07635</td><td>7.34</td><td>4.25</td><td>8.73</td><td>L-ornithine N5-oxygenase</td><td></td></tr><tr><td></td><td><i>SidC</i></td><td>HMPREF1120_07636</td><td>2.46</td><td></td><td></td><td>Nonribosomal siderophore peptide synthase SidC</td><td></td></tr><tr><td></td><td><i>Sit1</i></td><td>HMPREF1120_01434</td><td>4.47</td><td>7.10</td><td></td><td>MFS transporter, SIT family, siderophore-iron: H+ symporter</td><td>Heymann et al., 2000; Petris, 2004</td></tr><tr><td></td><td></td><td>HMPREF1120_02555</td><td>7.07</td><td>5.76</td><td>7.22</td><td>MFS transporter, SIT family, siderophore-iron: H+ symporter</td><td></td></tr><tr><td></td><td></td><td>HMPREF1120_07838</td><td>14.26</td><td>16.02</td><td>10.33</td><td>MFS transporter, SIT family, siderophore-iron: H+ symporter</td><td></td></tr><tr><td>Copper pransport</td><td><i>Crt</i></td><td>HMPREF1120_00028</td><td></td><td></td><td>4.74</td><td>Copper transporter family</td><td>Petris, 2004</td></tr><tr><td></td><td></td><td>HMPREF1120_05417</td><td></td><td></td><td>7.31</td><td>Copper transporter family</td><td></td></tr><tr><td></td><td></td><td>HMPREF1120_00028</td><td></td><td></td><td>4.72</td><td>Copper transporter</td><td></td></tr><tr><td></td><td><i>Atx1</i></td><td>HMPREF1120_03801</td><td></td><td></td><td>4.78</td><td>Heavy metal associated domain, Cu receptor</td><td>Lin et al., 1997</td></tr></table>
7a5b1623a9dc65531889834e4732bbe0c6a46d14662084e8fea55217de5f2c9c.png
complex
<table><tr><td>Structural themes</td><td>Referential themes</td></tr><tr><td rowspan="2">To be prepared for emergency situations</td><td>Focus on overview of accident site and patient and on need of feedback</td></tr><tr><td><i>To observe the situation</i> -<i>Ready to act Confirmation</i> and <i>Validation of one&#8217;s knowledge</i></td></tr><tr><td rowspan="3">Confidence in one&#8217;s own leadership</td><td>Focus on handling leadership.</td></tr><tr><td><i>Responsibility of leadership in emergency situations</i> and</td></tr><tr><td><i>Combining theory and practice</i></td></tr><tr><td>Developing professional knowledge</td><td>Focus on how the work strategy changes based on the competency of the colleague and the need for competence and skills development.</td></tr><tr><td> </td><td><i>Lack of a prehospital work strategy, Supporting novices, - Being alone,</i><i>Being familiar with the equipment, Seeking new knowledge</i> and <i>Practicing critical scenarios</i></td></tr></table>
1b298a1c53cf5891bda2005dada9772673eeea7511f29d70d2a0dc1789911663.png
simple
<table><tr><td> Variable</td><td>Healthy controls (<i>n</i> = 17)</td><td>Individuals with schizophrenia (<i>n</i> = 16)</td><td><i>t </i>(df = 31)*</td><td><i>P</i> value</td></tr><tr><td>Age (years)</td><td>43.65 &#177; 11.32</td><td>48.69 &#177;8.38</td><td>&#8722;1.446</td><td>.158</td></tr><tr><td>Gender</td><td>3 females; 14 males</td><td>4 females; 12 males</td><td>NA</td><td>NA</td></tr><tr><td>Education (years)</td><td>15.47&#177; 1.81</td><td>13.00 &#177; 2.25</td><td>3.487</td><td>.001</td></tr><tr><td>Subject's SES</td><td>2.23&#177; 1.01</td><td>3.63 1.41</td><td>&#8722;2.992</td><td>.006</td></tr><tr><td>Parental SES</td><td>2.54 &#177; 0.88</td><td>3.13 &#177; 1.45</td><td>&#8722;1.275</td><td>.213</td></tr><tr><td>Onset age (years)</td><td>NA</td><td>30.23 &#177; 11.95</td><td>NA</td><td>NA</td></tr><tr><td>Duration (years)</td><td>NA</td><td>17.15&#177; 11.32</td><td>NA</td><td>NA</td></tr><tr><td>Chlorpromazine equivalent (mg)</td><td>NA</td><td>381.13 &#177; 247.18</td><td>NA</td><td>NA</td></tr><tr><td>Medication type</td><td>NA</td><td>First generation = 3 Second generation = 9</td><td>NA</td><td>NA</td></tr><tr><td>Positive scale PANSS</td><td>NA</td><td>23.87 &#177;9.41</td><td>NA</td><td>NA</td></tr><tr><td>Negative scale PANSS</td><td>NA</td><td>22.33&#177; 9.56</td><td>NA</td><td>NA</td></tr><tr><td>General psychopathology PANSS</td><td>NA</td><td>43.00 &#177; 14.64</td><td>NA</td><td>NA</td></tr><tr><td>Total psychopathology PANSS</td><td>NA</td><td>89.20 &#177; 30.17</td><td>NA</td><td>NA</td></tr></table>
17ea6248dad21918ec259bfcb8b1167b14e15a11c1f6b68c4df07cd9c3e9ec50.png
simple
<table><tr><td>Flavonoid class</td><td>Molecular Weight</td><td>Glycosylation</td><td>Metabolic conversion</td><td>Colonic microflora</td></tr><tr><td>General</td><td>Decreases bioavailability</td><td>Generally removed</td><td>Major factor in bioavailability; can take place in small intestine, liver and colon; usually to glucuronides but also sulphation and methylation [39]; facilitates urinary and biliary excretion [39].</td><td>Influence availability; catabolize compounds to low molecular weight compounds that are readily absorbed [58].</td></tr><tr><td>Flavan-3-ols (monomeric)</td><td></td><td></td><td>Major bioactive forms: conjugates of epicatechin [41]; catechin: methyl, sulfate and glucuronic acid conjugates; epicatechin: mainly to sulfate conjugates, no glucuronidation [41].</td><td></td></tr><tr><td>Proanthocyanidins</td><td>Decreases bioavailability [40].</td><td></td><td>Major bioactive forms: conjugates of epicatechin [41]; oligomeric procyanidins can absorb in small intestine [51].</td><td>Influences polymeric proanthocyanidin degradation [50].</td></tr><tr><td>Flavonols</td><td></td><td>Sugars and their position affects bioavailability [44].</td><td>Potentially active metabolites: glucuronides [44].</td><td>Facilitates glucuronidation [60].</td></tr><tr><td>Anthocyanins</td><td>Anthocyanin derivatives (flavan-3-ol-anthocyanin dimer) can potentially be absorbed with less efficiency [47].</td><td>Sometimes found with sugars intact in circulation [55].</td><td>Major intestinal metabolites: glucuronide and sulfate conjugates of protocatechuic acid and phloroglucinaldehyde [46]; anthocyanin derivatives metabolically more resistant than parent compounds [47]. </td><td></td></tr><tr><td>Isoflavones</td><td></td><td>Aglycone more bioavailable; possible deglycosylation prior hepatic metabolism [48].</td><td></td><td>Metabolize daidzein to equol [58].</td></tr><tr><td>Flavanones</td><td></td><td>Rapid absorption, low bioavailability [49].</td><td></td><td>Extensive first-pass metabolism partly by intestinal bacteria degraded into phenolic compounds [49].</td></tr></table>
b341a9bb1786cce467068909afd66a3c7c18f99b45a1266e170e5c7c65edc0f5.png
simple
<table><tr><td>Rabbit no.</td><td>Control collagen<sup>a </sup>(absorbance)</td><td>Loaded collagen (absorbance)</td><td>Difference</td></tr><tr><td>1</td><td>37.8</td><td>31.8</td><td>-6.0</td></tr><tr><td>2</td><td>29.8</td><td>28.2</td><td>-1.6</td></tr><tr><td>3</td><td>31.1</td><td>33.0</td><td>1.9</td></tr><tr><td>4</td><td>42.6</td><td>38.3</td><td>-4.3</td></tr><tr><td>5</td><td>31.0</td><td>32.1</td><td>1.1</td></tr><tr><td>6</td><td>39.5</td><td>37.5</td><td>-2.0</td></tr><tr><td>Mean</td><td>35.3</td><td>33.5</td><td>-1.8</td></tr><tr><td>SD</td><td>5.3</td><td>3.8</td><td>3.0</td></tr><tr><td>Significance<sup>b</sup></td><td></td><td></td><td>&gt;0.05</td></tr></table>
6d8183e6aad8588bad9a799a5905ec0b81af59b88628cd9609cf8fe4c5ca9819.png
complex
<table><tr><td>#</td><td>Name</td><td colspan="3">Tag/Fusion protein, position<sup>a</sup> and length<sup>b</sup></td><td>TEV protease cleavage site</td><td>Mode of expression</td><td>EAEA repeat</td><td>Selection marker<sup>c</sup></td><td>Plasmid size (bp)</td></tr><tr><td>1</td><td>PPpRSFC</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>NA</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>4,840</td></tr><tr><td>2</td><td>pPpRSFC-MFalpha</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>NA</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>5,104</td></tr><tr><td>3</td><td>pPpRSFC-MFalpha-noEAEA</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>NA</td><td>Secretory</td><td>No</td><td>Zeocin</td><td>5,092</td></tr><tr><td>4</td><td>pPpRSFC-pGAP</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>NA</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>3,771</td></tr><tr><td>5</td><td>pPpRSFC-pGAP-MFalpha</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>NA</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>4,035</td></tr><tr><td>6</td><td>pPpRSFC-pGAP-MFalpha-noEAEA</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>NA</td><td>Secretory</td><td>No</td><td>Zeocin</td><td>4,023</td></tr><tr><td>7</td><td>pPpRSFC-N-eGFP</td><td>eGFP</td><td>N</td><td>240</td><td>No</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>5,584</td></tr><tr><td>8</td><td>pPpRSFC-C-eGFP</td><td>eGFP</td><td>C</td><td>239</td><td>No</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>5,584</td></tr><tr><td>9</td><td>pPpRSFC-MFalpha-N-eGFP</td><td>eGFP</td><td>N</td><td>239</td><td>No</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>5,848</td></tr><tr><td>10</td><td>pPpRSFC-MFalpha-C-eGFP</td><td>eGFP</td><td>C</td><td>239</td><td>No</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>5,848</td></tr><tr><td>11</td><td>pPpRSFC-N-Myc</td><td>MYC</td><td>N</td><td>11</td><td>No</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>4,870</td></tr><tr><td>12</td><td>pPpRSFC-C-Myc</td><td>MYC</td><td>C</td><td>10</td><td>No</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>4,870</td></tr><tr><td>13</td><td>pPpRSFC-MFalpha-N-Myc</td><td>MYC</td><td>N</td><td>10</td><td>No</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>5,134</td></tr><tr><td>14</td><td>pPpRSFC-MFalpha-C-Myc</td><td>MYC</td><td>C</td><td>10</td><td>No</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>5,134</td></tr><tr><td>15</td><td>pPpRSFC-N-FLAG</td><td>FLAG</td><td>N</td><td>9</td><td>No</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>4,864</td></tr><tr><td>16</td><td>pPpRSFC-C-FLAG</td><td>FLAG</td><td>C</td><td>8</td><td>No</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>4,864</td></tr><tr><td>17</td><td>pPpRSFC-MFalpha-N-FLAG</td><td>FLAG</td><td>N</td><td>8</td><td>No</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>5,128</td></tr><tr><td>18</td><td>pPpRSFC-MFalpha-C-FLAG</td><td>FLAG</td><td>C</td><td>8</td><td>No</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>5,128</td></tr><tr><td>19</td><td>pPpRSFC-N-His-ncs</td><td>His</td><td>N</td><td>7</td><td>No</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>4,858</td></tr><tr><td>20</td><td>pPpRSFC-C-His-ncs</td><td>His</td><td>C</td><td>6</td><td>No</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>4,858</td></tr><tr><td>21</td><td>pPpRSFC-MFalpha-N-His-ncs</td><td>His</td><td>N</td><td>6</td><td>No</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>5,122</td></tr><tr><td>22</td><td>pPpRSFC-MFalpha-C-His-ncs</td><td>His</td><td>C</td><td>6</td><td>No</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>5,122</td></tr><tr><td>23</td><td>pPpRSFC-N-His</td><td>His</td><td>N</td><td>7</td><td>Yes</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>4,879</td></tr><tr><td>24</td><td>pPpRSFC-C-His</td><td>His</td><td>C</td><td>6</td><td>Yes</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>4,879</td></tr><tr><td>25</td><td>pPpRSFC-MFalpha-N-His</td><td>His</td><td>N</td><td>6</td><td>Yes</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>5,143</td></tr><tr><td>26</td><td>pPpRSFC-MFalpha-C-His</td><td>His</td><td>C</td><td>6</td><td>Yes</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>5,143</td></tr><tr><td>27</td><td>pPpRSFC-N-MBP</td><td>MBP</td><td>N</td><td>367</td><td>Yes</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>5,959</td></tr><tr><td>28</td><td>pPpRSFC-C-MBP</td><td>MBP</td><td>C</td><td>366</td><td>Yes</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>5,959</td></tr><tr><td>29</td><td>pPpRSFC-MFalpha-N-MBP</td><td>MBP</td><td>N</td><td>366</td><td>Yes</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>6,223</td></tr><tr><td>30</td><td>pPpRSFC-MFalpha-C-MBP</td><td>MBP</td><td>C</td><td>366</td><td>Yes</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>6,223</td></tr><tr><td>31</td><td>pPpRSFC-N-Strep</td><td>Strep</td><td>N</td><td>9</td><td>Yes</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>4,885</td></tr><tr><td>32</td><td>pPpRSFC-C-Strep</td><td>Strep</td><td>C</td><td>8</td><td>Yes</td><td>Intracellular</td><td>NA</td><td>Zeocin</td><td>4,885</td></tr><tr><td>33</td><td>pPpRSFC-MFalpha-N-Strep</td><td>Strep</td><td>N</td><td>8</td><td>Yes</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>5,149</td></tr><tr><td>34</td><td>pPpRSFC-MFalpha-C-Strep</td><td>Strep</td><td>C</td><td>8</td><td>Yes</td><td>Secretory</td><td>Yes</td><td>Zeocin</td><td>5,149</td></tr><tr><td>35</td><td>pPpRSFC-HIS</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>NA</td><td>Intracellular</td><td>NA</td><td>HIS4</td><td>7,683</td></tr><tr><td>36</td><td>pPpRSFC-HIS-MFalpha</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>NA</td><td>Secretory</td><td>Yes</td><td>HIS4</td><td>7,947</td></tr><tr><td>37</td><td>pPpRSFC-HIS-MFalpha-noEAEA</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>NA</td><td>Secretory</td><td>No</td><td>HIS4</td><td>7,935</td></tr><tr><td>38</td><td>pPpRSFC-HIS-pGAP</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>NA</td><td>Intracellular</td><td>NA</td><td>HIS4</td><td>6,614</td></tr><tr><td>39</td><td>pPpRSFC-HIS-pGAP-MFalpha</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>NA</td><td>Secretory</td><td>Yes</td><td>HIS4</td><td>6,878</td></tr><tr><td>40</td><td>pPpRSFC-HIS-pGAP-MFalpha-noEAEA</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>NA</td><td>Secretory</td><td>No</td><td>HIS4</td><td>6,866</td></tr></table>
9e2aceaf9ac0d394349e390bd93e4479d7b3c23ca13f31ecccd7d51a29fa6768.png
simple
<table><tr><td>Characteristic</td><td>Value</td></tr><tr><td>Total number</td><td>35</td></tr><tr><td>Median age (IQR) in months</td><td>20 (16&#8211;22)</td></tr><tr><td>Females (%)</td><td>19 (54%)</td></tr><tr><td>Median children in household (range)</td><td>3 (1&#8211;6)</td></tr><tr><td>Smokers in household (%)</td><td>11 (31%)</td></tr><tr><td>Received 3 doses of pentavalent vaccine</td><td>91.4%</td></tr><tr><td>Received at least 1 dose of pentavalent vaccine</td><td>100.0%</td></tr></table>
e0021b12d885955cfcfd8ad03c7b83ab7be28aeecb3eed175fe58c9fc5d367da.png
simple
<table><tr><td>#</td><td>Assumption</td></tr><tr><td>1</td><td>There is active secretion of compounds from blood to the lumen of the kidney's proximal tubules and reverse reabsorption (Liu et al., 2012)</td></tr><tr><td>2</td><td>Only an unbound drug could be filtrated or secreted from plasma to the lumen of the kidneys</td></tr><tr><td>3</td><td>The urinary excretion (Q<sub>urine</sub>) is similar for all compounds</td></tr><tr><td>4</td><td>Delay (lag) in absorption (Nerella et al., 1993; van der Walt et al., 2013) is included in all models to create a more precise description of plasma PK data</td></tr><tr><td>5</td><td>The site of action for SGLT2 inhibitors is in the lumen of the kidney's proximal tubules</td></tr><tr><td>6</td><td>The maximal inhibition level of SGLT2 (Imax) induced by compounds is equal to 1 (100%) (Grempler et al., 2012)</td></tr><tr><td>7</td><td>All rate equations are to be described as mass action law</td></tr></table>
b7bc978bd8072bbe84caecb47ce159a43bfec0e1bb1ad6a775b5785b64b495f3.png
complex
<table><tr><td rowspan="2"></td><td colspan="3"><i>MOCOS</i></td></tr><tr><td colspan="3"><i>c.1881delG /c.1782delG</i></td></tr><tr><td></td><td>G/G</td><td>G/del</td><td>del/del</td></tr><tr><td>Affected animals</td><td></td><td></td><td>4</td></tr><tr><td>Obligate carriers</td><td></td><td>3</td><td></td></tr><tr><td>Tyrolean Grey population controls</td><td>1151</td><td>50</td><td></td></tr><tr><td>Controls of other breeds<sup>a</sup></td><td>1225</td><td></td><td></td></tr><tr><td>Total</td><td>2376</td><td>53</td><td>4</td></tr></table>
23bcdc7bfcd53f98f96728a7381abe4cf1e072e63024237ddb2baba4f8703c93.png
simple
<table><tr><td>Health Claims (Dedicated Children&#8217;s Channels)</td><td>2010 (%)</td><td>% Change v 2008 (+/&#8722;)</td><td>2010 All Channels (%)</td></tr><tr><td>Contains essential nutrients e.g., calcium, vitamins, antioxidants</td><td>39.7</td><td>+29</td><td>33.4</td></tr><tr><td>Part of your five a day</td><td>28.9</td><td>+4.9</td><td>10.3</td></tr><tr><td>Organic</td><td>10.4</td><td>+8.8</td><td>5.0</td></tr><tr><td>Wholegrain</td><td>8.3</td><td>&#8722;11.8</td><td>7.8</td></tr><tr><td>Low fat</td><td>4.7</td><td>+2.8</td><td>9.8</td></tr><tr><td>No added sugar</td><td>3.7</td><td>&#8722;0.5</td><td>2.1</td></tr><tr><td>Contains only natural ingredients</td><td>3.1</td><td>&#8722;12.2</td><td>15.9</td></tr><tr><td>Contains fibre</td><td>0.6</td><td>+0.6</td><td>1.3</td></tr><tr><td>Is low calorie/light</td><td>0.6</td><td>&#8722;5.1</td><td>5.1</td></tr></table>
db3eed840fea40688951d40de87e352ef026d198175a8ecb758724759e90ebba.png
complex
<table><tr><td rowspan="2">Configuration</td><td colspan="4">Packets Received per Second</td></tr><tr><td>CSR1</td><td>CSR2</td><td>CSR3</td><td>Average</td></tr><tr><td>CSR devices transmit each packet one</td><td>0.62</td><td>1.41</td><td>1.08</td><td>1.04</td></tr><tr><td>CSR devices transmit each packet three times</td><td>1.16</td><td>1.76</td><td>1.91</td><td>1.61</td></tr></table>
b1992d3394b7fed685b05d5c8b314ad89779656a845734333a1b9cad4e1dcd24.png
simple
<table><tr><td>Variables</td><td>Control subjects (n = 62)</td><td>Type 1 diabetes (n = 53)</td><td>Ketosis-onset diabetes (n = 208)</td><td>Non-ketotic type 2 diabetes (n = 215)</td><td><i>p </i>values</td><td>*<i>p </i>values</td></tr><tr><td>Male (%)</td><td>43 (69.4%)</td><td>31 (58.5%)</td><td>153 (73.6%)</td><td>122 (56.7%)</td><td>0.002</td><td>0.030</td></tr><tr><td>Age (years)</td><td>47 &#177; 11</td><td>49 &#177; 18</td><td>49 &#177; 15</td><td>56 &#177; 14</td><td>&lt;0.001</td><td>&lt;0.001</td></tr><tr><td>Smoking (n, %)</td><td>38 (61.3%)</td><td>17 (32.1%)</td><td>84 (40.4%)</td><td>65 (30.2%)</td><td>&lt;0.001</td><td>0.001</td></tr><tr><td>Alcohol (n, %)</td><td>40 (64.5%)</td><td>14 (26.4%)</td><td>37 (17.8%)</td><td>36 (16.7%)</td><td>&lt;0.001</td><td>&lt;0.001</td></tr><tr><td>Hypertension (%)</td><td>25 (40.3%)</td><td>11 (20.8%)</td><td>81 (38.9%)</td><td>98 (45.6%)</td><td>0.011</td><td>0.035</td></tr><tr><td>CCEs (%)</td><td>0 (0.0%)</td><td>2 (3.8%)</td><td>10 (4.8%)</td><td>31 (14.4%)</td><td>0.002</td><td>0.023</td></tr><tr><td>LLDs (%)</td><td>15 (24.2%)</td><td>10 (18.9%)</td><td>63 (30.3%)</td><td>70 (32.6%)</td><td>0.641</td><td>0.712</td></tr><tr><td>AHDs (%)</td><td>19 (30.6%)</td><td>8 (15.1%)</td><td>68 (32.7%)</td><td>95 (44.2%)</td><td>0.012</td><td>0.029</td></tr><tr><td>Aspirin (%)</td><td>8 (12.9%)</td><td>18 (34.0%)</td><td>66 (31.7%)</td><td>74 (34.4%)</td><td>0.009</td><td>0.013</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>24.14 &#177; 3.67</td><td>22.34 &#177; 4.35</td><td>25.05 &#177; 3.54</td><td>25.16 &#177; 3.59</td><td>&lt;0.001</td><td>&lt;0.001</td></tr><tr><td>WHR</td><td>0.92 &#177; 0.07</td><td>0.89 &#177; 0.07</td><td>0.91 + 0.06</td><td>0.91 + 0.06</td><td>0.019</td><td>0.475</td></tr><tr><td>**Weight category</td><td> </td><td> </td><td> </td><td> </td><td>&lt;0.001</td><td>&lt;0.001</td></tr><tr><td>Underweight</td><td>3 (4.4%)</td><td>8 (15.1%)</td><td>3 (1.4%)</td><td>2 (0.9%)</td><td>&#8212;&#8212;</td><td>&#8212;&#8212;</td></tr><tr><td>Overweight</td><td>20 (32.3%)</td><td>6 (11.3%)</td><td>48 (23.1%)</td><td>49 (22.8%)</td><td>&#8212;&#8212;</td><td>&#8212;&#8212;</td></tr><tr><td>Obesity</td><td>22 (35.5%)</td><td>11 (20.8%)</td><td>97 (46.6%)</td><td>109 (50.7%)</td><td>&#8212;&#8212;</td><td>&#8212;&#8212;</td></tr><tr><td>SBP (mmHg)</td><td>124 &#177; 16</td><td>125 &#177; 17</td><td>127 &#177; 15</td><td>130 &#177; 17</td><td>0.042</td><td>0.146</td></tr><tr><td>DBP (mmHg)</td><td>78 &#177; 12</td><td>79 &#177; 10</td><td>81 &#177; 11</td><td>81 &#177; 9</td><td>0.101</td><td>0.023</td></tr><tr><td>*TG (mmol/l)</td><td>1.18 (0.88-1.92)</td><td>1.21 (0.84-1.55)</td><td>1.44 (1.00-2.19)</td><td>1.49 (1.08-2.21)</td><td>0.001</td><td>0.019</td></tr><tr><td>TC (mmol/l)</td><td>4.84 &#177; 1.02</td><td>4.83 &#177; 1.09</td><td>5.03 &#177; 1.22</td><td>4.82 &#177; 1.22</td><td>0.323</td><td>0.695</td></tr><tr><td>HDL-C (mmol/l)</td><td>1.28 &#177; 0.35</td><td>1.13 &#177; 0.26</td><td>1.05 &#177; 0.27</td><td>1.11 &#177; 0.25</td><td>&lt;0.001</td><td>&lt;0.001</td></tr><tr><td>LDL-C (mmol/l)</td><td>2.71 &#177; 0.88</td><td>3.24 &#177; 0.97</td><td>3.40 &#177; 1.03</td><td>3.12 &#177; 0.97</td><td>&lt;0.001</td><td>0.075</td></tr><tr><td>*Cr (&#956;mol/l)</td><td>71 (56&#8211;82)</td><td>59 (48&#8211;79)</td><td>68 (58&#8211;80)</td><td>67 (54&#8211;79)</td><td>0.036</td><td>0.442</td></tr><tr><td>*UAE (mg/24 h)</td><td>&#8212;&#8212;</td><td>9.9 (7.1-18.1)</td><td>10.3 (6.5-23.8)</td><td>8.9 (6.4-24.8)</td><td>0.823</td><td>0.917</td></tr><tr><td>*eGFR (ml/min/1.73 m<sup>2</sup>)</td><td>103 (93&#8211;116)</td><td>109 (89&#8211;136)</td><td>112 (92&#8211;134)</td><td>98 (82&#8211;118)</td><td>0.432</td><td>0.588</td></tr><tr><td>*FPG (mmol/l)</td><td>4.96 (4.67-5.24)</td><td>7.99 (6.02-11.44)</td><td>9.74 (7.63-12.45)</td><td>7.53 (6.39-9.67)</td><td>&lt;0.001</td><td>&lt;0.001</td></tr><tr><td>*2 h PPG (mmol/l)</td><td>5.84 (5.04-6.58)</td><td>14.66 (10.49-19.61)</td><td>16.66 (12.94-20.79)</td><td>13.14 (10.39-16.66)</td><td>&lt;0.001</td><td>&lt;0.001</td></tr><tr><td>*FCP (ng/mL)</td><td>2.05 (1.6-3.03)</td><td>0.6 (0.3-0.84)</td><td>1.23 (0.74-1.92)</td><td>2.02 (1.36-2.93)</td><td>&lt;0.001</td><td>0.030</td></tr><tr><td>*2 h C-P (ng/mL)</td><td>7.99 (6.56-9.92)</td><td>0.92 (0.62-1.77)</td><td>2.31 (1.55-3.66)</td><td>4.65 (3.12-6.35)</td><td>&lt;0.001</td><td>0.004</td></tr><tr><td>HA1C (%)</td><td>5.3 &#177; 0.34</td><td>12.39 &#177; 2.36</td><td>11.83 &#177; 2.05</td><td>9.81 &#177; 2.58</td><td>&lt;0.001</td><td>&lt;0.001</td></tr></table>
d089d46e0aac4744d68e51c71864971469cd32202b6095b9d4ab71ba3a002df7.png
simple
<table><tr><td>Surface</td><td>Contact angle (deg.)</td><td>Contact angle hysteresis (deg.)</td><td>Sliding angle (deg.)</td></tr><tr><td>TO-SHS</td><td>169&#177;4</td><td>45&#177;15</td><td>&gt;45</td></tr><tr><td>TO-SLIPS</td><td>124&#177;1</td><td>1.4&#177;0.5</td><td>3.0&#177;0.3</td></tr></table>
0b470a9a3f4e1dc2b15dcbaeafb83566d7f7087fe12d1b4841b1a1359acbea4b.png
simple
<table><tr><td>Dose (mg kg<sup>&#8722;1</sup>) </td><td>Fatty change</td><td>Hydropic swelling</td><td>Mild inflammation</td><td>Mild fibrosis</td></tr><tr><td>Saline</td><td>0/4</td><td>0/4</td><td>0/4</td><td>0/4</td></tr><tr><td>30</td><td>0/4</td><td>0/4</td><td>0/4</td><td>0/4</td></tr><tr><td>100</td><td>0/4</td><td>0/4</td><td>4/4</td><td>0/4</td></tr><tr><td>300</td><td>0/4</td><td>1/4</td><td>4/4</td><td>0/4</td></tr><tr><td>1000</td><td>2/4</td><td>4/4</td><td>4/4</td><td>0/4</td></tr><tr><td>3000</td><td>2/4</td><td>4/4</td><td>4/4</td><td>2/4</td></tr></table>
bc1d089cb5a6423693ff6ef478ae2284be704851b8791ebb38a3b7fba677614a.png
simple
<table><tr><td>Sample</td><td><i>a</i> (m<sup>2</sup>&#183;kW<sup>&#8722;1</sup>&#183;s<sup>&#8722;1/2</sup>)</td><td><i>b</i> (s<sup>&#8722;1/2</sup>)</td><td><i>R</i><sup>2</sup></td></tr><tr><td>NC-F, 1 g</td><td>0.03537</td><td>&#8722;0.1046</td><td>0.9459</td></tr><tr><td>NC-F, 2 g</td><td>0.03117</td><td>0.23889</td><td>0.30557</td></tr><tr><td>NC-C; 1 g</td><td>0.01161</td><td>&#8722;0.01993</td><td>0.99933</td></tr><tr><td>NC-C; 2 g</td><td>0.011</td><td>&#8722;0.00607</td><td>0.99423</td></tr></table>
1c27e2bd73692e4e9c26b510bf1f27b2d8d5e06707b7e6632c56c00696f972cb.png
simple
<table><tr><td></td><td>OR<sup>a</sup> (95% CI)</td><td><i>p</i>-Value</td></tr><tr><td>Cannabis<sup>b</sup></td><td></td><td></td></tr><tr><td>Use at 1 time-point</td><td>1.32 (0.94&#8211;1.86)</td><td>0.112</td></tr><tr><td>Use at 2 time-points</td><td>1.71 (1.08&#8211;2.70)</td><td>0.023</td></tr><tr><td>Use at 3 time-points</td><td>2.08 (1.16&#8211;3.74)</td><td>0.025</td></tr><tr><td>Use at 4 time-points</td><td>2.44 (1.06&#8211;5.63)</td><td>0.036</td></tr><tr><td>Cocaine<sup>b</sup></td><td></td><td></td></tr><tr><td>Use at 1 time-point</td><td>1.04 (0.71&#8211;1.53)</td><td>0.842</td></tr><tr><td>Use at 2 time-points</td><td>0.68 (0.41&#8211;1.14)</td><td>0.154</td></tr><tr><td>Use at 3 time-points</td><td>1.16 (0.59&#8211;2.28)</td><td>0.674</td></tr><tr><td>Use at 4 time-points</td><td>0.59 (0.21&#8211;1.63)</td><td>0.304</td></tr><tr><td>Alcohol<sup>b</sup></td><td></td><td></td></tr><tr><td>Use at 1 time-point</td><td>1.13 (0.84&#8211;1.52)</td><td>0.420</td></tr><tr><td>Use at 2 time-points</td><td>1.09 (0.74&#8211;1.61)</td><td>0.656</td></tr><tr><td>Use at 3 time-points</td><td>1.36 (0.84&#8211;2.21)</td><td>0.209</td></tr><tr><td>Use at 4 time-points</td><td>2.32 (1.25&#8211;4.28)</td><td>0.007</td></tr></table>
f6d43e09845c6d149db61ad98306c11227148106c54f0234c1b9065fb634d4ad.png
complex
<table><tr><td></td><td></td><td colspan="2"><i>n</i>, mean (SD)</td><td colspan="2">GLM analysis</td></tr><tr><td>Subgroup variable</td><td>Category</td><td>PTA</td><td>TAU</td><td>Difference and 95%CI</td><td><i>p</i>-value</td></tr><tr><td>Age at screening (year)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>&#8804;61</td><td>33,6.08 (1.49)</td><td>45,5.69 (1.53)</td><td>0.08 (&#8722;0.44,0.59)</td><td>0.7752</td></tr><tr><td></td><td>&gt;61</td><td>35,6.51 (1.54)</td><td>45,5.79 (1.54)</td><td>0.70 (0.23,1.17)</td><td>0.0036</td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Male</td><td>43,6.33 (1.52)</td><td>52,5.86 (1.49)</td><td>0.29 (&#8722;0.17,0.75)</td><td>0.2108</td></tr><tr><td></td><td>Female</td><td>25,6.24 (1.56)</td><td>38,5.58 (1.58)</td><td>0.51 (&#8722;0.03,1.04)</td><td>0.0636</td></tr><tr><td>Number of comorbidities</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>&#8804;1</td><td>43,6.13 (1.64)</td><td>59,5.94 (1.45)</td><td>0.21 (&#8722;0.18,0.60)</td><td>0.2892</td></tr><tr><td></td><td>&gt;1</td><td>25,6.59 (1.26)</td><td>31,5.37 (1.63)</td><td>0.84 (0.15,1.54)</td><td>0.0167</td></tr><tr><td>Parkinson&#8217;s disease duration (year)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>&#8804;4</td><td>37,6.56 (1.30)</td><td>52,5.88 (1.55)</td><td>0.47 (&#8722;0.03,0.96)</td><td>0.0630</td></tr><tr><td></td><td>&gt;4</td><td>31,5.98 (1.71)</td><td>38,5.56 (1.50)</td><td>0.33 (&#8722;0.17,0.83)</td><td>0.1917</td></tr></table>
22e8a575b6dcddbb52fdd319806f9cb517409ef80b0a3ab8a6e117d2cb0a1f23.png
simple
<table><tr><td></td><td>p3-m2</td><td>p3-m1</td><td>p3-p4</td><td>p3 L</td><td>p3 W</td><td>p4 L</td><td>p4 Wtr</td><td>p4 Wtal</td><td>P3 L</td><td>P3W</td></tr><tr><td>Type Sh 434</td><td>6.3</td><td>4.8</td><td>3. 15</td><td>1</td><td>1.35</td><td>1.5</td><td>1.5</td><td>1.35</td><td></td><td></td></tr><tr><td>MPC/L-0001 (LUS-29)</td><td>4.75</td><td>3.35</td><td>2</td><td>0.8</td><td>1</td><td>1.35</td><td>1.25</td><td>1.15</td><td></td><td></td></tr><tr><td>LUS-078</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1.0;1.0</td><td>1.75;1.8</td></tr><tr><td>RHN-A/12</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1.0</td><td>1.5</td></tr></table>
0fde81c23a286f90cf7f9f598104287443766e82f7adaeaffd164ae157102336.png
complex
<table><tr><td>Life Satisfaction<sup>a</sup></td><td>2005</td><td>2007</td><td>2009</td><td>2011</td><td>2013</td></tr><tr><td colspan="6">Health</td></tr><tr><td> 1</td><td>781 (22.2)</td><td>535 ((17.6)</td><td>461 (17.4)</td><td>207 (8.93)</td><td>130 (6.6)</td></tr><tr><td> 2</td><td>1455 (41.4)</td><td>1365 (44.8)</td><td>935 (35.3)</td><td>693 (29.8)</td><td>614 (31.4)</td></tr><tr><td> 3</td><td>662 (18.8)</td><td>658 (21.6)</td><td>821 (31.0)</td><td>930 (40.0)</td><td>844 (43.2)</td></tr><tr><td> 4</td><td>582 (16.6)</td><td>470 (15.4)</td><td>413 (15.6)</td><td>475 (20.4)</td><td>352 (18.0)</td></tr><tr><td> 5</td><td>35 (1.0)</td><td>19 (0.6)</td><td>19 (0.7)</td><td>21 (0.9)</td><td>14 (0.7)</td></tr><tr><td colspan="6">Finance</td></tr><tr><td> 1</td><td>449 (12.8)</td><td>291 (9.6)</td><td>299 (11.3)</td><td>164 (7.1)</td><td>115 (5.9)</td></tr><tr><td> 2</td><td>1335 (38.0)</td><td>1145 (37.6)</td><td>949 (35.8)</td><td>718 (30.9)</td><td>530 (27.1)</td></tr><tr><td> 3</td><td>1153 (32.8)</td><td>1072 (35.2)</td><td>957 (36.1)</td><td>962 (41.4)</td><td>904 (46.3)</td></tr><tr><td> 4</td><td>552 (15.7)</td><td>520 (17.1)</td><td>429 (16.2)</td><td>449 (19.3)</td><td>372 (19.0)</td></tr><tr><td> 5</td><td>26 (0.7)</td><td>19 (0.6)</td><td>17 (0.6)</td><td>33 (1.4)</td><td>33 (1.7)</td></tr><tr><td colspan="6">Housing</td></tr><tr><td> 1</td><td>95 (2.7)</td><td>54 (1.8)</td><td>54 (2.0)</td><td>31 (1.3)</td><td>20 (1.0)</td></tr><tr><td> 2</td><td>614 (17.5)</td><td>376 (12.3)</td><td>259 (9.8)</td><td>287 (12.3)</td><td>161 (8.2)</td></tr><tr><td> 3</td><td>1086 (30.9)</td><td>974 (32.0)</td><td>1010 (38.1)</td><td>1011 (43.5)</td><td>902 (46.2)</td></tr><tr><td> 4</td><td>1595 (45.4)</td><td>1544 (50.7)</td><td>1263 (47.6)</td><td>926 (39.8)</td><td>816 (41.8)</td></tr><tr><td> 5</td><td>127 (3.6)</td><td>99 (3.3)</td><td>66 (2.5)</td><td>71 (3.1)</td><td>55 (2.8)</td></tr><tr><td colspan="6">Family Relationships</td></tr><tr><td> 1</td><td>47 (1.3)</td><td>19 (0.7)</td><td>24 (0.9)</td><td>8 (0.4)</td><td>13 (0.7)</td></tr><tr><td> 2</td><td>218 (6.2)</td><td>135 (4.6)</td><td>97 (3.8)</td><td>130 (5.8)</td><td>86 (4.5)</td></tr><tr><td> 3</td><td>980 (27.9)</td><td>897 (30.5)</td><td>900 (34.8)</td><td>971 (43.1)</td><td>739 (38.6)</td></tr><tr><td> 4</td><td>2073 (59.1)</td><td>1735 (59.0)</td><td>1476 (57.0)</td><td>1075 (47.7)</td><td>950 (49.6)</td></tr><tr><td> 5</td><td>190 (5.4)</td><td>157 (5.3)</td><td>92 (3.6)</td><td>70 (3.1)</td><td>126 (6.6)</td></tr><tr><td colspan="6">Neighbor Relationships</td></tr><tr><td> 1</td><td>20 (0.6)</td><td>11 (0.4)</td><td>35 (1.3)</td><td>17 (0.7)</td><td>6 (0.3)</td></tr><tr><td> 2</td><td>216 (6.1)</td><td>159 (5.2)</td><td>124 (4.7)</td><td>146 (6.3)</td><td>117 96.0)</td></tr><tr><td> 3</td><td>955 (27.2)</td><td>1001 (32.9)</td><td>1138 (43.2)</td><td>1105 (47.9)</td><td>928 (47.7)</td></tr><tr><td> 4</td><td>2087 (59.4)</td><td>1721 (56.5)</td><td>1283 (48.7)</td><td>986 (42.7)</td><td>797 (40.9)</td></tr><tr><td> 5</td><td>238 (6.8)</td><td>155 (5.1)</td><td>56 (2.1)</td><td>53 (2.3)</td><td>99 (5.1)</td></tr></table>
9474928101c79398e63c8932c67e597bf8d53db20ca0fdf1408cfdc7e0dcadb1.png
simple
<table><tr><td>Pool</td><td>DMRs (Number)</td><td>DMRs (%)</td></tr><tr><td>Bulgarian females (patients/controls)</td><td>293</td><td>1.1</td></tr><tr><td>Bulgarian males (patients/controls)</td><td>948</td><td>3.4</td></tr><tr><td>Serbian females (patients/controls)</td><td>947</td><td>3.4</td></tr><tr><td>Serbian males (patients/controls)</td><td>944</td><td>3.4</td></tr></table>
ad1ccd9ae5c7160b8f874d5b8a48a9d796a3e62b2fb064302f3090cde23bb5d6.png
complex
<table><tr><td>Time</td><td>AUC</td><td>CRI</td><td>Predicting</td><td>Sensitivity (CI)</td><td>Specificity (CI)</td><td>PPV (CI)</td><td>NPV (CI)</td></tr><tr><td colspan="8">A. Training set</td></tr><tr><td>12 h</td><td>0.83</td><td>&lt;0.04</td><td>Poor outcome</td><td>0.27 (0.11&#8211;0.50)</td><td>1.00 (0.86&#8211;1.00)</td><td>1.00 (0.54&#8211;1.00)</td><td>0.60 (0.43&#8211;0.75)</td></tr><tr><td> </td><td> </td><td>&gt;0.90</td><td>Good outcome</td><td>0.13 (0.03&#8211;0.32)</td><td>1.00 (0.85&#8211;1.00)</td><td>1.00 (0.29&#8211;1.00)</td><td>0.51 (0.35&#8211;0.67)</td></tr><tr><td>18 h</td><td>0.69</td><td>&lt;0.19</td><td>Poor outcome</td><td>0.28 (0.10&#8211;0.53)</td><td>1.00 (0.85&#8211;1.00)</td><td>1.00 (0.48&#8211;1.00)</td><td>0.63 (0.45&#8211;0.79)</td></tr><tr><td> </td><td> </td><td>&gt;0.91</td><td>Good outcome</td><td>0.05 (0.00&#8211;0.22)</td><td>1.00 (0.81&#8211;1.00)</td><td>1.00 (-)</td><td>0.46 (0.30&#8211;0.63)</td></tr><tr><td>24 h</td><td>0.87</td><td>&lt;0.35</td><td>Poor outcome</td><td>0.45 (0.23&#8211;0.68)</td><td>1.00 (0.85&#8211;1.00)</td><td>1.00 (0.66&#8211;1.00)</td><td>0.68 (0.49&#8211;0.83)</td></tr><tr><td> </td><td> </td><td>&gt;0.61</td><td>Good outcome</td><td>0.57 (0.35&#8211;0.77)</td><td>1.00 (0.83&#8211;1.00)</td><td>1.00 (0.75&#8211;1.00)</td><td>0.67 (0.47&#8211;0.83)</td></tr><tr><td>36 h</td><td>0.74</td><td>&lt;0.32</td><td>Poor outcome</td><td>0.28 (0.10&#8211;0.53)</td><td>1.00 (0.86&#8211;1.00)</td><td>1.00 (0.48&#8211;1.00)</td><td>0.65 (0.75&#8211;1.00)</td></tr><tr><td> </td><td> </td><td>&gt;0.91</td><td>Good outcome</td><td>0.04 (0.00&#8211;0.21)</td><td>1.00 (0.81&#8211;1.00)</td><td>1.00 (-)</td><td>0.44 (0.28&#8211;0.60)</td></tr><tr><td colspan="8">B. Test set</td></tr><tr><td>12 h</td><td>0.74</td><td>&lt;0.02</td><td>Poor outcome</td><td>0.13 (0.02&#8211;0.40)</td><td>1.00 (0.83&#8211;1.00)</td><td>1.00 (0.16&#8211;1.00)</td><td>0.60 (0.42&#8211;0.77)</td></tr><tr><td> </td><td> </td><td>&gt;1.00</td><td>Good outcome</td><td>0.00 (0.00&#8211;0.17)</td><td>1.00 (0.78&#8211;1.00)</td><td>-</td><td>0.43 (0.26&#8211;0.60)</td></tr><tr><td>18 h</td><td>0.94</td><td>&lt;0.18</td><td>Poor outcome</td><td>0.59 (0.33&#8211;0.82)</td><td>1.00 (0.85&#8211;1.00)</td><td>1.00 (0.69&#8211;1.00)</td><td>0.76 (0.56&#8211;0.90)</td></tr><tr><td> </td><td> </td><td>&gt;0.57</td><td>Good outcome</td><td>0.64 (0.41&#8211;0.83)</td><td>1.00 (0.80&#8211;1.00)</td><td>1.00 (0.77&#8211;1.00)</td><td>0.68 (0.46&#8211;0.85)</td></tr><tr><td>24 h</td><td>0.87</td><td>&lt;0.29</td><td>Poor outcome</td><td>0.55 (0.32&#8211;0.76)</td><td>1.00 (0.86&#8211;1.00)</td><td>1.00 (0.73&#8211;1.00)</td><td>0.71 (0.53&#8211;0.85)</td></tr><tr><td> </td><td> </td><td>&gt;0.69</td><td>Good outcome</td><td>0.25 (0.10&#8211;0.47)</td><td>1.00 (0.85&#8211;1.00)</td><td>1.00 (0.54&#8211;1.00)</td><td>0.55 (0.38&#8211;0.70)</td></tr><tr><td>36 h</td><td>0.84</td><td>&lt;0.22</td><td>Poor outcome</td><td>0.30 (0.12&#8211;0.54)</td><td>1.00 (0.86&#8211;1.00)</td><td>1.00 (0.54&#8211;1.00)</td><td>0.63 (0.46&#8211;0.78)</td></tr><tr><td> </td><td> </td><td>&gt;1.00</td><td>Good outcome</td><td>0.00 (0.00&#8211;0.14)</td><td>1.00 (0.83&#8211;1.00)</td><td>-</td><td>0.45 (0.30&#8211;0.61)</td></tr></table>
74b34a444770511fea7b730b5b004cab3452b1f768921bd5ba2479d7605efb23.png
simple
<table><tr><td>Author</td><td>Patient (<i>n</i>) (age/sex)</td><td>Procedure</td><td>Cardiac rhythm</td><td>Cause</td><td>Management</td><td>Outcome</td></tr><tr><td>Chowdhury and West [3]</td><td>50 y &#9792;</td><td>Awake craniotomy (frontal tumor)</td><td>Bradycardia, asystole (25 s)</td><td>TCR (scalp traction)</td><td>Release scalp traction; cessation propofol and remifentanil infusions</td><td>No neurological deficit</td></tr><tr><td>Prabhu et al. [4]</td><td>65 y &#9794;</td><td>Awake craniotomy (temporal tumor) </td><td>Bradycardia and asystole (8&#8211;10 s &#215; 2 times)</td><td>TCR (dura cautery)</td><td>Cessation of cautery, atropine</td><td>No neurological deficit</td></tr><tr><td>Sinha et al. [5]</td><td>18 y &#9794;</td><td>Epilepsy surgery </td><td>Bradycardia (2 episodes), asystole (9 s)</td><td>&#8593;Parasympathetic response 2&#176; to amygdala resection; warm and cold saline irrigation</td><td>Atropine; cessation of stimulus</td><td>No neurological deficit</td></tr><tr><td>Sato et al. [6]</td><td>6/42 [18&#8211;34 y; &#9792; = 3, &#9794; = 2]</td><td>Epilepsy surgery</td><td>Sinus bradycardia (&lt;1 min)</td><td>&#8593;Parasympathetic tone 2&#176; to limbic stimulation</td><td>Procedure interruption; atropine</td><td>No neurological deficit</td></tr><tr><td>Tyler et al. [7]</td><td>22 y &#9792;</td><td>Craniotomy (parietal tumor)</td><td>Asystole</td><td>Intracranial hematoma (dural closure)</td><td>Hematoma evacuation</td><td>No neurological deficit</td></tr><tr><td>Wasnick et al. [8]</td><td>70 &#9794;</td><td>Epidural suction drain</td><td>Severe bradycardia</td><td>Intracranial hypotension</td><td>Release of suction</td><td>No neurological deficit</td></tr><tr><td>Alfery et al. [9]</td><td>18 &#9792;</td><td>VP shunt</td><td>VT, VF</td><td>Intracranial hypotension</td><td>Lidocaine, CPR</td><td>No neurological deficit</td></tr><tr><td>Karamchandani et al. [10]</td><td>65 &#9792;</td><td>Subgaleal suction drain</td><td>Multiple severe bradycardia</td><td>Intracranial hypotension</td><td>Release of suction, atropine</td><td>No neurological deficit</td></tr><tr><td>Bhagat et al. [11]</td><td>2 patients[both 60 &#9794;]</td><td>Subgaleal suction drain</td><td>Severe bradycardia, Asystole</td><td>Intracranial hypotension</td><td>Release of suction, atropine</td><td>No neurological deficit</td></tr></table>
3c3157e3a15317ad54dbe04bf894cec6f1db455924743925090bb1b8fa1b635d.png
complex
<table><tr><td>Method</td><td>Rank</td><td>Rank</td><td>TPR in top</td><td>TPR in top</td><td>TPR in top</td><td>TPR in top</td><td>AUC</td><td>Rank difference</td></tr><tr><td></td><td>median</td><td>average</td><td>1% (%)</td><td>5% (%)</td><td>10% (%)</td><td>30% (%)</td><td></td><td><i>p</i>-value</td></tr><tr><td colspan="4">Genome-wide prioritizations</td><td colspan="5"></td></tr><tr><td>Scuba</td><td>8.13</td><td><i>17.45</i> &#177; 22.33</td><td><i>10.4</i></td><td>41.7</td><td><i>58.3</i></td><td><i>79.2</i></td><td><i>0.83</i></td><td>-</td></tr><tr><td>MKL1class [12]</td><td>14.28</td><td>25.79 &#177; 26.96</td><td>2.1</td><td>27.1</td><td>45.8</td><td>66.7</td><td>0.74</td><td>1.2 &#183;10<sup>&#8722;5</sup> *</td></tr><tr><td>ProDiGe [13]</td><td><i>7.89</i></td><td>18.40 &#177; 23.77</td><td><i>10.4</i></td><td><i>43.8</i></td><td>54.2</td><td><i>79.2</i></td><td>0.82</td><td>9.5 &#183;10<sup>&#8722;2</sup></td></tr></table>